WO2008148849A2 - Piperidine/piperazine derivatives - Google Patents

Piperidine/piperazine derivatives Download PDF

Info

Publication number
WO2008148849A2
WO2008148849A2 PCT/EP2008/057008 EP2008057008W WO2008148849A2 WO 2008148849 A2 WO2008148849 A2 WO 2008148849A2 EP 2008057008 W EP2008057008 W EP 2008057008W WO 2008148849 A2 WO2008148849 A2 WO 2008148849A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
het
amino
formula
Prior art date
Application number
PCT/EP2008/057008
Other languages
French (fr)
Other versions
WO2008148849A3 (en
WO2008148849A8 (en
Inventor
Jean-Pierre André Marc BONGARTZ
Joannes Theodorus Maria Linders
Lieven Meerpoel
Guy Rosalia Eugeen Van Lommen
Erwin Coesemans
Mirielle Braeken
Christophe Francis Robert Nestor Buyck
Monique Jenny Marie Berwaer
Katharina Antonia Germania J.M. De Waepenaert
Peter Walter Maria Roevens
Petr Vladimirivich Davidenko
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38616252&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008148849(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to MX2009013334A priority Critical patent/MX2009013334A/en
Priority to RU2009148796/04A priority patent/RU2478628C2/en
Priority to BRPI0812923-1A2A priority patent/BRPI0812923A2/en
Priority to JP2010510806A priority patent/JP5443343B2/en
Priority to AU2008258558A priority patent/AU2008258558B2/en
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Priority to ES08760584.6T priority patent/ES2522617T3/en
Priority to CN200880018624.9A priority patent/CN101678013B/en
Priority to CA2687243A priority patent/CA2687243C/en
Priority to EP08760584.6A priority patent/EP2155198B1/en
Priority to US12/663,011 priority patent/US8946228B2/en
Publication of WO2008148849A2 publication Critical patent/WO2008148849A2/en
Publication of WO2008148849A3 publication Critical patent/WO2008148849A3/en
Priority to EP09757551.8A priority patent/EP2296659B1/en
Priority to UY0001031863A priority patent/UY31863A/en
Priority to AU2009253892A priority patent/AU2009253892B2/en
Priority to PE2009000769A priority patent/PE20100083A1/en
Priority to CA2725933A priority patent/CA2725933C/en
Priority to PE2013002163A priority patent/PE20140572A1/en
Priority to PCT/EP2009/056800 priority patent/WO2009147170A2/en
Priority to JP2011512112A priority patent/JP5579170B2/en
Priority to US12/993,491 priority patent/US9107946B2/en
Priority to ES09757551.8T priority patent/ES2617619T3/en
Priority to ARP090102006A priority patent/AR073450A1/en
Priority to TW098118476A priority patent/TWI460175B/en
Publication of WO2008148849A8 publication Critical patent/WO2008148849A8/en
Priority to US14/561,252 priority patent/US9227935B2/en
Priority to US14/793,896 priority patent/US9724418B2/en
Priority to US14/957,924 priority patent/US20160081997A1/en
Priority to US15/627,475 priority patent/US20180028660A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/21—Radicals derived from sulfur analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to the use of a DGAT inhibitor, in particular a DGATl inhibitor, for the manufacture of a medicament for the prevention or the treatment of a disease by elevating the levels of one or more satiety hormones, in particular GLP-I.
  • the present invention also concerns piperidine/piperazine derivatives having DGAT inhibitory activity, in particular DGATl inhibitory activity.
  • the invention further relates to methods for their preparation and pharmaceutical compositions comprising them.
  • the invention also relates to the use of said compounds for the manufacture of a medicament for the prevention or the treatment of a disease mediated by DGAT, in particular DGAT 1.
  • Triglycerides represent the major form of energy stored in eukaryotes. Disorders or imbalances in triglyceride metabolism are implicated in the pathogenesis of and increased risk for obesity, insulin resistance syndrome and type II diabetes, nonalcoholic fatty liver disease and coronary heart disease (see, Lewis, et al, Endocrine Reviews (2002) 23:201 and Malloy and Kane, Adv. Intern. Med. (2001) 47:11 1).
  • hypertriglyceridemia is often an adverse consequence of cancer therapy (see, Bast, et al. Cancer Medicine, 5th Ed., (2000) B.C. Decker, Hamilton, Ontario, CA).
  • DGAT acyl CoA:diacylglycerol acyltransferase
  • DAG 1 ,2-diacylglycerol
  • TG triglycerides
  • DGAT uniquely controlled the catalysis of the final step of acylation of diacylglycerol to triglyceride in the two major pathways for triglyceride synthesis, the glycerol phosphate and monoacylglycerol pathways. Because triglycerides are considered essential for survival, and their synthesis was thought to occur through a single mechanism, inhibition of triglyceride synthesis through inhibiting the activity of DGAT has been largely unexplored. Genes encoding mouse DGATl and the related human homo logs ARGPl (human DGATl) and ARGP2 (human ACAT2) now have been cloned and characterized (Cases, et al, Pro.c Nat. I Acad.
  • the gene for mouse DGATl has been used to create DGAT knock-out mice to better elucidate the function of the DGAT gene.
  • mice unable to express a functional DGATl enzyme are viable and still able to synthesize triglycerides, indicating that multiple catalytic mechanisms contribute to triglyceride synthesis (Smith, et al, Nature Genetics (2000) 25:87).
  • Other enzymes that catalyze triglyceride synthesis for example, DGAT2 and diacylglycerol transacylase, also have been identified (Cases, et al, J. Biol. Chem.
  • DGAT2 plays a fundamental role in mammalian triglyceride synthesis and is required for survival.
  • DGAT2 deficient mice are lipopenic and die soon after birth, apparently from profound reductions in substrates for energy metabolism and from impaired permeability barrier function in the skin.(Farese, et al., J. Biol. Chem. (2004) 279: 11767).
  • Dgatl-/- mice are resistant to diet-induced obesity and remain lean. Even when fed a high fat diet (21 % fat) Dgatl-/- mice maintain weights comparable to mice fed a regular diet (4% fat) and have lower total body triglyceride levels.
  • the obesity resistance in Dgatl-/- mice is not due to decreased caloric intake, but the result of increased energy expenditure and decreased resistance to insulin and leptin (Smith, et al, Nature Genetics (2000) 25:87; Chen and Farese, Trends Cardiovasc. Med. (2000) 10: 188; and Chen, et al, J. Clin. Invest. (2002) 109:1049).
  • Dgatl-/- mice have reduced rates of triglyceride absorption (Buhman, et al, J. Biol. Chem. (2002) 277:25474). In addition to improved triglyceride metabolism, Dgatl-/- mice also have improved glucose metabolism, with lower glucose and insulin levels following a glucose load, in comparison to wild-type mice (Chen and Farese, Trends Cardiovasc. Med. (2000) 10: 188).
  • the compounds of the present invention exhibit DGAT inhibitory activity, in particular DGATl inhibitory activity, and can therefore be used to prevent or treat a disease associated with or mediated by DGAT, such as for example obesity, type II diabetes, heart disease and cancer.
  • DGAT DGAT inhibitory activity
  • the compounds of the invention differ from the prior art compounds in structure, in their pharmacological activity, pharmacological potency, and/or pharmacological profile.
  • DGAT inhibitors can be used to elevate the levels of one or more satiety hormones, in particular glucagon- like-peptide-1 (GLP-I) and therefore DGAT inhibitors, in particular DGATl inhibitors, can also be used to prevent or treat a disease which can benefit from elevated levels of a satiety hormone, in particular GLP-I.
  • GLP-I glucagon- like peptide 1
  • Glucagon- like peptide 1 is an intestinal hormone which generally stimulates insulin secretion during hyperglycemia, suppresses glucagon secretion, stimulates (pro) insulin biosynthesis and decelerates gastric emptying and acid secretion.
  • GLP-I is secreted from L cells in the small and large bowel following the ingestion of fat and proteins. GLP-I has been suggested, among other indications, as a possible therapeutic agent for the management of type 2 non- insulin-dependent diabetes mellitus as well as related metabolic disorders, such as obesity.
  • GLP-I a disease which can benefit from elevated levels of GLP-I can be treated with small molecules (compared to large molecules such as proteins or protein- like compounds, e.g. GLP-I analogues).
  • WO 2006/034441 discloses heterocyclic derivatives and their use as stearoyl CoA desaturase inhibitors (SCD-I inhibitors).
  • WO 2006/086445 relates to a combination therapy of a SCD-I inhibitor and another drug to treat adverse weight gain. -A-
  • WO 2006/004200 and JP2007131584 relate to urea and amino derivatives having DGAT inhibitory activity.
  • WO 2004/047755 relates to fused bicyclic nitrogen-containing heterocycles having DGAT inhibitory activity.
  • WO2005/072740 relates to an anorectic action of a compound having DGAT inhibitory activity.
  • the present invention relates to the use of a DGAT inhibitor for the manufacture of a medicament for the prevention or the treatment, in particular for the treatment, of a disease which can benefit from elevated levels of one or more satiety hormones, in particular GLP-I.
  • A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom;
  • Z represents a bivalent radical selected from d- ⁇ alkanediyl, C2-6alkenediyl or C 2 -6alkynediyl; wherein each of said d- ⁇ alkanediyl, C2-6alkenediyl or C2-6alkynediyl may optionally be substituted with hydroxyl or amino; and wherein two hydrogen atoms attached to the same carbon atom in Ci_6alkanediyl may optionally be replaced by d- ⁇ alkanediyl;
  • R x represents hydrogen or C 1-4 alkyl
  • R 1 represents adamantanyl, C 3- 6Cycloalkyl; aryl 1 or Het 1 ;
  • R 2 represents C 3-6 Cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-l,4-benzodioxinyl, 1,3- benzodioxolyl, 2,3-dihydrobenzofuranyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C 3-6 Cycloalkyl, phenyl, naphtalenyl, 2,3- dihydro-l,4-benzodioxinyl, 1,3-benzodioxolyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms may optionally be substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently selected from hydroxyl; carboxyl; halo; Ci_ 6 alkyl optionally substituted with
  • the present invention further relates to the use of a compound of formula (I'") for the manufacture of a medicament for the prevention or the treatment of a disease mediated by DGAT, in particular the present invention relates to the use of a compound of formula (F") for the manufacture of a medicament for the prevention or the treatment of a disease which can benefit from inhibition of DGAT, in particular for the treatment of a disease which can benefit from inhibition of DGAT, in particular DGATl, wherein the compound of including any stereochemical ⁇ isomeric form thereof, wherein
  • A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom;
  • Z represents a bivalent radical selected from Ci_6alkanediyl, C2-6alkenediyl or C2-6alkynediyl; wherein each of said Ci_6alkanediyl, C2-6alkenediyl or C2-6alkynediyl may optionally be substituted with hydroxyl or amino; and wherein two hydrogen atoms attached to the same carbon atom in Ci_6alkanediyl may optionally be replaced by Ci_6alkanediyl;
  • R x represents hydrogen or Ci_ 4 alkyl
  • R 1 represents adamantanyl, C 3 - 6 cycloalkyl; aryl 1 or Het 1 ;
  • R 2 represents hydrogen, Ci_ 6 alkyl, C 2 - 6 alkenyl, C 3 _ 6 Cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-l,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C 3 _ 6 Cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-l,4-benzodioxinyl, 1,3-benzodioxolyl or 6-membered aromatic heterocycle containing 1 or 2 N atoms may optionally be substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently selected from hydroxyl; carboxyl; halo; Ci_6alkyl optionally substituted with hydroxy; polyhaloCi- ⁇
  • R 4 represents hydrogen or Ci_ 4 alkyl
  • R 5 represents hydrogen; Ci_ 4 alkyl; Ci_ 4 alkylcarbonyl;
  • R 6 represents hydrogen or Ci_ 4 alkyl
  • aryl 1 represents phenyl, naphthalenyl or fluorenyl; each of said phenyl, naphthalenyl or fluorenyl optionally substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with carboxyl,
  • the present invention also relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of a disease mediated by DGAT, in particular the present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of a disease which can benefit from inhibition of DGAT, in particular for the treatment of a disease which can benefit from inhibition of DGAT, in particular DGATl.
  • the present invention also relates to the use of a compound of formula (I) or (I'") for the manufacture of a medicament for the prevention or the treatment of a disease which can benefit from elevated levels of one or more satiety hormones, in particular GLP-I, in particular the present invention relates to the use of a compound of formula (I) or (F") for the manufacture of a medicament for the treatment of a disease which can benefit from elevated levels of GLP-I.
  • Co-3alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 0 (then it represents a direct bond) to 3 carbon atoms such as methyl, ethyl, propyl, 1 -methyl- ethyl;
  • Ci_ 2 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having 1 or 2 carbon atoms such as methyl, ethyl;
  • Ci_4alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as methyl, ethyl, propyl, 1-methylethyl, butyl;
  • Ci_salkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 5 carbon atoms such as the group defined for Ci_ 4 alkyl and pentyl, 2-methylbutyl and the like
  • halo is generic to fluoro, chloro, bromo and iodo.
  • polyhaloCi- ⁇ alkyl as a group or part of a group is defined as Ci_ 6 alkyl substituted with one or more, such as for example 2, 3, 4 or 5 halo atoms, for example methyl substituted with one or more fluoro atoms, for example, difluoromethyl or trifluoromethyl, 1,1-difluoro-ethyl, l,l-difluoro-2,2,2-trifluoro-ethyl and the like.
  • halogen atoms are attached to a Ci_6alkyl group within the definition of polyhaloCi- ⁇ alkyl, they may be the same or different.
  • Oxo means 0.
  • unsubstituted monocyclic heterocycles comprise, but are not limited to, non-aromatic (fully saturated or partially saturated) or aromatic A-, 5-, 6- or 7-membered monocyclic heterocycles such as for example azetidinyl, tetrahydrofuranyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, thiazolidinyl, tetrahydrothienyl, dihydrooxazolyl, isothiazolidinyl, isoxazolidinyl, oxadiazolidinyl, triazolidinyl, thiadiazolidinyl, pyrazolidinyl, piperidinyl, hexahydropyrimidinyl, hexahydropyrazinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl, hexahydrodiaze
  • unsubstituted bicyclic or tricyclic heterocycles comprise, but are not limited to, non- aromatic (fully saturated or partially saturated) or aromatic 8- to 17-membered bicyclic or tricyclic heterocycles such as for example decahydroquinolinyl, octahydroindolyl, 2,3-dihydrobenzofuranyl, 1,3-benzodioxolyl, 2,3-dihydro-l,4-benzodioxinyl, indolinyl, benzofuryl, isobenzofuryl, benzothienyl, isobenzothienyl, indolizinyl, indolyl, isoindolyl, benzoxazolyl, benzimidazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, benzopyrazolyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl, be
  • Examples of a 6-membered aromatic heterocycle containing 1 or 2 N atoms in the definition of R 2 are pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl.
  • each definition is independent.
  • Het or Het 1 is meant to include all the possible isomeric forms of the heterocycles, for instance, pyrrolyl comprises lH-pyrrolyl and 2H-pyrrolyl.
  • the carbocycles or heterocycles covered by for instance the terms aryl, aryl 1 , Het, Het 1 or R 3 may be attached to the remainder of the molecule of formula (I) through any ring carbon or heteroatom as appropriate, if not otherwise specified.
  • the heterocycle when the heterocycle is imidazolyl, it may be 1-imidazolyl, 2-imidazolyl, 4-imidazolyl and the like, or when the carbocycle is naphthalenyl, it may be 1-naphthalenyl,
  • N ,A X is linked to the ring moiety ⁇ — ⁇ .
  • salts of the compounds of formula (I) are those wherein the counterion is pharmaceutically acceptable.
  • salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
  • the pharmaceutically acceptable salts as mentioned hereinbefore or hereinafter are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form.
  • the latter can conveniently be obtained by treating the base form with such appropriate acids as inorganic acids, for example, hydrohalic acids, e.g.
  • hydrochloric, hydrobromic and the like sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxy- acetic, 2-hydroxypropanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-l,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfonic,
  • the compounds of formula (I) containing acidic protons may be converted into their therapeutically active non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases.
  • the pharmaceutically acceptable salts as mentioned hereinbefore or hereinafter are meant to also comprise the therapeutically active non-toxic metal or amine addition salt forms (base addition salt forms) which the compounds of formula (I) are able to form.
  • Appropriate base addition salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g.
  • primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline, the benzathine, JV-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-l,3- propanediol, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
  • salt form can be converted by treatment with acid into the free acid form.
  • salt also comprises the quaternary ammonium salts (quaternary amines) which the compounds of formula (I) are able to form by reaction between a basic nitrogen of a compound of formula (I) and an appropriate quaternizing agent, such as, for example, an optionally substituted Ci_6alkylhalide, arylhalide, Ci_6alkyl- carbonylhalide, arylcarbonylhalide, or arylCi- ⁇ alkylhalide, e.g. methyliodide or benzyliodide.
  • an appropriate quaternizing agent such as, for example, an optionally substituted Ci_6alkylhalide, arylhalide, Ci_6alkyl- carbonylhalide, arylcarbonylhalide, or arylCi- ⁇ alkylhalide, e.g. methyliodide or benzyliodide.
  • Ci_6alkyl trifluoromethanesulfonates Ci_6alkyl methanesulfo nates
  • Ci_6alkyl/?-toluenesulfonates Ci_6alkyl trifluoromethanesulfonates
  • Ci_6alkyl methanesulfo nates Ci_6alkyl/?-toluenesulfonates.
  • a quaternary amine has a positively charged nitrogen.
  • Pharmaceutically acceptable counterions include chloro, bromo, iodo, trifluoroacetate, acetate, triflate, sulfate, sulfonate.
  • the counterion of choice can be introduced using ion exchange resins.
  • solvate comprises the hydrates and solvent addition forms which the compounds of formula (I) are able to form, as well as the salts thereof. Examples of such forms are e.g. hydrates, alcoholates and the like.
  • iV-oxide forms of the present compounds are meant to comprise the compounds of formula (I) wherein one or several tertiary nitrogen atoms are oxidized to the so-called iV-oxide.
  • stereochemically isomeric forms as used hereinbefore or hereinafter defines all the possible stereoisomeric forms which the compounds of formula (I), and their TV-oxides, salts, or solvates may possess.
  • the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure as well as each of the individual isomeric forms of formula (I) and their TV-oxides, salts or solvates, substantially free, i.e. associated with less than 10%, preferably less than 5%, in particular less than 2% and most preferably less than 1% of the other isomers.
  • a compound of formula (I) is for instance specified as (E)
  • this means that the compound is substantially free of the (Z) isomer.
  • stereogenic centers may have the R- or S-conf ⁇ guration; substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or transconfiguration.
  • Compounds encompassing double bonds can have an E (ent ought) or Z (zusammen) -stereochemistry at said double bond.
  • the terms cis, trans, R, S, E and Z are well known to a person skilled in the art.
  • an R or S descriptor is assigned (based on Cahn-Ingold-Prelog sequence rule) to the lowest-numbered chiral center, the reference center.
  • the configuration of the second stereogenic center is indicated using relative descriptors [R*,R* ] or [i?*,i_>*], where the first R* is always specified as the reference center and [R*,R*] indicates centers with the same chirality and [i?*,i_>*] indicates centers of unlike chirality.
  • the stereo descriptor would be specified as S-[R *,S* ⁇ . If " ⁇ " and " ⁇ ” are used : the position of the highest priority substituent on the asymmetric carbon atom in the ring system having the lowest ring number, is arbitrarily always in the " ⁇ " position of the mean plane determined by the ring system.
  • the position of the highest priority substituent on the other asymmetric carbon atom in the ring system relative to the position of the highest priority substituent on the reference atom is denominated " ⁇ ", if it is on the same side of the mean plane determined by the ring system, or " ⁇ ", if it is on the other side of the mean plane determined by the ring system.
  • the compounds of (I) may be synthesized in the form of racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures.
  • the racemic compounds of formula (I) may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali.
  • An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography using a chiral stationary phase.
  • Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.
  • Preferably if a specific stereoisomer is desired said compound will be synthesized by stereospecif ⁇ c methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
  • R 2 represents C 3-6 Cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-l,4-benzodioxinyl, 1,3- benzodioxolyl, wherein said C 3-6 Cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-l,4- benzodioxinyl, 1,3-benzodioxolyl may optionally be substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently selected from hydroxyl; carboxyl; halo; Ci_ 6 alkyl optionally substituted with hydroxy; polyhalod- ⁇ alkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhalo-Ci_6alkyloxy; Ci_6alkyloxycarbonyl wherein Ci_ 6 alkyl may optionally be substituted with ary
  • R 6 R 5 N-Ci_ 4 alkyl; Ci_ 4 alkyloxy; Het; aryl; R 6 R 5 N-C( O)-Ci_ 4 alkyl;
  • R represents hydrogen or Ci_ 4 alkyl
  • R , 5 represents hydrogen; Ci_ 4 alkyl; Ci_ 4 alkylcarbonyl; R 6 represents hydrogen or Ci_ 4 alkyl; or
  • a third embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein A represents N.
  • a fourth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein A represents CH, in particular wherein A represents CH and the dotted line does not represent a bond.
  • a sixth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein R 2 represents d- ⁇ cycloalkyl, phenyl, 2,3-dihydro-l,4-benzodioxinyl or a 6- membered aromatic heterocycle containing 1 or 2 N atoms such as for example pyridyl, wherein said phenyl or heterocycle are optionally substituted with one to four substituents, preferably each substituent independently selected from halo, d- ⁇ alkyl, Ci_6alkyloxy, Ci_6alkylthio, Ci_6alkyloxycarbonyl, nitro, amino, mono- or di(Ci_
  • a seventh embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein the compound of formula (I) is a compound of formula (F)
  • An eighth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein the compound of formula (I) is a compound of formula (I")
  • R 3a and R 3a each independently represent hydrogen; hydroxyl; carboxyl; halo; Ci_ 6 alkyl; polyhaloCi- ⁇ alkyl; Ci_ 6 alkyloxy optionally substituted with Ci_ 4 alkyloxy;
  • Ci_6alkylthio; polyhaloCi- ⁇ alkyloxy; Ci_6alkyloxycarbonyl; cyano; aminocarbonyl; mono-or di(Ci_ 4 alkyl)aminocarbonyl; Ci_ 6 alkylcarbonyl; nitro; amino; mono-or di(Ci_ 4 alkyl)amino; -S( O) p -Ci_ 4 alkyl; and wherein R 3c represents hydrogen; hydroxyl; carboxyl; halo; Ci_ 6 alkyl; polyhaloCi- ⁇ alkyl; Ci_ 6 alkyloxy optionally substituted with Ci_ 4 alkyloxy; Ci_6alkylthio; polyhalo-Ci_6alkyloxy; Ci_6alkyloxycarbonyl wherein
  • a nineth embodiment of the present invention are those compounds of formula (I) or any subgroup thereof as mentioned hereinbefore as embodiment wherein the compound of formula (I) is a compound of formula (F) or (I") and wherein R 3a and R 3b each independently represent halo, Ci_ 6 alkyl or Ci_ 6 alkyloxy; in particular halo or Ci_ 6 alkyl; mmoorree iinn pplorttiiccuullaair both R 3a and R 3b represent halo, more in particular both R 3a and R 3b represent chloro.
  • An eleventh embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein p represents 2.
  • a twelfth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein Z represents Ci_6alkanediyl or C2-6alkenediyl, in particular Ci_6alkanediyl, more in particular -CH 2 -.
  • a thirteenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein R x represents hydrogen.
  • a sixteenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein R 7 represents hydrogen.
  • a seventeenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein R 7 represents halo, Ci_4alkyl or Ci_4alkyl substituted with hydroxyl; in particular halo.
  • An eightteenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein aryl represents phenyl or phenyl substituted with halo, Ci_ 6 alkyl, polyhaloCi- ⁇ alkyl or Ci_ 6 alkyloxycarbonyl.
  • aryl 1 represents phenyl or fluorenyl, said phenyl or fluorenyl optionally substituted with halo, Ci_6alkyl or polyhaloCi- ⁇ alkyl;
  • Het 1 represents a A-, 5-or 6-membered non-aromatic or aromatic heterocycle, such as for example azetidinyl, thiazolidinyl, thiazolyl, pyrrolidinyl, piperidinyl, said 5- or 6- membered heterocycle optionally substituted with hydroxyl, oxo, C ⁇ alkyl, Ci_ 6 alkyloxycarbonyl, aryl or Het;
  • R 7 represents hydrogen.
  • Preferred compounds of formula (I) are selected from
  • Another embodiment of the present invention is the use of a compound of formula (F") as indicated hereinabove, wherein the compound of formula (F") is a compound wherein R 2 represents hydrogen, Ci_ 6 alkyl or C 2 - 6 alkenyl.
  • the above reaction can be performed as a fast synthesis reaction thereby using appropriate reagents well-known for fast synthesis, such as for example dicyclohexylcarbodiimide (DCC) linked to an appropriate carrier, e.g. polystyrene.
  • appropriate fast-synthesis reagents can be used, such as for example l-ethenyl-4-(isocyanatomethyl)-benzene polymer with ethenylbenzene.
  • Compounds of formula (I-a) can also be prepared by reacting an intermediate of formula (II) with an intermediate of formula (HF) wherein Wi represents a suitable leaving group, such as for example halo, e.g. chloro and the like, in the presence of a suitable base, such as for example sodium hydride, sodium bicarbonate, N 5 N- diisopropyl-ethanamine or N,N-diethyl-ethanamine, and a suitable solvent, such as for example N,N-dimethylformamide, dichloromethane, acetonitrile or tetrahydrofuran
  • a suitable base such as for example sodium hydride, sodium bicarbonate, N 5 N- diisopropyl-ethanamine or N,N-diethyl-ethanamine
  • a suitable solvent such as for example N,N-dimethylformamide, dichloromethane, acetonitrile or tetrahydrofuran
  • a suitable solvent such as for example acetonitrile, N 5 N- dimethylformamide or dichloromethane or an alcohol, e.g. methanol
  • a suitable base such as for example N,N-diethyl-ethanamine.
  • Intermediates of formula (IV) are commercially available or can be prepared by reacting R 2 -Xi- ⁇ H2 with phosgene in the presence of a suitable
  • the above reaction can also be performed as a fast synthesis reaction thereby using appropriate reagents well-known for fast synthesis, such as for example for the purif ⁇ cation of the reaction mixture l-ethenyl-4-(isocyanatomethyl)-benzene polymer with ethenylbenzene and tris-2-aminoethylamine linked to polystyrene can be used.
  • a suitable solvent such as for example toluene or acetonitrile
  • a suitable solvent such as for example acetonitrile, N, ⁇ /-d
  • a suitable base such as for example N,7V-diethyl-ethanamine
  • a suitable solvent such as for example dichloromethane or tetrahydrofuran.
  • a suitable base such as for example JV, ⁇ /-diethyl-ethanamine
  • a suitable solvent such as for example N, ⁇ /-dimethylformamide.
  • Compounds of formula (I-d) wherein Xi represents a direct bond, said compounds being represented by formula (I-d-1), can be prepared by reacting an intermediate of formula (VIF) wherein Wi represents a suitable leaving group, such as for example halo, e.g. chloro and the like, with an intermediate of formula (V) in the presence of a suitable base, such as for example N-methyl morpholine, and a suitable solvent, such as
  • a suitable base such as for example JV,jV-diisopropyl-ethanamine or ⁇ jV-diethyl-ethanamine
  • a suitable solvent such as for example dichloromethane.
  • a suitable solvent such as for example acetonitrile
  • a suitable base such as for example pyridine
  • a suitable solvent such as example dichloromethane
  • Compounds of formula (I) wherein the R 1 substituent is substituted with amino can be prepared from the corresponding compound wherein the amino function is protected by a suitable protecting group, such as for example a tertiair butyloxycarbonyl group, in the presence of a suitable acid, such as for example trifluoroacetic acid, and a suitable solvent, such as for example dichloromethane.
  • a suitable protecting group such as for example a tertiair butyloxycarbonyl group
  • a suitable acid such as for example trifluoroacetic acid
  • a suitable solvent such as for example dichloromethane
  • a suitable base such as for example N,7V-diethyl-ethanamine or N,7V-diisopropyl-ethanamine
  • a suitable solvent such as for example dichloromethane or acetonitrile.
  • the compounds of formula (I) may further be prepared by converting compounds of formula (I) into each other according to art-known group transformation reactions.
  • the compounds of formula (I) may be converted to the corresponding TV-oxide forms following art-known procedures for converting a trivalent nitrogen into its /V-oxide form.
  • Said /V-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide.
  • Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide;
  • appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboper- oxoic acid or halo substituted benzenecarboperoxoic acid, e.g.
  • 3-chlorobenzenecarbo- peroxoic acid peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. tert.butyl hydro-peroxide.
  • Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.
  • This reaction can also be performed as a fast synthesis reaction thereby using appropriate reagents well-known for fast synthesis, such as for example dicyclohexylcarbodiimide (DCC) or carbonyl diimidazole (CDI), linked to an appropriate carrier, e.g. polystyrene.
  • appropriate fast-synthesis reagents can be used, such as for example l-ethenyl-4- (isocyanatomethyl)-benzene polymer with ethenylbenzene.
  • the compounds of formula (I) and some of the intermediates in the present invention may contain an asymmetric carbon atom.
  • Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures.
  • diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter current distribution, chiral liquid chromatography and the like methods.
  • Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective crystallization or chromatographic techniques, e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the corresponding enantiomers.
  • Pure stereochemically isomeric forms may also be obtained from the pure stereochemically isomeric forms of the appropriate intermediates and starting materials, provided that the intervening reactions occur stereospecifically.
  • An alternative manner of separating the enantiomeric forms of the compounds of formula (I) and intermediates involves liquid chromatography or SCF (Super Critical Fluid) chromatography, in particular using a chiral stationary phase.
  • a suitable protecting group such as for example tertiair butyloxycarbonyl
  • a suitable solvent such as for example dichloromethane
  • the intermediate of formula (IX) can optionally be converted into an intermediate of formula (IX') by reaction with Ci_4alkyl halide, e.g. CH3I, in the presence of a suitable base, such as for example NaH, and a suitable solvent, such as for example N, ⁇ /-dimethylformamide.
  • Ci_4alkyl halide e.g. CH3I
  • a suitable base such as for example NaH
  • a suitable solvent such as for example N, ⁇ /-dimethylformamide.
  • Intermediates of formula (II-a) wherein R x represents hydrogen, said intermediates being represented by formula (II-a-1), can be prepared by reacting an intermediate of formula (IV) with an intermediate of formula (X) in the presence of a suitable solvent, such as for example dichloromethane, followed by hydrogenating (H 2 or N 2 H 4 . H 2 O) the resulting intermediate of formula (XI) in the presence of a suitable catalyst, such as for example platinum on charcoal or raney nickel, optionally a suitable catalyst poison, such as for example a thiophene solution, and a suitable solvent, such as for example tetrahydrofuran or an alcohol, e.g. methanol.
  • a suitable solvent such as for example dichloromethane
  • the intermediate of formula (XI) can optionally be converted into an intermediate of formula (XF) by reaction with Ci_4alkyl halide, e.g. CH3I, in the presence of a suitable base, such as for example NaH, and a suitable solvent, such as for example ⁇ /,iV-dimethylformamide.
  • Ci_4alkyl halide e.g. CH3I
  • a suitable base such as for example NaH
  • a suitable solvent such as for example ⁇ /,iV-dimethylformamide.
  • a suitable base such as for example JV,jV-diethyl-ethanamine
  • a suitable solvent such as for example toluene
  • the resulting intermediate of formula (XX) in the presence of a suitable catalyst, such as for example platinum on charcoal or raney nickel, optionally a suitable catalyst poison, such as for example a thiophene solution, and a suitable solvent, such as for example tetrahydrofuran or an alcohol, e.g. methanol.
  • a suitable catalyst such as for example platinum on charcoal or raney nickel
  • a suitable catalyst poison such as for example a thiophene solution
  • a suitable solvent such as for example tetrahydrofuran or an alcohol, e.g. methanol.
  • the intermediate of formula (XX) can optionally be converted into an intermediate of formula (XX') by reaction with Ci_4alkyl halide, e.g. CH3I, in the presence of a suitable base, such as for example NaH, and a suitable solvent, such as for example ⁇ /,iV-dimethylformamide.
  • a suitable catalyst such as for example platina on charcoal
  • a suitable catalyst poison such as for example thiophene
  • a suitable solvent such as for example acetic acid.
  • Intermediates of formula (III) can be prepared by hydro lizing an intermediate of formula (XII) with a suitable base, such as for example potassium hydroxide or sodium hydroxide, in the presence of a suitable solvent, such as for example water, tetrahydrofuran, dioxane or an alcohol, e.g. methanol.
  • a suitable base such as for example potassium hydroxide or sodium hydroxide
  • a suitable solvent such as for example water, tetrahydrofuran, dioxane or an alcohol, e.g. methanol.
  • R 1 represents Het 1 wherein said Het 1 is a heterocycle substituted with optionally substituted phenyl or an optionally substituted heterocycle
  • a suitable catalyst such as for example palladium acetate
  • a suitable catalyst ligand such as for example l,l '-(l,5-pentanediyl)bis[l,l '- diphenylphosphine]
  • a suitable base such as for example potassium acetate
  • a suitable solvent such as for example JV-methyl-pyrrolidin-2-one or by reacting the optionally substituted heterocyle with optionally substituted phenyl carrying a suitable leaving group, such as for example halo, e.g.
  • bromo, iodo and the like or an optionally substituted heterocylce carrying a suitable leaving group, such as for example halo, e.g. bromo, iodo and the like, in the presence of a suitable catalyst, such as for example palladium acetate, in the presence of a suitable catalyst ligand, such as for example 1,3- propanediylbis[diphenylphosphine], a suitable base, such as for example potassium acetate or cesium carbonate, and a suitable solvent, such as for example JV-methyl- pyrrolidin-2-one.
  • a suitable catalyst such as for example palladium acetate
  • a suitable catalyst ligand such as for example 1,3- propanediylbis[diphenylphosphine]
  • a suitable base such as for example potassium acetate or cesium carbonate
  • a suitable solvent such as for example JV-methyl- pyrrolidin-2-one.
  • a suitable base such as for example N, JV-diethyl-ethanamine
  • a suitable solvent such as for example dichloromethane
  • (V-a) Intermediates of formula (V-a) can also be prepared by reacting an intermediate of formula (XIII) with an intermediate of formula (III) in the presence of a suitable activating agent, such as for example oxalyl chloride, in the presence of a suitable base, such as for example JV,jV-diethyl-ethanamine, and a suitable solvent, such as for example dichloromethane or ⁇ /, ⁇ f-dimethylformamide, followed by deprotecting the resulting intermediate of formula (XV) with H 2 in the presence of a suitable catalyst, such as for example palladium on charcoal, and a suitable solvent, such as for example tetrahydrofuran and/or a suitable alcohol, e.g. methanol.
  • a suitable activating agent such as for example oxalyl chloride
  • a suitable base such as for example JV,jV-diethyl-ethanamine
  • a suitable solvent such as for example dichloromethane or ⁇ /,
  • Deprotection can also be performed in the presence of 1-chloroethyl carbonochloridic acid ester as deprotecting agent in the presence of a suitable solvent such as for example dichloroethane and an alcohol, e.g. methanol.
  • a suitable solvent such as for example dichloroethane and an alcohol, e.g. methanol.
  • Intermediates of formula (V-a) can also be prepared according to the following reaction scheme wherein an intermediate of formula (XXI) wherein P represents a suitable protecting group, such as for example benzyloxycarbonyl or tertiair butyloxy or benzyl, and wherein W 6 represents a suitable leaving group, such as for example halo, e.g.
  • said intermediate of formula (XXIII) is reacted with an intermediate of formula (XIV) in the presence of a suitable base, such as for example NaHCO 3 , and a suitable solvent, such as for example acetonitrile, resulting in an intermediate of formula (XXIV), which is deprotected in a next step in the presence of H 2 , a suitable catalyst, such as for example palladium on charcoal, and a suitable solvent, such as for example an alcohol, e.g.
  • a suitable base such as for example NaHCO 3
  • a suitable solvent such as for example acetonitrile
  • a suitable base such as for example N,N- diethyl- ethanamine or ⁇ f-diisopropyl-ethanamine
  • a suitable solvent such as for example dichloromethane or ⁇ '-dimethylformamide.
  • an intermediate of formula (III) can react with an intermediate of formula (XXIII) in the presence of a suitable dehydrating (coupling) agent, such as for example ⁇ 7> -(ethylcarbonimidoyl)- ⁇ /, ⁇ 7 - dimethyl-l,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), l-[bis(di-methylamino)methylene]-lH- benzotriazo liumhexafluorophosphate( 1 -)3 -oxide (HBTU), 1 - [bis(dimethyl- amino)methylene]-5-chloro-lH-benzotriazolium-hexafluorophosphate(l-) 3-oxide (HCTU), O-benzotriazolyl tetramethylisouronium tetrafluoroborate (TBTU) or diethyl cyanophosphonate (
  • the intermediate of formula (XXIV) can also react with an Ci_ 4 alkyl halide, e.g. CH 3 I, in the presence of a suitable base, such as for example NaH, and a suitable solvent, such as for example N, ⁇ /-dimethylformamide, to form an intermediate of formula (XXIV) which can be deprotected according to the above described protocol to result in an intermediate of formula (V-a').
  • a suitable base such as for example NaH
  • a suitable solvent such as for example N, ⁇ /-dimethylformamide
  • a suitable acid such as for example HCl, trifluoroacetic acid and the like
  • a suitable solvent such as for example an alcohol, e.g. isopropanol, or dichloromethane.
  • ⁇ CTU O-benzotriazolyl tetramethylisouronium tetrafluoroborate
  • DECP diethyl cyanophosphonate
  • a suitable solvent such as for example N,N- dimethylformamide, dichloromethane, acetonitrile or tetrahydrofuran
  • a suitable base such as for example JV,jV-diisopropyl-ethanamine or JV,iV-diethyl-ethanamine.
  • the resulting intermediate of formula (XXXIV) can then be reduced in a next step in the presence of a suitable reducing agent, such as for example borane, in the presence of a suitable solvent, such as for example tetrahydrofuran, to an intermediate of formula (XXXV), which can then be converted into an intermediate of formula (IV-a) with phosgene in the presence of HCl in diethylether and a suitable solvent, such as for example toluene or acetonitrile.
  • a suitable reducing agent such as for example borane
  • a suitable solvent such as for example tetrahydrofuran
  • Intermediates of formula (XXXIV) can also be converted into an intermediate of formula (IV-b) with phosgene in the presence of HCl in diethylether and a suitable solvent, such as for example toluene or acetonitrile or dichloromethane.
  • Intermediates of formula (IV-a) can also be prepared by reacting an intermediate of formula (XXXII) with an intermediate of formula (XXXVI) wherein W 4 represents a suitable leaving group, such as for example halo, e.g. chloro and the like, in the presence of a suitable solvent, such as for example acetonitrile, resulting in an intermediate of formula (XXXV) with can be converted into an intermediate of formula (IV-a) as described hereinabove for intermediate (XXXV).
  • Intermediates of formula (VII) can be prepared by hydrolysis of an intermediate of formula (XL) in the presence of LiOH, an acid, such as for example HCl, and a suitable solvent, such as for example an alcohol, e.g. methanol.
  • Intermediates of formula (XL) wherein R 2 contains Het-Ci_ 4 alkyl as substituent, said intermediates being represented by formula (XL-a) can be prepared by reacting an intermediate of formula (XLI) wherein W5 represents a suitable leaving group, such as for example halo, e.g. bromo and the like, with an intermediate of formula (XXXII).
  • Intermediates of formula (XLI- a) as depicted below, can be prepared by reacting an intermediate of formula (XLII) with N-bromosuccinimide in the presence of 2,2'-(l,2-diazenediyl)bis[2- methylpropanenitrile] and a suitable solvent, such as for example CCl 4 .
  • Intermediates of formula (XLII) wherein Xi represents CH 2 said intermediates being represented by formula (XLII-a)
  • Intermediates of formula (XLV) can be prepared by reacting an intermediate of formula (IV '-a) with 1,1-dimethylethyl-nitrous acid ester, CuCl 2 , 1,1-dichloroethene in a suitable solvent, such as for example acetonitrile.
  • Intermediates of formula (XXXVII) can be prepared by reacting an intermediate of formula (IV) with an intermediate of formula (XXXVIII) in the presence of a suitable base, such as for example JV,jV-diethyl-ethanamine, and a suitable solvent, such as for example dichloromethane.
  • a suitable base such as for example sodium hydroxide
  • a suitable solvent such as for example dioxane and optionally an alcohol, e.g. methanol.
  • Intermediates of formula (XXXVII- a) can be prepared by reacting an intermediate of formula (IX) with an intermediate of formula (XXXVIII) in the presence of a suitable dehydrating (coupling) agent, such as for example ⁇ /"-(ethylcarbonimidoyl)- ⁇ /,iV-dimethyl- 1 ,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), 1 - [bis(di-methylamino)methylene] - lH-benzotriazo liumhexafluorophosphate( 1 - )3-oxide ( ⁇ BTU), 1 -[bis(dimethyl-amino)methylene]-5-chloro- lH-benzotriazolium- hexafluorophosphate(l-) 3-oxide ( ⁇ CTU), O-benzotriazolyl tetra
  • Said intermediate is in a next step reacted with an intermediate of formula (XLVIII) wherein P represents a suitable leaving group, such as for example benzyl, in the presence of Na 2 CCh and a suitable solvent, such as for example N, ⁇ /-dimethylformamide resulting in an intermediate of formula (XLIX).
  • said intermediate is hydrogenated with H 2 in the presence of a suitable catalyst, such as for example platinum on charcoal, a catalyst poison, such as for example thiophene, and a suitable solvent, such as for example tetrahydrofuran, resulting in an intermediate of formula (L).
  • a suitable catalyst such as for example platinum on charcoal
  • a catalyst poison such as for example thiophene
  • a suitable solvent such as for example tetrahydrofuran
  • This intermediate is then reacted with an intermediate of formula (III) in the presence of a suitable dehydrating (coupling) agent, such as for example ⁇ / I -(ethylcarbonimidoyl)-iV,jV- dimethyl- 1,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), l-[bis(di-methylamino)methylene]-lH- benzotriazo liumhexafluorophosphate( 1 -)3 -oxide (HBTU), 1 - [bis(dimethyl- amino)methylene]-5-chloro-lH-benzotriazolium-hexafluorophosphate(l-) 3-oxide (HCTU), O-benzotriazolyl tetramethylisouronium tetrafluoroborate (TBTU) or diethyl cyanophosphonate (DECP), optionally combined
  • a suitable base such as for example JV,jV-diethyl-ethanamine
  • a suitable solvent such as for example N,N- dimethylformamide.
  • This reaction can be performed as a fast synthesis reaction thereby using appropriate reagents well-known for fast synthesis, such as for example dicyclohexylcarbodiimide (DCC) linked to an appropriate carrier, e.g. polystyrene.
  • DCC dicyclohexylcarbodiimide
  • the intermediate of formula (LI) is deprotected with H 2 , in the presence of a suitable catalyst, such as for example palladium on charcoal, a suitable base, such as for example N,7V-diethyl-ethanamine, and a suitable solvent, such as for example tetrahydrofuran resulting in an intermediate of formula (LII) which can in a next step be reacted with an intermediate of formula (IV) in the presence of a suitable solvent, such as for example dichloro methane, to obtain an intermediate of formula (XLIII-a).
  • a suitable catalyst such as for example palladium on charcoal
  • a suitable base such as for example N,7V-diethyl-ethanamine
  • a suitable solvent such as for example tetrahydrofuran
  • Intermediates of formula (XLIV-a) can be prepared by reacting an intermediate of formula (VII) wherein Xi is substituted with a protected (P, such as for example teriair butyloxycarbonyl) amino group, said intermediate being represented by formula (VII- a), with an intermediate of formula (V) in the presence of a suitable dehydrating (coupling) agent, such as for example ⁇ /"-(ethylcarbonimidoyl)- ⁇ /, ⁇ /-dimethyl-l,3- propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), l-[bis(di-methylamino)methylene]-lH- benzotriazo liumhexafluorophosphate( 1 -)3 -oxide (HBTU), 1 - [bis(dimethyl- amino)methylene]-5-chloro-lH-benzotriazolium-
  • Intermediates of formula (VII) wherein Xi represents CHOH said intermediates being represented by formula (VII-b) can be prepared by reducing an intermediate of formula (LIU) in the presence Of ZnBr 2 , Si(CHs) 3 -CN and an acid, such as for example HCl, in the presence of a suitable solvent, such as for example dichloromethane.
  • Intermediates of formula (LIII) can be prepared by reacting an intermediate of formula (LIV) wherein Wi3 represents a suitable leaving group, such as for example halo, e.g. bromo and the like, with N, ⁇ /-dimethylformamide in the presence of BuLi and a suitable solvent, such as for example tetrahydrofuran.
  • the present invention relates to the use of a DGAT inhibitor, in particular a DGATl inhibitor, to elevate levels of one or more satiety hormones, in particular GLP-I levels.
  • the present invention also relates to the use of a DGAT inhibitor, in particular a DGATl inhibitor, for the manufacture of a medicament for the prevention or the treatment, in particular for the treatment, of a disease which can benefit from an elevated level of one or more satiety hormones, in particular a disease which can benefit from an elevated GLP-I level.
  • GLP-I levels are elevated in plasma or in portal blood, more in particular in plasma.
  • GLP-I plasma level or an elevated GLP-I level in portal blood it is meant that the GLP-I level of a subject having taken a DGATl inhibitor is elevated or increased compared to the subject under the same conditions but not having taken the DGATl inhibitor.
  • GLP-I levels are elevated in fasting conditions or postprandial, more in particular postprandial.
  • Therapeutic uses for a compound which elevates GLP-I level include, but are not limited to, improving learning, enhancing neuro -protection, and/or alleviating a symptom of a disease or disorder of the central nervous system, e.g., through modulation of neurogenesis, and e.g., Parkinson's Disease, Alzheimer's Disease, Huntington's Disease, ALS, stroke, hemorrhage, cerebrovascular accident, ADD, and neuropsychiatric syndromes; converting liver stem/progenitor cells into functional pancreatic cells; preventing beta-cell deterioration and stimulation of beta-cell proliferation; treating pancreatitis; treating obesity; suppressing appetite and inducing satiety; treating irritable bowel syndrome or inflammatory bowel disease such as Crohn's disease and ulcerative colitis; reducing the morbidity and/or mortality associated with myocardial infarction and stroke; treating acute coronary syndrome characterized by an absence of Q-wave myocardial infarction; attenuating post-surgical catabo
  • GLP-I cerebral heart disease risk factor
  • Further diseases which can benefit from an elevated GLP-I level include, but are not limited to, ischemic myocardial stunning; ishemic/reperfusion injury; acute myocardial infarction; left ventricular dysfunction; vascular disease; neuropathy, including periphere sensoric neuropathy associated with type II diabetes; bone-related disorders, including osteoporosis, obesity, diabetes. Because of the effect on GLP-I, the DGAT inhibitors can also be used to provide cardioprotection. References supporting the above indications include Experimental Neurology, Vol.
  • the present compounds of formula (I), their JV-oxide forms, their pharmaceutically acceptable salts or their solvates can be used as a medicine.
  • the present invention relates to a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof for use as a medicine, in particular for use as a medicine for the prevention or the treatment of a disease which can benefit from an elevated GLP-I level.
  • the present invention also relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of a disease which can benefit from an elevated GLP-I level, such as the diseases and disorders mentioned above.
  • a method of treating a warm-blooded mammal, including a human, suffering from or a method of preventing a warm-blooded mammal, including a human, to suffer from a disease which can benefit from an elevated level of GLP-I in particular a method of treating a warm-blooded mammal, including a human, suffering from a disease which can benefit from an elevated level of GLP-I.
  • Said methods comprise the administration of an effective amount of a DGAT inhibitor, in particular a DGATl inhibitor, to a warm-blooded mammal, including a human.
  • a method of treating a warm-blooded mammal, including a human, suffering from or a method of preventing a warm-blooded mammal, including a human, to suffer from a disease which can benefit from an elevated level of GLP-I in particular a method of treating a warm-blooded mammal, including a human, suffering from a disease which can benefit from an elevated level of GLP-I .
  • Said methods comprise the administration of an effective amount of a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, to a warmblooded mammal, including a human.
  • the present invention also relates to a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof for use as a medicine, in particular for use as a medicine for the prevention or the treatment of a diseases which can benefit from inhibition of DGAT, in particular DGATl.
  • the invention also relates to the use of a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, for the manufacture of a medicament for the prevention or the treatment of a disease or disorder which can benefit from inhibition of DGAT, in particular DGATl .
  • DGATl Diseases or disorders which can benefit from inhibition of DGAT, in particular DGATl include, but are not limited to metabolic disorders, such as obesity and obesity related disorders (including peripheral vascular disease, cardiac failure, myocardial ischaemia, cerebral ischaemia, cardiac myopathies), diabetes, in particular type II diabetes mellitus, and complications arising therefrom (such as retinopathy, neuropathy, nephropathy), syndrome X, insulin resistance, impaired glucose tolerance, conditions of impaired fasting glucose, hypoglycemia, hyperglycemia, hyperuricemia, hyperinsulinemia, pancreatitis, hypercholesterolemia, hyperlipidemia, dyslipidemia, mixed dyslipidemia, hypertriglyceridemia and nonalcoholic fatty liver disease, fatty liver, increased mesenteric fat, non-alcoholic steatohepatitis, liver fibrosis, metabolic acidosis, ketosis, dysmetabolic syndrome; dermatological conditions such as acne, psoriasis; cardiovascular diseases, such as atherosclerosis, ar
  • DGAT diseases or disorders which can benefit from inhibition of DGAT, in particular DGATl, are selected from obesity, hypercholesterolemia, hyperlipidemia, dyslipidemia, mixed dyslipidemia, hypertriglyceridemia, fatty liver, nonalcoholic fatty liver disease, liver fibrosis, non-alcoholic steatohepatitis and diabetes, in particular type II diabetes.
  • a method of treating a warm-blooded mammal, including a human, suffering from or a method of preventing a warm-blooded mammal, including a human, to suffer from a disease which can benefit from inhibition of DGAT in particular a method of treating a warm-blooded mammal, including a human, suffering from a disease which can benefit from inhibition of DGAT.
  • Said methods comprise the administration of an effective amount of a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, to a warm-blooded mammal, including a human.
  • the present invention also provides compositions for preventing or treating a disease which can benefit from an elevated GLP-I level or which can benefit from inhibition of DGAT, in particular DGATl, in particular for treating a disease which can benefit from elevated GLP-I levels or which can benefit from inhibition of DGAT, in particular DGATl.
  • Said compositions comprise a therapeutically effective amount of a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier.
  • compositions of the present invention may be formulated into various pharmaceutical forms for administration purposes.
  • compositions there may be cited all compositions usually employed for systemically administering drugs.
  • an effective amount of the particular compound, optionally in salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection.
  • any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
  • injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations.
  • the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.
  • Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions.
  • These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment.
  • the compounds of the present invention may also be administered via inhalation or insufflation by means of methods and formulations employed in the art for administration via this way.
  • the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry powder. Any system developed for the delivery of solutions, suspensions or dry powders via oral or nasal inhalation or insufflation are suitable for the administration of the present compounds.
  • the compounds of the present invention may also be topically administered in the form of drops, in particular eye drops.
  • Said eye drops may be in the form of a solution or a suspension. Any system developed for the delivery of solutions or suspensions as eye drops are suitable for the administration of the present compounds.
  • Unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.
  • the exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.
  • the pharmaceutical composition will preferably comprise from 0.05 to 99 % by weight, more preferably from 0.1 to 70 % by weight, even more preferably from 0.1 to 50 % by weight of the compound of formula (I), and, from 1 to 99.95 % by weight, more preferably from 30 to 99.9 % by weight, even more preferably from 50 to 99.9 % by weight of a pharmaceutically acceptable carrier, all percentages being based on the total weight of the composition.
  • the present invention also relates to a) a combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a dipeptidyl peptidase-4 inhibitor (DPP- 4 inhibitor).
  • a DGAT inhibitor in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof
  • DPP- 4 inhibitor dipeptidyl peptidase-4 inhibitor
  • DPP-4 is a membrane-spanning cell surface aminopeptidase widely expressed in many tissues, such as liver, lung, kidney, intestinal brush-border membranes, lymphocytes, endothelial cells. DPP-4 cleaves peptides with a proline or alanine residue in the second aminoterminal position. Many gastro -intestinal hormones are substrates for DPP-4, among them GLP-I. A DPP-4 inhibitor thus inhibits cleavage of GLP-I and hence provides for an increase in the level of GLP-I. Therefore, a combination as indicated above can be used to combine the activity of the DGAT inhibitor and the DPP4 inhibitor in order to elevate GLP-I levels.
  • a DGAT inhibitor in particular a DGATl inhibitor, more in particular a compound of formula (I), a N- oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof
  • a DPP4 inhibitor By administering a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N- oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, with a DPP4 inhibitor, different mechanisms may be targeted in order to achieve elevated levels of GLP-I.
  • the use of such a combination may reduce the dosage of the DGAT inhibitor and the DPP4 inhibitor required for a desired elevation in GLP-I level as compared to when the DGAT inhibitor or the DPP4 inhibitor is administered as a monotherapy. Therefore, these combinations may reduce or eliminate side effects of monotherapy while not interfering with the GLP-I level increasing activity.
  • a DGAT inhibitor in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof
  • a DPP4 inhibitor can be used as a medicine.
  • the present invention also relates to a product comprising (a) a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) a DPP4 inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-I .
  • the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • Said DPP4 inhibitor which may be combined with a DGAT inhibitor according to the present invention, in particular a DGATl inhibitor may be a known DPP4 inhibitor such as for example sitagliptin, vildagliptin, and saxagliptin.
  • a combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a GLP-I analogue may be a known DPP4 inhibitor such as for example sitagliptin, vildagliptin, and saxagliptin.
  • Said GLP-I analogue can be considered as an agonist at the GLP-I receptor.
  • a DGAT inhibitor in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a GLP-I analogue can be used as a medicine.
  • the present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) a GLP-I analogue, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP- 1.
  • the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • Said GLP-I analogue which may be combined with a DGAT inhibitor according to the present invention may be a known GLP-I analogue such as for example exenatide, exenatide LAR or liraglutide.
  • a DGAT inhibitor in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an anti-diabeticum can be used as a medicine.
  • the present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an anti-diabeticum, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-I or DGAT inhibition, such as for example diabetes, in particular type II diabetes.
  • the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • Said anti-diabeticum which may be combined with a DGAT inhibitor according to the present invention may be a known anti-diabeticum such as for example metformin, glibenclamide, rosiglitazon, pioglitazon, repaglinide, glimepiride, acarbose, glicazide, glipizide, nateglinide, tolbutamide, a protein tyrosine phosphatase 1 inhibitor, or a 11-beta-hydroxysteroid dehydrogenase inhibitor, d) a combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a phosphodiesterase (PDE) inhibitor, in particular a PDElOA or PDEl IA inhibitor.
  • a known anti-diabeticum such as
  • Phosphodiesterase (PDE) inhibitors in particular PDElOA or PDEl IA inhibitors
  • PDE Phosphodiesterase
  • PDElOA or PDEl IA inhibitors are known to be insulin secretagogues, and to enhance the signalling of GLP-I by inhibition of the hydrolysis of cAMP.
  • a DGAT inhibitor in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof
  • PDE phosphodiesterase
  • the present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) a phosphodiesterase (PDE) inhibitor, in particular a PDElOA or PDEl IA inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-I or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity.
  • a DGAT inhibitor in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof
  • PDE phosphodiesterase
  • the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • Said phosphodiesterase (PDE) inhibitor in particular a PDElOA or PDEl IA inhibitor, which may be combined with a DGAT inhibitor according to the present invention may be a known PDE inhibitor such as for example papaverine, PQ-10, dipyridamole , ibudilast or tadalafil.
  • a combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an appetite suppressant e) a combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an appetite suppressant.
  • the combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an appetite suppressant can be used as a medicine.
  • the present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an appetite suppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-I or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity.
  • the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • Said appetite suppressants which may be combined with a DGAT inhibitor according to the present invention may be a known appetite suppressant such as for example sibutramine and phentermine. f) a combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an anti-obesity drug with a CNS (central nervous system) mode of action such as for example a CB 1 antagonist or inverse agonists.
  • a DGAT inhibitor in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof
  • an anti-obesity drug with a CNS (central nervous system) mode of action such as for example a CB 1 antagonist or inverse agonists.
  • a DGAT inhibitor in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an anti-obesity drug with a C ⁇ S (central nervous system) mode of action can be used as a medicine.
  • the present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an anti- obesity drug with a C ⁇ S (central nervous system) mode of action, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-I or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity.
  • the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • Said anti-obesity drugs with a C ⁇ S (central nervous system) mode of action which may be combined with a DGAT inhibitor according to the present invention may be a known a anti-obesity drug such as for example Rimonabant, orlistat, SLV-319, or MK-0364.
  • a DGAT inhibitor in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an hypolipidemic drug such as for example 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors, squalene synthase inhibitors, FXR (farnesoid X receptor) and LXR (liver X receptor) ligands, cholestyramine, fibrates, nicotinic acid and aspirin.
  • HMG-CoA 3-hydroxy-3-methyl-glutaryl coenzyme A
  • FXR farnesoid X receptor
  • LXR liver X receptor
  • a DGAT inhibitor in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an hypolipidemic drug can be used as a medicine.
  • the present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an hypolipidemic drug, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-I or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity.
  • the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • Said hypolipidemic drug which may be combined with a DGAT inhibitor according to the present invention may be a known hypolipidemic drug such as for example lovastatin, pravastatin, simvastatin, pravastatin, cerivastatin, mevastatin, velo statin, fluvastatin, dalvastatin, atorvastatin, rosuvastatin and rivastatin.
  • a DGAT inhibitor in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an agonist of peroxisome proliferator- activator receptor such as for example fenofibrate.
  • a DGAT inhibitor in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an agonist of peroxisome proliferator- activator receptor such as for example fenofibrate, can be used as a medicine.
  • the present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an agonist of peroxisome proliferator-activator receptor such as for example fenofibrate, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-I or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity.
  • a DGAT inhibitor in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof
  • an agonist of peroxisome proliferator-activator receptor such as for example fenofibrate
  • the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers, i) a combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an antihypertensive agent.
  • a combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an antihypertensive agent can be used as a medicine.
  • the present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an antihypertensive agent, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-I or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity.
  • the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • Said anti-hypertensive agent which may be combined with a DGAT inhibitor according to the present invention may be a known anti-hypertensive agent, e g loop diuretics such as ethacrynic acid, furosemide and torsemide, angiotensin converting enzyme (ACE) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perinodopril, quinapril, ramipril and trandolapril; inhibitors of the Na-K- ATPase membrane pump such as digoxin; neutralendopeptidase (NEP) inhibitors; ACE/NEP inhibitors such as omapatrilat, sampatrilat and fasidotril; angiotensin II antagonists such as candesartan, eprosartan, irbesartan, los
  • 'm.p means melting point
  • 'THF' means tetrahydrofuran
  • 'EtOAc' means ethyl acetate
  • 'MeOH' means methanol
  • 'DIPE' means diisopropyl ether
  • 'DMF' means N,N-dimethylformamide
  • 'Et 3 N' means triethylamine
  • 'DPPENT' means l,l '-(l,5-pentanediyl)bis[l,r-diphenylphosphine]
  • PS- Carbodiimide means polystyrene resin-bound N-cyclohexylcar
  • a means pro analysis, "eq.” means equivalent, "DIPEA” means diisopropylethylamine, "TFA” means trifluoroacetic acid, "TBTU “ means O-benzotriazolyl tetramethylisouronium tetrafluoroborate, and "MP-carbonate” is macroporous triethylammonium methylpolystyrene carbonate (a macroporous polystyrene anion-exchange resin that is a resin-bound equivalent of tetraalkylammonium carbonate).
  • ArgoScoopTM resin (Biotage) dispenser is a variable volumn resin scoop designed for convenient dispensing of polymer scavengers and reagents.
  • MiniBlockTM (Mettler Toledo) is a flexible, easy to use tool designed for parallel synthesis.
  • Example A2 a Preparation of intermediate 4
  • l,3-dichloro-2-isocyanatobenzene (0.02660 mol) in CH 2 Cl 2 p. a. (20 ml) was added dropwise while the reaction mixture was stirred on the ice bath.
  • the reaction mixture was let to warm up to room temperature and was stirred at room temperature.
  • the reaction mixture was filtered off and washed with DIPE (q.s.).
  • the precipitate was dried in vacuo. Yield : 8.923 g of intermediate 4 (94 %; yellow powder)
  • 2,6-Dichloro-4-chloromethyl-phenylamine (11 g, 0.0445 mol) was added portionwise to a stirring solution of pyrrolidine (15.84 g, 0.223 mol) in CH 3 CN (250 ml). The reaction mixture was placed in a water bath (exothermic reaction). The solvent was evaporated and the residue was dissolved in CH 2 Cl 2 (150 ml) and a 50 % saturated NaHCO 3 solution (100 ml). The mixture was stirred for 15 minutes. The organic layer was separated, dried (MgSO 4 ), filtered and the solvent was evaporated and co- evaporated with toluene.
  • Phase A 90 % of a 0.5 % NH 4 OAc solution in water + 10 % CH 3 CN; phase B: CH 3 OH; phase C: CH3CN).
  • the different product fractions were collected and worked- up.
  • the solvents were evaporated and co-evaporated with toluene, yielding 2.24 g of intermediate 33', and 0.732 g of the desired intermediate 33 (18 %).
  • Compound 18 was prepared according to the above-described procedure except for reactant intermediate 7 which should be replaced by intermediate 16 (prepared according to A7.b).
  • Compound 54 was prepared according to the above-described procedure except for reactant intermediate 7 which should be replaced by 2-methyl-5-(3-trifluoromethyl- phenyl)-thiazole-4-carboxylic acid (prepared according to A8.b).
  • PS- Trisamine (4.35 mmol/g; Novabiochem) (0.0002 mol) was added and the mixture was stirred for 4 hours.
  • the reaction mixture was filtered and the filtrate was stirred with PS-TsOH (0.1 g) overnight.
  • the mixture was filtered and the filtrate was purified by HPLC over Purospher Star RP- 18 (20 g, 5 ⁇ m; eluent: ((0.5% NH 4 OAc in
  • N'-(ethylcarbonimidoyl)- ⁇ /, ⁇ /-dimethyl- 1 ,3-propanediamine monohydrochloride (0.000302 mol) was added to a mixture of intermediate 5 (prepared according to A2.b) (0.000275 mol), l-methyl-5-oxo-3-pyrrolidinecarboxylic acid (0.000275 mol), 1- hydroxy-iH-benzotriazole (0.000028 mol) and N-ethyl-N-(l-methylethyl)-2- propanamine (0.000329 mol) in T ⁇ F, dried over 3A molecular sieves (5 ml) and then stirred for 64 hours at room temperature. The solvent was evaporated (under N 2 ).
  • Phase A 90 % of a 0.5 % NH 4 OAc solution in water + 10 % CH 3 CN; phase B: CH 3 OH; phase C: CH 3 CN).
  • the desired fractions were collected and the solvents were partially evaporated.
  • a saturated aqueous NaHCO 3 solution was added and the organic products were extracted with CH 2 Cl 2 .
  • the layers were separated and the CH 2 Cl 2 layer was dried (MgSO 4 ), filtered and the solvent was evaporated and co-evaporated with toluene. The residue was stirred in DIPE and the solid was filtered off and dried (50 0 C, 72 hours, in vacuo). Yield: 0.184 g of compound 130.
  • Example B8 80 % of a 0.5 % NH 4 OAc solution in water + 10 % CH 3 CN; phase B: CH 3 OH; phase C: CH 3 CN).
  • the desired fractions were collected and the solvents were partially evaporated.
  • the mixture was filtered over diatomaceous earth (Dicalite®).
  • the layers were separated and the organic layer was dried (MgSO 4 ), filtered and the solvent was evaporated and co-evaporated with toluene, yielding 1.006 g.
  • the crude compound was purified by reversed-phase high-performance liquid chromatography (Shandon Hyperprep® Cl 8 BDS (Base Deactivated Silica) 8 ⁇ m, 250 g, LD. 5 cm). A gradient with 3 mobile phases was applied. Phase A: a 0.25 % NH 4 HCO 3 solution in water; phase B: CH 3 OH; phase C: CH 3 CN). The desired fractions were collected and the solvent was evaporated until only the water layer was obtained.
  • reaction mixture was stirred for 18 hours under N 2 atmosphere. Then an aqueous saturated NaHCO 3 solution (15 ml) was added and the mixture was stirred for 2 hours.
  • Tables 1 to 7 list the compounds that were prepared by analogy to one of the above Examples.
  • Table 1 Table 1 :
  • the HPLC measurement was performed using an Alliance HT 2790 (Waters) system comprising a quaternary pump with degasser, an autosampler, a column oven (set at 40 °C, unless otherwise indicated), a diode-array detector (DAD) and a column as specified in the respective methods below.
  • Flow from the column was split to a MS spectrometer.
  • the MS detector was configured with an electrospray ionization source. Mass spectra were acquired by scanning from 100 to 1000 in 1 second using a dwell time of 0.1 second.
  • the capillary needle voltage was 3 kV and the source temperature was maintained at 140 0 C. Nitrogen was used as the nebulizer gas.
  • Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
  • the LC measurement was performed using an Acquity UPLC (Waters) system comprising a binary pump, a sample organizer, a column heater (set at 55 °C), a diode- array detector (DAD) and a column as specified in the respective methods below.
  • Flow from the column was split to a MS spectrometer.
  • the MS detector was configured with an electrospray ionization source. Mass spectra were acquired by scanning from 100 to 1000 in 0.18 seconds using a dwell time of 0.02 seconds.
  • the capillary needle voltage was 3.5 kV and the source temperature was maintained at 140 0 C. Nitrogen was used as the nebulizer gas.
  • Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
  • Method 1 In addition to general procedure B: Reversed phase UPLC (Ultra Performance Liquid Chromatography) was carried out on a bridged ethylsiloxane/silica hybrid (BEH) Cl 8 column (1.7 ⁇ m, 2.1 x 50 mm; Waters Acquity) with a flow rate of 0.8 ml/min. Two mobile phases (mobile phase A: 0.1 % formic acid in IHtO/methanol 95/5; mobile phase B: methanol) were used to run a gradient condition from 95 % A and 5 % B to 5 % A and 95 % B in 1.3 minutes and hold for 0.2 minutes. An injection volume of 0.5 ⁇ l was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
  • BEH bridged ethylsiloxane/silica hybrid
  • Method 2 In addition to general procedure A: Reversed phase HPLC was carried out on an Xterra MS Cl 8 column (3.5 ⁇ m, 4.6 x 100 mm) with a flow rate of 1.6 ml/min. Three mobile phases (mobile phase A: 95% 25 mM ammoniumacetate + 5 % acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 1 % A, 49 % B and 50 % C in 6.5 minutes, to 1 % A and 99 % B in 1 minute and hold these conditions for 1 minute and reequilibrate with 100 % A for 1.5 minutes. An injection volume of 10 ⁇ l was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
  • Method 3 For a number of compounds only the mass spectra were recorded (no R(t)).
  • the MS detector was configured with an electrospray ionization source. Mass spectra were acquired by scanning from 100 to 1000 in 1 second using a dwell time of 0.1 second. The capillary needle voltage was 3 kV and the source temperature was maintained at 140 0 C. Nitrogen was used as the nebulizer gas. Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
  • Method 6 In addition to general procedure A: Column heater was set at 60 0 C. Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 ⁇ m, 4.6 x 100 mm) with a flow rate of 1.6 ml/min. Three mobile phases (mobile phase A: 95% 25 mM ammoniumacetate + 5 % acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50 % B and 50 % C in 6.5 minutes, to 100 % B in 0.5 minute and hold these conditions for 1 minute and reequilibrate with 100 % A for 1.5 minutes. An injection volume of 10 ⁇ l was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
  • Reversed phase HPLC was carried out on a Waters XTerra MS Cl 8 column (3.5 ⁇ m, 2.1 x 30 mm) with a flow rate of 1.0 ml/min.
  • Two mobile phases (mobile phase A: 0.1 % aqueous solution of formic acid; mobile phase B: acetonitrile) were used. First, 100 % A was hold for 0.1 minutes. Then a gradient was applied to 5 % A and 95 % B in 3 minutes and hold for 0.8 minutes. The injection volume was 1 ⁇ l. The column was at room temperature.
  • melting points were determined by using a DSC823e (Mettler-Toledo). Melting points were measured with a temperature gradient of 30 °C/minute. Maximum temperature was 400 0 C. Values are peak values. The results are gathered in Table 10
  • m.p. were determined by using a Gallenkamp apparatus from Sanyo Gallenkamp.
  • the inhibiting activity of the present compounds on DGATl activity was screened in a single well procedure assay using DGATl comprising membrane preparations and DGATl substrate comprising micelles and determining formed radio-active triacylglycerol coming in close proximity of a flashplate surface by radio luminescence.
  • DGATl activity is meant the transfer of coenzyme A activated fatty acids to the 3- position of 1,2-diacylglycerols, thus forming a triglyceride molecule, by enzyme DGATl.
  • 72h transfected SF9 cells were collected by centrifugation (13000rpm-15 min-4°C) and lysed in 2x 500ml lysisbuffer (0.1M Sucrose, 5OmM KCl, 4OmM KH 2 PO 4 , 3OmM EDTA pH 7.2. Cells were homogenized by cell disruptor. After centrifugation 1380rpm-15min-4°C (SN discarded), pellet was resuspended in 500 ml lysisbuffer and total cell membranes collected by ultracentrifugation at 34000rpm(100 00Og) for 60 min (4°C).
  • the sonification process consists of sonification cycles of 10 seconds in the sonification bath followed by 10 seconds cool down on ice and repeating this sonification cycle till a homogeneous solution is obtained (takes about 15 minutes).
  • the thus obtained micelles are stored at -20 0 C till later use and contain DAG at a final concentration of 1.61 mM.
  • 10 ⁇ l enzyme mix and 10 ⁇ l substrate mix were added to 30 ⁇ l of assay buffer, optionally in the presence of 1 ⁇ l DMSO (blank and controls) or 1 ⁇ l of the compound to be tested.
  • This reaction mixture was incubated for 120 minutes at 37°C and the enzymatic reaction stopped by adding 20 ⁇ l of the stop mix.
  • the plates were sealed and the vesicles allowed to settle overnight at room temperature. Plates were centrifuged for 5 minutes at 1500rpm and measured in Leadseeker.
  • %CTRL min (sample - LC) / (HC - LC)
  • HC high control
  • LC low control
  • sample refers to the radioluminescence value measured in the wells with substrate, enzyme and test compound at a particular concentration.
  • % CTRL min values form a sigmoidal dose response descending curve and from this curve pICso values were calculated (-logICso where IC50 represents the concentration at which the test compound gives 50% inhibition of DGATl activity).
  • Table 11 shows the pICso values for the compounds of formula (I).
  • the inhibiting activity of the compounds on DGAT2 was also determined in the above assay, slightly modified to obtain optimal assay conditions for DGAT2.
  • the tested compounds did not show inhibiting activity for DGAT2 (Human DGAT2 (NM032564) was cloned and expressed as described in J.Biolog. Chem. 276(42), pp38870-38876 (2001)).
  • Table 11 pICso values (IC 50 values expressed in
  • Elevation of GLP-I plasma levels by a DGAT inhibitor can be studied as follows :
  • Dogs are deprived from food for a period of 22hours. At time 0, animals are given a liquid meal, containing 18% fat (w/w), by gavage with a stomach tube. The test compound is given orally together with the meal. Afterwards, a postprandial plasma profile is determined for GLP-I. Therefore, blood is collected at predetermined time intervals in ice-cooled Vacutainers EDTA-plasma tubes and GLP-I levels are measured in the samples taken at 0 hour (just before the meal) and at 0.5, 1, 2, 4, 6, 8 and 24 hours after dosing. Six dogs (3 males and 3 females) are included per dosage group and the plasma GLP-I profile is compared with their own GLP-I profile previously determined in the same conditions but without administration of the test compound.
  • GLP-I determinations in plasma are performed with a Glucagon- like peptide- 1 (active) ELISA kit 96-well plate of LINCO Research.
  • Active ingredient (a.i.) as used throughout these examples relates to a compound of formula (I), including any stereochemically isomeric form thereof, a JV-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; in particular to any one of the exemplified compounds.
  • Typical examples of recipes for the formulation of the invention are as follows: 1. Tablets
  • aqueous suspension is prepared for oral administration so that each milliliter contains 1 to 5 mg of active ingredient , 50 mg of sodium carboxymethyl cellulose, 1 mg of sodium benzoate, 500 mg of sorbitol and water ad 1 ml.
  • Injectable A parenteral composition is prepared by stirring 1.5 % (weight/volume) of active ingredient in 0.9 % NaCl solution.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

The invention relates to a DGAT inhibitor of formula (I), including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents -O-C(=O)-; -C(=O)-C(=O)-; -NRX-C(=O)-; -Z-C(=O)-; -Z-NRX-C(=O)-; -C(=O)-Z-; -NRX-C(=O)-Z-; -C(=S)-; -NRX-C(=S)-; -Z-C(=S)-; -Z-NRX-C(=S)-; - C(=S)-Z-; -NRX-C(=S)-Z-; Z represents a bivalent radical selected from C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl; wherein each of said C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl may optionally be substituted; and wherein two hydrogen atoms attached to the same carbon atom in C1-6alkanediyl may optionally be replaced by C1-6alkanediyl; Y represents -C(=O)-NRX- or -NRX-C(=O)-; R1 represents adamantanyl, C3-6cycloalkyl; aryl1 or Het1; R2 represents C3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3- dihydrobenzofuranyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C3-6Cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl or heterocycle may optionally be substituted; R7 represents hydrogen, halo, C1-4alkyl, C1-4alkyl substituted with hydroxyl; provided that the following compounds (A), (B) are excluded; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine, as a DGAT inhibitor, of said compounds.

Description

PIPERIDINE/PIPERAZINE DERIVATIVES
Field of the invention The present invention relates to the use of a DGAT inhibitor, in particular a DGATl inhibitor, for the manufacture of a medicament for the prevention or the treatment of a disease by elevating the levels of one or more satiety hormones, in particular GLP-I. The present invention also concerns piperidine/piperazine derivatives having DGAT inhibitory activity, in particular DGATl inhibitory activity. The invention further relates to methods for their preparation and pharmaceutical compositions comprising them. The invention also relates to the use of said compounds for the manufacture of a medicament for the prevention or the treatment of a disease mediated by DGAT, in particular DGAT 1.
Background to the Invention
Triglycerides represent the major form of energy stored in eukaryotes. Disorders or imbalances in triglyceride metabolism are implicated in the pathogenesis of and increased risk for obesity, insulin resistance syndrome and type II diabetes, nonalcoholic fatty liver disease and coronary heart disease (see, Lewis, et al, Endocrine Reviews (2002) 23:201 and Malloy and Kane, Adv. Intern. Med. (2001) 47:11 1).
Additionally, hypertriglyceridemia is often an adverse consequence of cancer therapy (see, Bast, et al. Cancer Medicine, 5th Ed., (2000) B.C. Decker, Hamilton, Ontario, CA).
A key enzyme in the synthesis of triglycerides is acyl CoA:diacylglycerol acyltransferase, or DGAT. DGAT is a microsomal enzyme that is widely expressed in mammalian tissues and that catalyzes the joining of 1 ,2-diacylglycerol (DAG) and fatty acyl CoA to form triglycerides (TG) at the endoplasmic reticulum (reviewed in Chen and Farese, Trends Cardiovasc. Med. (2000) 10: 188 and Farese, et al, Curr. Opin. Lipidol. (2000) 11 :229). It was originally thought that DGAT uniquely controlled the catalysis of the final step of acylation of diacylglycerol to triglyceride in the two major pathways for triglyceride synthesis, the glycerol phosphate and monoacylglycerol pathways. Because triglycerides are considered essential for survival, and their synthesis was thought to occur through a single mechanism, inhibition of triglyceride synthesis through inhibiting the activity of DGAT has been largely unexplored. Genes encoding mouse DGATl and the related human homo logs ARGPl (human DGATl) and ARGP2 (human ACAT2) now have been cloned and characterized (Cases, et al, Pro.c Nat. I Acad. Sci. (1998) 95:13018; Oelkers, et al, J. Biol. Chem. (1998) 273:26765). The gene for mouse DGATl has been used to create DGAT knock-out mice to better elucidate the function of the DGAT gene.
Unexpectedly, mice unable to express a functional DGATl enzyme (Dgatl-/- mice) are viable and still able to synthesize triglycerides, indicating that multiple catalytic mechanisms contribute to triglyceride synthesis (Smith, et al, Nature Genetics (2000) 25:87). Other enzymes that catalyze triglyceride synthesis, for example, DGAT2 and diacylglycerol transacylase, also have been identified (Cases, et al, J. Biol. Chem.
(2001) 276:38870). Gene knockout studies in mice have revealed that DGAT2 plays a fundamental role in mammalian triglyceride synthesis and is required for survival. DGAT2 deficient mice are lipopenic and die soon after birth, apparently from profound reductions in substrates for energy metabolism and from impaired permeability barrier function in the skin.(Farese, et al., J. Biol. Chem. (2004) 279: 11767).
Significantly, Dgatl-/- mice are resistant to diet-induced obesity and remain lean. Even when fed a high fat diet (21 % fat) Dgatl-/- mice maintain weights comparable to mice fed a regular diet (4% fat) and have lower total body triglyceride levels. The obesity resistance in Dgatl-/- mice is not due to decreased caloric intake, but the result of increased energy expenditure and decreased resistance to insulin and leptin (Smith, et al, Nature Genetics (2000) 25:87; Chen and Farese, Trends Cardiovasc. Med. (2000) 10: 188; and Chen, et al, J. Clin. Invest. (2002) 109:1049). Additionally, Dgatl-/- mice have reduced rates of triglyceride absorption (Buhman, et al, J. Biol. Chem. (2002) 277:25474). In addition to improved triglyceride metabolism, Dgatl-/- mice also have improved glucose metabolism, with lower glucose and insulin levels following a glucose load, in comparison to wild-type mice (Chen and Farese, Trends Cardiovasc. Med. (2000) 10: 188).
The finding that multiple enzymes contribute to catalyzing the synthesis of triglyceride from diacylglycerol is significant, because it presents the opportunity to modulate one catalytic mechanism of this biochemical reaction to achieve therapeutic results in an individual with minimal adverse side effects. Compounds that inhibit the conversion of diacylglycerol to triglyceride, for instance by specifically inhibiting the activity of DGATl, will find use in lowering corporeal concentrations and absorption of triglycerides to therapeutically counteract the pathogenic effects caused by abnormal metabolism of triglycerides in obesity, insulin resistance syndrome and overt type II diabetes, congestive heart failure and atherosclerosis, and as a consequence of cancer therapy.
Because of the ever increasing prevalence of obesity, type II diabetes, heart disease and cancer in societies throughout the world, there is a pressing need in developing new therapies to effectively treat and prevent these diseases. Therefore there is an interest in developing compounds that can potently and specifically inhibit the catalytic activity of DGAT, in particular DGATl.
We have now unexpectedly found that the compounds of the present invention exhibit DGAT inhibitory activity, in particular DGATl inhibitory activity, and can therefore be used to prevent or treat a disease associated with or mediated by DGAT, such as for example obesity, type II diabetes, heart disease and cancer. The compounds of the invention differ from the prior art compounds in structure, in their pharmacological activity, pharmacological potency, and/or pharmacological profile.
We have also unexpectedly found that DGAT inhibitors can be used to elevate the levels of one or more satiety hormones, in particular glucagon- like-peptide-1 (GLP-I) and therefore DGAT inhibitors, in particular DGATl inhibitors, can also be used to prevent or treat a disease which can benefit from elevated levels of a satiety hormone, in particular GLP-I. Glucagon- like peptide 1 (GLP-I) is an intestinal hormone which generally stimulates insulin secretion during hyperglycemia, suppresses glucagon secretion, stimulates (pro) insulin biosynthesis and decelerates gastric emptying and acid secretion. GLP-I is secreted from L cells in the small and large bowel following the ingestion of fat and proteins. GLP-I has been suggested, among other indications, as a possible therapeutic agent for the management of type 2 non- insulin-dependent diabetes mellitus as well as related metabolic disorders, such as obesity.
Thus, by the present finding, a disease which can benefit from elevated levels of GLP-I can be treated with small molecules (compared to large molecules such as proteins or protein- like compounds, e.g. GLP-I analogues).
Background prior art
WO 2006/034441 discloses heterocyclic derivatives and their use as stearoyl CoA desaturase inhibitors (SCD-I inhibitors).
WO 2006/086445 relates to a combination therapy of a SCD-I inhibitor and another drug to treat adverse weight gain. -A-
WO 2006/004200 and JP2007131584 relate to urea and amino derivatives having DGAT inhibitory activity.
WO 2004/047755 relates to fused bicyclic nitrogen-containing heterocycles having DGAT inhibitory activity. WO2005/072740 relates to an anorectic action of a compound having DGAT inhibitory activity.
Description of the invention
The present invention relates to the use of a DGAT inhibitor for the manufacture of a medicament for the prevention or the treatment, in particular for the treatment, of a disease which can benefit from elevated levels of one or more satiety hormones, in particular GLP-I.
The present
Figure imgf000006_0001
including any stereochemical^ isomeric form thereof, wherein
A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom;
X represents -O-C(=O)-; -C(=O)-C(=O)-; -NRX-C(=O)-; -Z-C(=O)-; -Z-NRX-C(=O)-; -C(=O)-Z-; -NRX-C(=O)-Z-; -C(=S)-; -NRX-C(=S)-; -Z-C(=S)-; -Z-NRX-C(=S)-;
-(X=S)-Z-; -NRX-C(=S)-Z-;
Z represents a bivalent radical selected from d-βalkanediyl, C2-6alkenediyl or C2-6alkynediyl; wherein each of said d-βalkanediyl, C2-6alkenediyl or C2-6alkynediyl may optionally be substituted with hydroxyl or amino; and wherein two hydrogen atoms attached to the same carbon atom in Ci_6alkanediyl may optionally be replaced by d-βalkanediyl;
Rx represents hydrogen or C1-4alkyl;
Y represents -C(=O)-NRX- or -NRX-C(=O)-;
R1 represents adamantanyl, C3-6Cycloalkyl; aryl1 or Het1; R2 represents C3-6Cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-l,4-benzodioxinyl, 1,3- benzodioxolyl, 2,3-dihydrobenzofuranyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C3-6Cycloalkyl, phenyl, naphtalenyl, 2,3- dihydro-l,4-benzodioxinyl, 1,3-benzodioxolyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms may optionally be substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently selected from hydroxyl; carboxyl; halo; Ci_6alkyl optionally substituted with hydroxy; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhalo-Ci_6alkyloxy; Ci_ βalkyloxy carbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; Ci_
4alkylcarbonylamino; -S(=O)p-Ci_4alkyl; R4R3N-C(=O)-; R4R3N-C i_6alkyl; C3- βcycloalkyl; C3-6cycloalkylCi_4alkyl; C3-6cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_ 4alkyl; aryl-C(=O)-Ci_4alkyl; aryl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-Ci_4alkyl; Het-C(=O)-; Het-O-; R represents hydrogen; Ci_4alkyl optionally substituted with hydroxyl or Ci_4alkyloxy;
R6R5N-Ci_4alkyl; Ci_4alkyloxy; Het; Het-Ci_4alkyl; aryl; R6R5N-C(=O)-Ci_4alkyl; R4 represents hydrogen or Ci_4alkyl; R5 represents hydrogen; Ci_4alkyl; Ci_4alkylcarbonyl; R6 represents hydrogen or Ci_4alkyl; or R5 and R6 may be taken together with the nitrogen to which they are attached to form a saturated monocyclic 5, 6 or 7-membered heterocycle which may further contain one or more heteroatoms each independently selected from O, S, S(=O)P or N; and which heterocycle may optionally be substituted with Ci_4alkyl; R7 represents hydrogen, halo, Ci_4alkyl, Ci_4alkyl substituted with hydroxyl; aryl represents phenyl or phenyl substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; carboxyl; halo; Ci_6alkyl optionally substituted with Ci_4alkyloxy, amino or mono-or di(Ci_4alkyl)amino; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxycarbonyl; cyano; amino carbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; -S(=O)p-Ci.4alkyl; aryl1 represents phenyl, naphthalenyl or fluorenyl; each of said phenyl, naphthalenyl or fluorenyl optionally substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with carboxyl, C i_4alkyloxy carbonyl or aryl-C(=O)-; hydroxyCi-βalkyl optionally substituted with aryl or aryl-C(=O)-; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxy-carbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_6alkyl)amino; R4R3N-C i_6alkyl; C3-6cycloalkyl-NRx-; aryl-NRx-; Het-NRX-; C3-6cycloalkylCi.4alkyl-NRx-; arylCi.4alkyl-NRx-; HetCi.4alkyl-NRx-; -S(=O)p-Ci_4alkyl; C3-6cycloalkyl; C3-6cycloalkylCi_4alkyl; C3_6cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_4alkyl; aryl-C(=O)-Ci_4alkyl; aryl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-Ci_4alkyl; Het-C(=O)-; Het-O-; Het represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=0)p or N; or a bicyclic or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each indendently selected from O, S, S(=0)p or N; said monocyclic heterocycle or said bi-or tricyclic heterocycle optionally being substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with Ci_4alkyloxy, amino or mono-or di(Ci_4alkyl)amino; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxycarbonyl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; -S(=O)p-Ci_4alkyl;
Het1 represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=0)p or N; or a bicyclic or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=0)p or N; said monocyclic heterocycle or said bi- or tricyclic heterocycle optionally being substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with aryl-C(=O)-; hydroxyCi-βalkyl optionally substituted with aryl or aryl-C(=O)-; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxy-carbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_6alkyl)amino; R4R3N-C i_6alkyl C3.6cycloalkyl-NRX-; aryl-NRx-; Het-NRX-; C3_6cycloalkylCi_4alkyl-NRx-; arylCi_4alkyl-NRx-; HetCi.4alkyl-NRx-;-S(=O)p-Ci.4alkyl; C3_6Cycloalkyl; C3_6CycloalkylCi_4alkyl; C3_6Cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_4alkyl; aryl-C(=O)-Ci_4alkyl; aryl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-Ci_4alkyl; Het-C(=O)-; Het-O-; p represents 1 or 2; provided that the following compounds
Figure imgf000009_0001
are excluded; a JV-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.
The present invention further relates to the use of a compound of formula (I'") for the manufacture of a medicament for the prevention or the treatment of a disease mediated by DGAT, in particular the present invention relates to the use of a compound of formula (F") for the manufacture of a medicament for the prevention or the treatment of a disease which can benefit from inhibition of DGAT, in particular for the treatment of a disease which can benefit from inhibition of DGAT, in particular DGATl, wherein the compound of
Figure imgf000009_0002
including any stereochemical^ isomeric form thereof, wherein
A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom;
X represents -O-C(=O)-; -C(=O)-C(=O)-; -NRX-C(=O)-; -Z-C(=O)-; -Z-NRX-C(=O)-;
-C(=O)-Z-; -NRX-C(=O)-Z-; -C(=S)-; -S(=O)p-; -NRX-C(=S)-; -Z-C(=S)-; -Z-NRX-
C(=S)-; -C(=S)-Z-; -NRX-C(=S)-Z-;
Z represents a bivalent radical selected from Ci_6alkanediyl, C2-6alkenediyl or C2-6alkynediyl; wherein each of said Ci_6alkanediyl, C2-6alkenediyl or C2-6alkynediyl may optionally be substituted with hydroxyl or amino; and wherein two hydrogen atoms attached to the same carbon atom in Ci_6alkanediyl may optionally be replaced by Ci_6alkanediyl;
Rx represents hydrogen or Ci_4alkyl;
Y represents -C(=O)-NRX- or -NRX-C(=O)-;
R1 represents adamantanyl, C3-6cycloalkyl; aryl1 or Het1;
R2 represents hydrogen, Ci_6alkyl, C2-6alkenyl, C3_6Cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-l,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C3_6Cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-l,4-benzodioxinyl, 1,3-benzodioxolyl or 6-membered aromatic heterocycle containing 1 or 2 N atoms may optionally be substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently selected from hydroxyl; carboxyl; halo; Ci_6alkyl optionally substituted with hydroxy; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhalo-Ci_6alkyloxy; Ci_6alkyloxycarbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; Ci_4alkylcarbonylamino; -S(=O)p-Ci_4alkyl; R4R3N-C(=O)-;
R4R3N-Ci_6alkyl; C3-6cycloalkyl; C3-6cycloalkylCi.4alkyl; C3-6cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_4alkyl; aryl-C(=O)-Ci_4alkyl; aryl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-Ci_4alkyl; Het-C(=O)-; Het-O-;
R represents hydrogen; Ci_4alkyl optionally substituted with hydroxyl or Ci_4alkyloxy; R6R5N-Ci_4alkyl; Ci_4alkyloxy; Het; Het-Ci_4alkyl; aryl; R6R5N-C(=O)-Ci_4alkyl;
R4 represents hydrogen or Ci_4alkyl;
R5 represents hydrogen; Ci_4alkyl; Ci_4alkylcarbonyl;
R6 represents hydrogen or Ci_4alkyl; or
R5 and R6 may be taken together with the nitrogen to which they are attached to form a saturated monocyclic 5, 6 or 7-membered heterocycle which may further contain one or more heteroatoms each independently selected from O, S, S(=O)P or N; and which heterocycle may optionally be substituted with Ci_4alkyl;
R7 represents hydrogen, halo, Ci_4alkyl, Ci_4alkyl substituted with hydroxyl; aryl represents phenyl or phenyl substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; carboxyl; halo; Ci_6alkyl optionally substituted with Ci_4alkyloxy, amino or mono-or di(Ci_4alkyl)amino; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxycarbonyl; cyano; amino carbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; -S(=O)p-Ci.4alkyl; aryl1 represents phenyl, naphthalenyl or fluorenyl; each of said phenyl, naphthalenyl or fluorenyl optionally substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with carboxyl,
C i_4alkyloxy carbonyl or aryl-C(=O)-; hydroxyCi-βalkyl optionally substituted with aryl or aryl-C(=O)-; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxy-carbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_6alkyl)amino; R4R3N-C i_6alkyl; C3-6cycloalkyl-NRx-; aryl-NRx-; Het-NRX-; C3-6cycloalkylCi.4alkyl-NRx-; arylCi_4alkyl-NRx-; HetCi_4alkyl-NRx-;
-S(=O)p-Ci_4alkyl; C3-6cycloalkyl; C3_6cycloalkylCi_4alkyl; C3_6cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_4alkyl; aryl-C(=O)-Ci_4alkyl; aryl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-Ci_4alkyl; Het-C(=O)-; Het-O-; Het represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=O)P or N; or a bicyclic or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=0)p or N; said monocyclic heterocycle or said bi-or tricyclic heterocycle optionally being substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with Ci_4alkyloxy, amino or mono-or di(Ci_4alkyl)amino; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxycarbonyl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; -S(=O)p-Ci_4alkyl;
Het1 represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=0)p or N; or a bicyclic or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=0)p or N; said monocyclic heterocycle or said bi- or tricyclic heterocycle optionally being substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with aryl-C(=O)-; hydroxyCi-βalkyl optionally substituted with aryl or aryl-C(=O)-; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxy-carbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_6alkyl)amino; R4R3N-C i_6alkyl; C3.6cycloalkyl-NRX-; aryl-NRx-; Het-NRX-; C3_6cycloalkylCi_4alkyl-NRx-; arylCi_4alkyl-NRx-; HetCi_4alkyl-NRx-;-S(=O)p-Ci_4alkyl; C3.6cycloalkyl;
C3_6CycloalkylCi_4alkyl; C3_6Cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_4alkyl; aryl- C(=O)-Ci_4alkyl; aryl-C(=O)-; Het; HetCMalkyl; Het-C(=O)-CMalkyl;
Het-C(=O)-; Het-O-; p represents 1 or 2; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.
The present invention also relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of a disease mediated by DGAT, in particular the present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of a disease which can benefit from inhibition of DGAT, in particular for the treatment of a disease which can benefit from inhibition of DGAT, in particular DGATl.
The present invention also relates to the use of a compound of formula (I) or (I'") for the manufacture of a medicament for the prevention or the treatment of a disease which can benefit from elevated levels of one or more satiety hormones, in particular GLP-I, in particular the present invention relates to the use of a compound of formula (I) or (F") for the manufacture of a medicament for the treatment of a disease which can benefit from elevated levels of GLP-I.
As used hereinbefore or hereinafter Co-3alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 0 (then it represents a direct bond) to 3 carbon atoms such as methyl, ethyl, propyl, 1 -methyl- ethyl; Ci_2alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having 1 or 2 carbon atoms such as methyl, ethyl; Ci_4alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as methyl, ethyl, propyl, 1-methylethyl, butyl; Ci_salkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 5 carbon atoms such as the group defined for Ci_4alkyl and pentyl, 2-methylbutyl and the like; Ci_6alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as the group defined for Ci_4alkyl and for Ci_5alkyl and hexyl, 2-methylpentyl and the like; Ci_6alkanediyl defines straight or branched chain saturated bivalent hydrocarbon radicals having from 1 to 6 carbon atoms such as methylene, 1 ,2-ethanediyl or 1 ,2-ethylidene, 1,3-propanediyl or 1,3- propylidene, 1 ,4-butanediyl or 1 ,4-butylidene, 1,5-pentanediyl and the like; C2-6alkenyl as a group or part of a group defines straight or branched chain hydrocarbon radicals having from 2 to 6 carbon atoms and having a double bond such as ethenyl, propenyl, butenyl, pentenyl, hexenyl, 3-methylbutenyl and the like; C2-6alkenediyl defines straight or branched chain bivalent hydrocarbon radicals having from 2 to 6 carbon atoms and having a double bond such as 1 ,2-ethenediyl, 1,3-propenediyl, 1,4- butenediyl, 1,5-pentenediyl and the like; C2-6alkynediyl as a group or part of a group defines straight or branched chain bivalent hydrocarbon radicals having from 2 to 6 carbon atoms and having a triple bond such as 1 ,2-ethynediyl, 1,3-propynediyl, 1 ,4-butynediyl, 1,5-pentynediyl and the like; C3 gCycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
The term halo is generic to fluoro, chloro, bromo and iodo. As used hereinbefore or hereinafter, polyhaloCi-βalkyl as a group or part of a group is defined as Ci_6alkyl substituted with one or more, such as for example 2, 3, 4 or 5 halo atoms, for example methyl substituted with one or more fluoro atoms, for example, difluoromethyl or trifluoromethyl, 1,1-difluoro-ethyl, l,l-difluoro-2,2,2-trifluoro-ethyl and the like. In case more than one halogen atoms are attached to a Ci_6alkyl group within the definition of polyhaloCi-βalkyl, they may be the same or different.
As used herein before, the term (=0) forms a carbonyl moiety when attached to a carbon atom, a sulfoxide moiety when attached to a sulfur atom and a sulfonyl moiety when two of said terms are attached to a sulfur atom. Oxo means =0.
The radical Het or Het1 as defined hereinabove may be an optionally substituted monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom, in particular 1, 2 or 3 heteroatoms, each independently selected from O, S, S(=O)P or N; or an optionally substituted bi- or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom, in particular 1, 2, 3, 4 or 5 heteroatoms, each independently selected from O, S, S(=O)P or N. Examples of such unsubstituted monocyclic heterocycles comprise, but are not limited to, non-aromatic (fully saturated or partially saturated) or aromatic A-, 5-, 6- or 7-membered monocyclic heterocycles such as for example azetidinyl, tetrahydrofuranyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, thiazolidinyl, tetrahydrothienyl, dihydrooxazolyl, isothiazolidinyl, isoxazolidinyl, oxadiazolidinyl, triazolidinyl, thiadiazolidinyl, pyrazolidinyl, piperidinyl, hexahydropyrimidinyl, hexahydropyrazinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl, hexahydrodiazepinyl, pyrrolinyl, imidazolinyl, pyrazolinyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, pyranyl and the like. Examples of such unsubstituted bicyclic or tricyclic heterocycles comprise, but are not limited to, non- aromatic (fully saturated or partially saturated) or aromatic 8- to 17-membered bicyclic or tricyclic heterocycles such as for example decahydroquinolinyl, octahydroindolyl, 2,3-dihydrobenzofuranyl, 1,3-benzodioxolyl, 2,3-dihydro-l,4-benzodioxinyl, indolinyl, benzofuryl, isobenzofuryl, benzothienyl, isobenzothienyl, indolizinyl, indolyl, isoindolyl, benzoxazolyl, benzimidazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, benzopyrazolyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinolizinyl, phthalazinyl, quinoxalinyl, quinazolinyl, naphthiridinyl, pteridinyl, benzopyranyl, pyrrolopyridyl, thienopyridyl, furopyridyl, isothiazolopyridyl, thiazolopyridyl, isoxazolopyridyl, oxazolopyridyl, pyrazolopyridyl, imidazopyridyl, pyrrolopyrazinyl, thienopyrazinyl, furopyrazinyl, isothiazolopyrazinyl, thiazolopyrazinyl, isoxazolopyrazinyl, oxazolopyrazinyl, pyrazolopyrazinyl, imidazopyrazinyl, pyrrolopyrimidinyl, thienopyrimidinyl, furopyrimidinyl, isothiazolopyrimidinyl, thiazolopyrimidinyl, isoxazolopyrimidinyl, oxazolopyrimidinyl, pyrazolopyrimidinyl, imidazopyrimidinyl, pyrrolopyridazinyl, thienopyridazinyl, furopyridazinyl, isothiazolopyridazinyl, thiazolopyridazinyl, isoxazolopyridazinyl, oxazolopyridazinyl, pyrazolopyridazinyl, imidazopyridazinyl, oxadiazolopyridyl, thiadiazolopyridyl, triazolopyridyl, oxadiazolopyrazinyl, thiadiazolopyrazinyl, triazolopyrazinyl, oxadiazolopyrimidinyl, thiadiazolopyrimidinyl, triazolopyrimidinyl, oxadiazolopyridazinyl, thiadiazolopyridazinyl, triazolopyridazinyl, imidazooxazolyl, imidazothiazolyl, imidazoimidazolyl, imidazopyrazolyl; isoxazolotriazinyl, isothiazolotriazinyl, pyrazolotriazinyl, oxazolotriazinyl, thiazolotriazinyl, imidazotriazinyl, oxadiazolotriazinyl, thiadiazolotriazinyl, triazolotriazinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl and the like. Optional substituents for Het heterocycles are hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with Ci_4alkyloxy, amino or mono-or di(Ci_ 4alkyl)amino; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyl-oxycarbonyl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_ 4alkyl)amino; -S(=O)p-Ci_4alkyl. Optional substituents for Het1 substituents are hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with aryl-C(=O)-; hydroxyCi-βalkyl optionally substituted with aryl or aryl-C(=O)-; polyhaloCi-βalkyl; Ci_ 6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxy-carbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_ βalkylcarbonyl; nitro; amino; mono-or di(Ci_6alkyl)amino; R4R3N-C i_6alkyl C3. 6cycloalkyl-NRx-; aryl-NRx-; Het-NRX-; C3-6cycloalkylCi.4alkyl-NRx-; arylCi_4alkyl- NRX-; HetCi_4alkyl-NRx-;-S(=O)p-Ci_4alkyl; C3-6cycloalkyl; C3-6cycloalkylCi.4alkyl; C3. 6cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_4alkyl; aryl-C(=O)-Ci_4alkyl; aryl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-Ci_4alkyl; Het-C(=O)-; Het-O-.
Examples of a 6-membered aromatic heterocycle containing 1 or 2 N atoms in the definition of R2 are pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl.
When any variable occurs more than one time in any constituent (e.g. aryl, Het), each definition is independent.
The term Het or Het1 is meant to include all the possible isomeric forms of the heterocycles, for instance, pyrrolyl comprises lH-pyrrolyl and 2H-pyrrolyl.
The carbocycles or heterocycles covered by for instance the terms aryl, aryl1, Het, Het1 or R3 may be attached to the remainder of the molecule of formula (I) through any ring carbon or heteroatom as appropriate, if not otherwise specified. Thus, for example, when the heterocycle is imidazolyl, it may be 1-imidazolyl, 2-imidazolyl, 4-imidazolyl and the like, or when the carbocycle is naphthalenyl, it may be 1-naphthalenyl,
2-naphthalenyl and the like.
Lines drawn from substituents into ring systems indicate that the bond may be attached to any of the suitable ring atoms.
When X is defined as for instance -NRX-C(=O)-, this means that the nitrogen of NRX is linked to the R2 substituent and the carbon atom of C(=O) is linked to the nitrogen of
N ,A the ring ^ — ^ . Thus the left part of the bivalent radical in the definition of X is linked to the R2 substituent and the right part of the bivalent radical in the definition of
N ,A X is linked to the ring moiety ^ — ^ .
Some of the compounds of formula (I) may also exist in their tautomeric form. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention. Whenever used hereinbefore or hereinafter that substituents can be selected each independently out of a list of numerous definitions, such as for example for R3 and R4, all possible combinations are intended which are chemically possible.
For therapeutic use, salts of the compounds of formula (I) are those wherein the counterion is pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
The pharmaceutically acceptable salts as mentioned hereinbefore or hereinafter are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acids as inorganic acids, for example, hydrohalic acids, e.g. hydrochloric, hydrobromic and the like; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxy- acetic, 2-hydroxypropanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-l,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfonic,
2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids. Conversely the salt form can be converted by treatment with alkali into the free base form.
The compounds of formula (I) containing acidic protons may be converted into their therapeutically active non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. The pharmaceutically acceptable salts as mentioned hereinbefore or hereinafter are meant to also comprise the therapeutically active non-toxic metal or amine addition salt forms (base addition salt forms) which the compounds of formula (I) are able to form. Appropriate base addition salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline, the benzathine, JV-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-l,3- propanediol, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
Conversely the salt form can be converted by treatment with acid into the free acid form.
The term salt also comprises the quaternary ammonium salts (quaternary amines) which the compounds of formula (I) are able to form by reaction between a basic nitrogen of a compound of formula (I) and an appropriate quaternizing agent, such as, for example, an optionally substituted Ci_6alkylhalide, arylhalide, Ci_6alkyl- carbonylhalide, arylcarbonylhalide, or arylCi-βalkylhalide, e.g. methyliodide or benzyliodide. Other reactants with good leaving groups may also be used, such as for example Ci_6alkyl trifluoromethanesulfonates, Ci_6alkyl methanesulfo nates, and Ci_6alkyl/?-toluenesulfonates. A quaternary amine has a positively charged nitrogen. Pharmaceutically acceptable counterions include chloro, bromo, iodo, trifluoroacetate, acetate, triflate, sulfate, sulfonate. The counterion of choice can be introduced using ion exchange resins.
The term solvate comprises the hydrates and solvent addition forms which the compounds of formula (I) are able to form, as well as the salts thereof. Examples of such forms are e.g. hydrates, alcoholates and the like.
The iV-oxide forms of the present compounds are meant to comprise the compounds of formula (I) wherein one or several tertiary nitrogen atoms are oxidized to the so-called iV-oxide.
It will be appreciated that some of the compounds of formula (I) and their TV-oxides, salts, and solvates may contain one or more centers of chirality and exist as stereochemically isomeric forms.
The term "stereochemically isomeric forms" as used hereinbefore or hereinafter defines all the possible stereoisomeric forms which the compounds of formula (I), and their TV-oxides, salts, or solvates may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure as well as each of the individual isomeric forms of formula (I) and their TV-oxides, salts or solvates, substantially free, i.e. associated with less than 10%, preferably less than 5%, in particular less than 2% and most preferably less than 1% of the other isomers. Thus, when a compound of formula (I) is for instance specified as (E), this means that the compound is substantially free of the (Z) isomer.
In particular, stereogenic centers may have the R- or S-confϊguration; substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or transconfiguration. Compounds encompassing double bonds can have an E (entgegen) or Z (zusammen) -stereochemistry at said double bond. The terms cis, trans, R, S, E and Z are well known to a person skilled in the art.
Stereochemically isomeric forms of the compounds of formula (I) are obviously intended to be embraced within the scope of this invention.
Following CAS-nomenclature conventions, when two stereogenic centers of known absolute configuration are present in a molecule, an R or S descriptor is assigned (based on Cahn-Ingold-Prelog sequence rule) to the lowest-numbered chiral center, the reference center. The configuration of the second stereogenic center is indicated using relative descriptors [R*,R* ] or [i?*,i_>*], where the first R* is always specified as the reference center and [R*,R*] indicates centers with the same chirality and [i?*,i_>*] indicates centers of unlike chirality. For example, if the lowest-numbered chiral center in the molecule has an S configuration and the second center is R, the stereo descriptor would be specified as S-[R *,S*\. If "α" and "β" are used : the position of the highest priority substituent on the asymmetric carbon atom in the ring system having the lowest ring number, is arbitrarily always in the "α" position of the mean plane determined by the ring system. The position of the highest priority substituent on the other asymmetric carbon atom in the ring system relative to the position of the highest priority substituent on the reference atom is denominated "α", if it is on the same side of the mean plane determined by the ring system, or "β", if it is on the other side of the mean plane determined by the ring system.
The compounds of (I) may be synthesized in the form of racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I) may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecifϊc methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
Whenever used hereinafter, the term "compounds of formula (I)" or any subgroup thereof, is meant to also include their JV-oxide forms, their salts, their stereochemically isomeric forms and their solvates. Of special interest are those compounds of formula (I) which are stereochemically pure.
A first embodiment of the present invention are those compounds of formula (I) having the following formula
Figure imgf000019_0001
including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents -NRX-C(=O)-; -Z-C(=O)-; -Z-NRX-C(=O)-; -C(=O)-Z-; -NRX-C(=O)-Z-; - C(=S)-; -NRX-C(=S)-; -Z-C(=S)-; -Z-NRX-C(=S)-; -C(=S)-Z-; -NRX-C(=S)-Z-; Z represents a bivalent radical selected from d-βalkanediyl, C2-6alkenediyl or C2-6alkynediyl; wherein each of said d-βalkanediyl, C2-6alkenediyl or C2-6alkynediyl may optionally be substituted with hydroxyl; Rx represents hydrogen or C1-4alkyl; Y represents -C(=O)-NRX- or -NRX-C(=O)-; R1 represents C3-6Cycloalkyl; aryl1 or Het1;
R2 represents C3-6Cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-l,4-benzodioxinyl, 1,3- benzodioxolyl, wherein said C3-6Cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-l,4- benzodioxinyl, 1,3-benzodioxolyl may optionally be substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently selected from hydroxyl; carboxyl; halo; Ci_6alkyl optionally substituted with hydroxy; polyhalod-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhalo-Ci_6alkyloxy; Ci_6alkyloxycarbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; d-βalkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; -S(=O)p-C1-4alkyl; R4R3N-C(=O)-; R4R3N-Ci_6alkyl; C3-6cycloalkyl; Cs-ecycloalkylC^alkyl; C3-6cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_4alkyl; aryl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-; Het-O-; R , 3 represents hydrogen; Ci_4alkyl optionally substituted with hydroxyl or Ci_4alkyloxy;
R6R5N-Ci_4alkyl; Ci_4alkyloxy; Het; aryl; R6R5N-C(=O)-Ci_4alkyl;
R represents hydrogen or Ci_4alkyl;
R , 5 represents hydrogen; Ci_4alkyl; Ci_4alkylcarbonyl; R6 represents hydrogen or Ci_4alkyl; or
R5 and R6 may be taken together with the nitrogen to which they are attached to form a saturated monocyclic 5, 6 or 7-membered heterocycle which may further contain one or more heteroatoms selected from O, S, S(=O)P or N; and which heterocycle may optionally be substituted with Ci_4alkyl; aryl represents phenyl or phenyl substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; carboxyl; halo; Ci_6alkyl optionally substituted with Ci_4alkyloxy, amino or mono-or di(Ci_4alkyl)amino; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxycarbonyl; cyano; amino carbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; -S(=O)p-Ci.4alkyl; aryl1 represents phenyl, naphthalenyl or fluorenyl; each of said phenyl, naphthalenyl or fluorenyl optionally substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with aryl-C(=O)-; hydroxyCi-βalkyl optionally substituted with aryl or aryl-C(=O)-; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxy-carbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; amino carbonyl; mono-or di(Ci_4alkyl)aminocarbonyl;
Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_6alkyl)amino; C3_6Cycloalkyl-NRx-; aryl-NRx-; Het-NRX-; C3-6cycloalkylCi_4alkyl-NRx-; arylCi_4alkyl-NRx-; HetCi_4alkyl-NRx-;-S(=O)p-Ci_4alkyl; C3-6cycloalkyl; C3-6cycloalkylCi_4alkyl; C3-6cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_4alkyl; aryl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-; Het-O-;
Het represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from O, S, S(=O)P or N; or a bicyclic or tricyclic non- aromatic or aromatic heterocycle containing at least one heteroatom selected from O, S, S(=O)p or N; said monocyclic heterocycle or said bi-or tricyclic heterocycle optionally being substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with Ci_4alkyloxy, amino or mono-or di(Ci_4alkyl)amino; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyl- oxycarbonyl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; -S(=0)p-Ci_4alkyl;
Het1 represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from O, S, S(=O)P or N; or a bicyclic or tricyclic non- aromatic or aromatic heterocycle containing at least one heteroatom selected from O, S, S(=O)p or N; said monocyclic heterocycle or said bi- or tricyclic heterocycle optionally being substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with aryl-C(=O)-; hydroxyCi-βalkyl optionally substituted with aryl or aryl-C(=O)-; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxy-carbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_6alkyl)amino; C3_6Cycloalkyl-NRx-; aryl-NRx-; Het-NRX-; C3-6cycloalkylCi_4alkyl-NRx-; arylCi_4alkyl-NRx-; HetCi_4alkyl-NRx-;-S(=O)p-Ci_4alkyl; C3-6cycloalkyl; C3-6cycloalkylCi_4alkyl; C3-6cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_4alkyl; aryl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-; Het-O-; p represents 1 or 2; provided that the following compounds
Figure imgf000021_0001
are excluded; a JV-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.
A second embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein X represents -O-C(=O)-; -NRX-C(=O)-; -Z-C(=O)-; -Z-NRX-C(=O)-; -C(=O)- Z-; -NRX-C(=O)-Z-; -NRX-C(=S)-; in particular wherein X represents -NRX-C(=O)-; -Z-C(=O)-; -Z-NRX-C(=O)-; -C(=O)-Z-; -NRX-C(=O)-Z-; -NRX-C(=S)-; more in particular wherein X represents -NRX-C(=O)-; -Z-C(=O)-; -Z-NRX-C(=O)-; even more in particular X represents -NRX-C(=O)- or -Z-NRX-C(=O)-; or X represents -NRX- C(=O)- or -Z-C(=O)-. Or X represents -O-C(=O)-; -C(=O)-C(=O)-; -NRX-C(=O)-; -Z- C(=O)-; -Z-NRX-C(=O)-; -C(=S)-; -NRX-C(=S)-; -Z-C(=S)-; -Z-NRX-C(=S)-.
A third embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein A represents N.
A fourth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein A represents CH, in particular wherein A represents CH and the dotted line does not represent a bond.
A fifth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein R1 represents aryl1 or Het1; in particular optionally substituted phenyl, optionally substituted fluorenyl or an optionally substituted monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=O)p or N, in particular S or N; more in particular phenyl or fluorenyl, said phenyl or fluorenyl optionally substituted with one or two substituents, said substituents independently selected from oxo, carboxyl, halo, Ci_6alkyl optionally substituted with carboxyl or C1-4alkyloxycarbonyl, Ci_6alkyloxy, d-βalkyloxycarbonyl, amino, aryl, Het or polyhaloC^alkyl; or a A-, 5-or 6-membered non-aromatic or aromatic heterocycle, such as for example azetidinyl, thiazolidinyl, thiazolyl, pyrrolidinyl, piperidinyl, said 5- or 6-membered heterocycle optionally substituted with one or two substituents, said substituents independently selected from hydroxyl, oxo, d-βalkyl, d-βalkyloxycarbonyl, aryl or Het.
A sixth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein R2 represents d-βcycloalkyl, phenyl, 2,3-dihydro-l,4-benzodioxinyl or a 6- membered aromatic heterocycle containing 1 or 2 N atoms such as for example pyridyl, wherein said phenyl or heterocycle are optionally substituted with one to four substituents, preferably each substituent independently selected from halo, d-βalkyl, Ci_6alkyloxy, Ci_6alkylthio, Ci_6alkyloxycarbonyl, nitro, amino, mono- or di(Ci_
4alkyl)amino, aryloxy, R > 4τ R N-Ci_6alkyl, Het-C(=O)-Ci_4alkyl.
A seventh embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein the compound of formula (I) is a compound of formula (F)
Figure imgf000023_0001
wherein R3a and R3a each independently represent hydrogen; hydroxyl; carboxyl; halo; d-βalkyl; polyhalod-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; d-βalkyloxycarbonyl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; d-βalkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; -S(=O)p-C1-4alkyl; and wherein R3c represents hydrogen; hydroxyl; carboxyl; halo; d-βalkyl; polyhalod-βalkyl; Ci_6alkyloxy optionally substituted with
Ci_4alkyloxy; Ci_6alkylthio; polyhalo-Ci_6alkyloxy; Ci_6alkyloxycarbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; d-βalkylcarbonyl; nitro; amino; mono-or di(d_4alkyl)amino; -S(=O)p-Ci_4alkyl; R4R3N-C(=O)-;
R4R3N-Ci_6alkyl; C3-6cycloalkyl; aryl; aryloxy; arylCi_4alkyl; aiyl-C(=O)-CMalkyl; aryl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-Ci_4alkyl; Het-C(=O)-; Het-O-.
An eighth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein the compound of formula (I) is a compound of formula (I")
Figure imgf000023_0002
wherein R3a and R3a each independently represent hydrogen; hydroxyl; carboxyl; halo; Ci_6alkyl; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy;
Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxycarbonyl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; -S(=O)p-Ci_4alkyl; and wherein R3c represents hydrogen; hydroxyl; carboxyl; halo; Ci_6alkyl; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhalo-Ci_6alkyloxy; Ci_6alkyloxycarbonyl wherein
Ci_6alkyl may optionally be substituted with aryl; cyano; Ci_6alkylcarbonyl; nitro; amino; mono-or di(d_4alkyl)amino; -S(=O)p-Ci_4alkyl; R4R3N-C(=O)-; R4R3N-Ci_6alkyl; C3-6cycloalkyl; aryl; aryloxy; arylCi_4alkyl; aiyl-C(=O)-CMalkyl; aryl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-Ci_4alkyl; Het-C(=O)-; Het-O-.
A nineth embodiment of the present invention are those compounds of formula (I) or any subgroup thereof as mentioned hereinbefore as embodiment wherein the compound of formula (I) is a compound of formula (F) or (I") and wherein R3a and R3b each independently represent halo, Ci_6alkyl or Ci_6alkyloxy; in particular halo or Ci_6alkyl; mmoorree iinn ppaarrttiiccuullaair both R3a and R3b represent halo, more in particular both R3a and R3b represent chloro.
A tenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein the compound of formula (I) is a compound of formula (F) or (I") and wherein R3c represents amino; mono-or di(Ci_4alkyl)amino; R4R3N-C(=O)-; R4R3N-Ci_6alkyl; Het-C(=O)- or HetCi_4alkyl; or R3c represents hydrogen.
An eleventh embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein p represents 2.
A twelfth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein Z represents Ci_6alkanediyl or C2-6alkenediyl, in particular Ci_6alkanediyl, more in particular -CH2-.
A thirteenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein Rx represents hydrogen.
A fourteenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein Y represents -NRX-C(=O)-.
A fifteenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein Y represents -C(=O)-NRX-. A sixteenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein R7 represents hydrogen.
A seventeenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein R7 represents halo, Ci_4alkyl or Ci_4alkyl substituted with hydroxyl; in particular halo.
An eightteenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein aryl represents phenyl or phenyl substituted with halo, Ci_6alkyl, polyhaloCi-βalkyl or Ci_6alkyloxycarbonyl.
A ninteenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein Het represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=O)P or N; or a bicyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=O)P or N, in particular N; said monocyclic heterocycle or said bicyclic heterocycle optionally being substituted with one or two substituents, each substituent independently being selected from oxo; or Ci_6alkyl.
A twenty embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein one or more, preferably all, of the following restrictions apply : a) X represents -NRX-C(=O)-; -Z-NRX-C(=O)-; or -NRX-C(=S)-; b) R1 represents aryl1 or Het1; c) R2 represents C3-6cycloalkyl, phenyl or 2,3-dihydro-l,4-benzodioxinyl, wherein said phenyl is optionally substituted with one to four substituents, each substituent independently selected from halo, Chalky!, Ci_6alkyloxy, Ci_6alkylthio, Ci_6alkyloxycarbonyl, nitro, amino, mono- or di(Ci_4alkyl)amino, aryloxy; d) A represents N; e) A represents CH; f) Z represents Ci_6alkanediyl or C2-6alkenediyl; g) Rx represents hydrogen. h) aryl1 represents phenyl or fluorenyl, said phenyl or fluorenyl optionally substituted with halo, Ci_6alkyl or polyhaloCi-βalkyl; i) Het1 represents a A-, 5-or 6-membered non-aromatic or aromatic heterocycle, such as for example azetidinyl, thiazolidinyl, thiazolyl, pyrrolidinyl, piperidinyl, said 5- or 6- membered heterocycle optionally substituted with hydroxyl, oxo, C^alkyl, Ci_6alkyloxycarbonyl, aryl or Het; j) Y represents -NRX-C(=O)-; k) R7 represents hydrogen.
A twenty first embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein one or more, preferably all, of the following restrictions apply : a) A represents CH; b) A represents N; c) the dotted line represents a bond in case A represents a carbon atom; d) the dotted line doesn't represents a bond in case A represents a carbon atom; e) X represents -O-C(=O)-; -NRX-C(=O)-; -Z-C(=O)-; -Z-NRX-C(=O)-; -NRX-C(=S)-; f) Z represents Ci_6alkanediyl; g) Rx represents hydrogen; h) Y represents -C(=O)-NRX- or -NRX-C(=O)-; i) R1 represents aryl1 or Het1; j) R2 represents C3_6cycloalkyl, phenyl, 2,3-dihydro-l,4-benzodioxinyl, or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C3_6Cycloalkyl, phenyl, 2,3-dihydro-l,4-benzodioxinyl, or 6-membered aromatic heterocycle containing 1 or 2 N atoms may optionally be substituted with at least one substituent, in particular one to four substituents, each substituent independently selected from halo; Ci_6alkyl; Ci_6alkyloxy; Ci_6alkylthio; Ci_6alkyloxycarbonyl; nitro; mono-or di(Ci_4alkyl)amino; R4R3N-C i_6alkyl; aryloxy; Het-C(=O)-Ci_4alkyl; k) R3 represents Ci_4alkyl; 1) R4 represents Ci_4alkyl; m) R7 represents hydrogen or halo; n) aryl represents phenyl or phenyl substituted with halo; Ci_6alkyl; polyhaloCi-βalkyl;
C i .βalkyloxycarbonyl; o) aryl1 represents phenyl or fluorenyl; each of said phenyl or fluorenyl optionally substituted with one or two substituents, each substituent independently being selected from oxo; carboxyl; halo; Ci_6alkyl optionally substituted with carboxyl or Ci_4alkyloxycarbonyl; Ci_6alkyloxy; Ci_6alkyloxy-carbonyl; amino; aryl; Het; p) Het represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=0)p or N; or a bicyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from N; said monocyclic heterocycle or said bicyclic heterocycle optionally being substituted with one or two substituents, each substituent independently being selected from oxo or Ci_6alkyl; q) Het1 represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from S or N; said monocyclic heterocycle optionally being substituted with at least one substituent, in particular one or two substituents, each substituent independently being selected from hydroxyl; oxo; Ci_6alkyl; Chalky Io xy-carbonyl; aryl; Het; r) p represents 2.
Preferred compounds of formula (I) are selected from
Figure imgf000027_0001
Figure imgf000028_0001
a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.
Another embodiment of the present invention is the use of a compound of formula (F") as indicated hereinabove, wherein the compound of formula (F") is a compound wherein R2 represents hydrogen, Ci_6alkyl or C2-6alkenyl.
The embodiments set out above for the compounds of formula (I) are also applicable, whenever possible, to the compound of formula (F").
In general, compounds of formula (I) wherein Y represents -NRX-C(=O)-, said compounds being represented by formula (I-a), can be prepared by reacting an intermediate of formula (II) with an intermediate of formula (III) in the presence of a suitable dehydrating (coupling) agent, such as for example ^-(ethylcarbonimidoyl)- Λ/,Λ/-dimethyl-l,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), l-[bis(di- methylamino)methylene]-lH-benzotriazoliumhexafluorophosphate(l-)3-oxide (ΗBTU), 1 -[bis(dimethyl-amino)methylene]-5-chloro- lH-benzotriazolium- hexafluorophosphate(l-) 3-oxide (ΗCTU), 0-benzotriazolyl tetramethylisouronium tetrafluoroborate (TBTU) or diethyl cyanophosphonate (DECP), optionally combined with hydroxy benzotriazole or chloro hydroxybenzotriazole, in the presence of a suitable solvent, such as for example N,Λ/-dimethylformamide, tetrahydrofuran or dichloromethane, and optionally in the presence of a suitable base, such as for example JV,jV-diisopropyl-ethanamine or JV,Λ/-diethyl-ethanamine.
Figure imgf000029_0001
(II) (in) M
The above reaction can be performed as a fast synthesis reaction thereby using appropriate reagents well-known for fast synthesis, such as for example dicyclohexylcarbodiimide (DCC) linked to an appropriate carrier, e.g. polystyrene. Also for the purification of the reaction mixture, appropriate fast-synthesis reagents can be used, such as for example l-ethenyl-4-(isocyanatomethyl)-benzene polymer with ethenylbenzene.
Compounds of formula (I-a) can also be prepared by reacting an intermediate of formula (II) with an intermediate of formula (HF) wherein Wi represents a suitable leaving group, such as for example halo, e.g. chloro and the like, in the presence of a suitable base, such as for example sodium hydride, sodium bicarbonate, N5N- diisopropyl-ethanamine or N,N-diethyl-ethanamine, and a suitable solvent, such as for example N,N-dimethylformamide, dichloromethane, acetonitrile or tetrahydrofuran
Figure imgf000029_0002
(H) (iir) (i-a)
Compounds of formula (I) wherein X represents X1-NH-C(=0)- with Xi representing a direct bond or Z, said compounds being represented by formula (I-b), can be prepared by reacting an intermediate of formula (IV) with an intermediate of formula (V) in the presence of a suitable solvent, such as for example acetonitrile, N5N- dimethylformamide or dichloromethane or an alcohol, e.g. methanol, optionally in the presence of a suitable base, such as for example N,N-diethyl-ethanamine. Intermediates of formula (IV) are commercially available or can be prepared by reacting R2-Xi-ΝH2 with phosgene in the presence of a suitable solvent, such as for example toluene.
R2— X1-N=C=O + HN ,-A~\ / ~Y~R1 *~
Figure imgf000029_0003
The above reaction can also be performed as a fast synthesis reaction thereby using appropriate reagents well-known for fast synthesis, such as for example for the purifϊcation of the reaction mixture l-ethenyl-4-(isocyanatomethyl)-benzene polymer with ethenylbenzene and tris-2-aminoethylamine linked to polystyrene can be used.
Compounds of formula (I-b) wherein Xi represents a direct bond, said compounds being represented by formula (I-b-1), can be prepared by reacting an intermediate of formula (IV) with C13COC(=O)-C1 or C(=O)C12, optionally in the presence of HCl in diethylether, and in the presence of a suitable solvent, such as for example toluene or acetonitrile, followed by reaction with an intermediate of formula (V) in the presence of a suitable solvent, such as for example acetonitrile, N,Λ/-dimethylformamide or dichloromethane, optionally in the presence of a suitable base, such as for example JV,jV-diethyl-ethanamine or JV,jV-diisopropyl-ethanamine. 1
Figure imgf000030_0001
(V)
(I-b-1)
Compounds of formula (I) wherein X represents X1-NH-C(=S)- with Xi representing a direct bond or Z, said compounds being represented by formula (I-c), can be prepared by reacting an intermediate of formula (VI) with an intermediate of formula (V) in the presence of a suitable base, such as for example N,7V-diethyl-ethanamine, and a suitable solvent, such as for example dichloromethane or tetrahydrofuran.
R -X
Figure imgf000030_0002
Compounds of formula (I) wherein X represents -X1-Q=O)- with Xi representing a direct bond or Z, said compounds being represented by formula (I-d), can be prepared by reacting an intermediate of formula (VII) with an intermediate of formula (V) in the presence of a suitable dehydrating (coupling) agent, such as for example 7V-(ethylcarbonimidoyl)-N,N-dimethyl- 1 ,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), l-[bis(di- methylamino)methylene]-lH-benzotriazoliumhexafluorophosphate(l-)3-oxide (ΗBTU), 1 -[bis(dimethyl-amino)methylene]-5-chloro- lH-benzotriazolium- hexafluorophosphate(l-) 3-oxide (ΗCTU), O-benzotriazolyl tetramethylisouronium tetrafluoroborate (TBTU) or diethyl cyanophosphonate (DECP), optionally combined with hydroxy benzotriazole or chloro hydroxybenzotriazole, in the presence of a suitable solvent, such as for example N,Λ/-dimethylformamide, dichloro methane, acetonitrile or tetrahydrofuran, and optionally in the presence of a suitable base, such as for example JV,jV-diisopropyl-ethanamine or JV,iV-diethyl-ethanamine. This reaction of an intermediate of formula (VII) with an intermediate of formula (V) can also be performed in the presence of a suitable activating agent, such as for example C1-C(=O)- C(=O)-C1, a suitable base, such as for example JV,Λ/-diethyl-ethanamine, and a suitable solvent, such as for example N,Λ/-dimethylformamide.
Figure imgf000031_0001
Compounds of formula (I-d) wherein Xi represents a direct bond, said compounds being represented by formula (I-d-1), can be prepared by reacting an intermediate of formula (VIF) wherein Wi represents a suitable leaving group, such as for example halo, e.g. chloro and the like, with an intermediate of formula (V) in the presence of a suitable base, such as for example N-methyl morpholine, and a suitable solvent, such as
Figure imgf000031_0002
(V) (VH') (I-d-1)
Compounds of formula (I'") wherein X represents -S(=O)P-, said compounds being represented by formula (F "-e), can be prepared by reacting an intermediate of formula (XVII) wherein W3 represents a suitable leaving group, such as for example halo, e.g. chloro and the like, with an intermediate of formula (V) in the presence of a suitable base, such as for example JV,jV-diisopropyl-ethanamine or ΛζjV-diethyl-ethanamine, and a suitable solvent, such as for example dichloromethane.
R7 R7
R2— S(=0)p-W3 + HN .A— ( Z)-Y-R1 *► R2— S(=OW-N A— ( Z)-Y-R1
(XVII)
(V)
(r-e)
Compounds of formula (I) wherein X represents -C(=O)-C2-6alkenediyl-, said compounds being represented by formula (I-f), can be prepared by reacting an intermediate of formula (XVIII) with an intermediate of formula (V) in the presence of a suitable solvent, such as for example an alcohol, e.g. ethanol. R7
O
R2 J3 + HN A— { V-Y-R1 →- R — L-C2-6alkenediyl— N A-→ /
C2-6alkenediyl-— N(CH3)2
(XVIII) (V)
(I-f)
Compounds of formula (I) wherein R is substituted with R R N-C^alkyl, said R being represented by -R2 -Ci_6alkyl-NR3R4 and said compounds being represented by formula (I-g), can be prepared by reacting an intermediate of formula (IXX) wherein W4 represents a suitable leaving group, such as for example CH3-S(=O)2-O-, with NHR3R4 in the presence of a suitable solvent, such as for example acetonitrile. Intermediates of formula (IXX) can be prepared by reacting the corresponding OH derivatives with CH3-S(=O)2-C1 in the presence of a suitable base, such as for example pyridine, and a suitable solvent, such as example dichloromethane.
+ NHR3R4
Figure imgf000032_0001
R7
(!XX) ^
R4R3N- Cr6alkyl R2-X-N^ A-^x ^
C-8)
Compounds of formula (I) wherein the R1 substituent is substituted with amino can be prepared from the corresponding compound wherein the amino function is protected by a suitable protecting group, such as for example a tertiair butyloxycarbonyl group, in the presence of a suitable acid, such as for example trifluoroacetic acid, and a suitable solvent, such as for example dichloromethane. Said protected compounds can be prepared according to the synthesis protocol described hereinabove for the compounds of formula (I) starting from an intermediate of formula (II).
Compounds of formula (I) wherein Y represents -C(=O)-NRX-, said compounds being represented by formula (I-h), can be prepared by reacting an intermediate of formula (XXV) with an intermediate of formula (XXVI) in the presence of DECP, a suitable base, such as for example N,7V-diethyl-ethanamine or N,7V-diisopropyl-ethanamine, and a suitable solvent, such as for example dichloromethane or acetonitrile.
Figure imgf000032_0002
(XXVI) (XXV) (!-h) Compounds of formula (I) wherein R7 represents Ci_4alkyl substituted with hydroxyl, said compounds being represented by formula (I-i), can be prepared by reacting an intermediate of formula (XLIII) with an appropriate acid, such as for example HCl and the like, in the presence of a suitable solvent, such as for example an alcohol, e.g. 2- propanol.
Figure imgf000033_0001
(XLIII) (I-i)
Compounds of formula (I) wherein X contains Z1, said Z1 being Z substituted with amino, said X being represented by Z1(NH2)-X2, wherein X2 represents the remainder of the linker X, and said compounds being represented by formula (I-j), can be prepared by deprotecting an intermediate of formula (XLIV) wherein P represents a suitable leaving group, such as for example tert butoxycarbonyl, with a suitable acid, such as for example trifluoroacetic acid, in the presence of a suitable solvent, such as for example dichloromethane.
Figure imgf000033_0002
(XLIV) (i-j)
The compounds of formula (I) may further be prepared by converting compounds of formula (I) into each other according to art-known group transformation reactions.
The compounds of formula (I) may be converted to the corresponding TV-oxide forms following art-known procedures for converting a trivalent nitrogen into its /V-oxide form. Said /V-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboper- oxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarbo- peroxoic acid, peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. tert.butyl hydro-peroxide. Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.
Compounds of formula (I) wherein R1 or R2 is unsubstituted, can be converted into a compound wherein R1 or R2 contain a Ci_4alkyl-S(=O)p- substituent, by reaction with Ci_4alkyl-S(=O)p-W5 wherein W5 represents a suitable leaving group, such as for example halo, e.g. chloro and the like, in the presence of a suitable base, such as for example JV,iV-diethyl-ethanamine, and in the presence of a suitable solvent, such as for example acetonitrile.
Compounds of formula (I) wherein R1 or R2 contains a Ci_6alkyloxycarbonyl substituent, can be converted into a compound of formula (I) wherein R1 or R2 contain a carboxyl substituent, by reaction with a suitable base, such as for example sodium hydroxide, in the presence of a suitable solvent, such as for example dioxane.
Compounds of formula (I) wherein R1 or R2 contain a Ci_6alkyloxycarbonyl substituent, can also be converted into a compound of formula (I) wherein R1 or R2 contain a CH2- OH substituent, by reaction with a suitable reducing agent, such as for example LiBH, in the presence of a suitable solvent, such as for example tetrahydrofuran or dioxane.
Compounds of formula (I) wherein R1 or R2 contain a Ci_6alkyloxycarbonyl substituent, can also be converted into a compound of formula (I) wherein R1 or R2 are unsubstituted by reaction with a suitable acid, such as for example hydrochloric acid and the like.
Compounds of formula (I) wherein R1 or R2 contain a Ci-salkyl-carbonyl substituent, can be converted into a compound of formula (I) wherein R1 or R2 contain a Ci_salkyl- CH(OH)- substituent, by reaction with a suitable reducing agent, such as for example NaBH4, in the presence of a suitable solvent, such as for example an alcohol, e.g. methanol.
Compounds of formula (I) wherein R1 or R2 contain a Ci_6alkyloxy substituent, can be converted into a compound of formula (I) wherein R1 or R2 contain a OH substituent, by reaction with a suitable reducing agent, such as for example BBr3, in the presence of a suitable solvent, such as for example dichloromethane or dichloroethane. Compounds of formula (I) wherein R1 or R2 contain a carboxyl substituent, can be converted into a compound of formula (I) wherein R1 or R2 contain a Het-C(=O)- substituent wherein Het represents an optionally substituted monocyclic saturated heterocycle containing at least one N atom, said heterocycle being linked via the N atom to the C(=O) group, by reaction with said heterocycle in the presence a suitable dehydrating (coupling) agent, such as for example Λ/I-(ethylcarbonimidoyl)-iV,jV- dimethyl-l,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), l-[bis(di-methylamino)methylene]-lH- benzotriazoliumhexafluorophosphate(l-)3 -oxide (HB TU) or l-[bis(dimethyl- amino)methylene]-5-chloro-lH-benzotriazolium-hexafluorophosphate(l-) 3-oxide (ΗCTU), optionally combined with hydroxy benzotriazole or chloro hydroxybenzotriazole, in the presence of a suitable solvent, such as for example N,N- dimethylformamide, dichloromethane, acetonitrile or tetrahydrofuran, and optionally in the presence of a suitable base, such as for example JV,jV-diisopropyl-ethanamine or JV,iV-diethyl-ethanamine. This reaction can also be performed as a fast synthesis reaction thereby using appropriate reagents well-known for fast synthesis, such as for example dicyclohexylcarbodiimide (DCC) or carbonyl diimidazole (CDI), linked to an appropriate carrier, e.g. polystyrene. Also for the purification of the reaction mixture, appropriate fast-synthesis reagents can be used, such as for example l-ethenyl-4- (isocyanatomethyl)-benzene polymer with ethenylbenzene.
The compounds of formula (I) and some of the intermediates in the present invention may contain an asymmetric carbon atom. Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures. For example, diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter current distribution, chiral liquid chromatography and the like methods. Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective crystallization or chromatographic techniques, e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the corresponding enantiomers. Pure stereochemically isomeric forms may also be obtained from the pure stereochemically isomeric forms of the appropriate intermediates and starting materials, provided that the intervening reactions occur stereospecifically. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) and intermediates involves liquid chromatography or SCF (Super Critical Fluid) chromatography, in particular using a chiral stationary phase.
Some of the intermediates and starting materials are known compounds and may be commercially available or may be prepared according to art-known procedures.
Intermediates of formula (II) wherein X represents X1-NH-C(=O)- with Xi representing a direct bond or Z, said intermediates being represented by formula (II-a), can be prepared by reacting an intermediate of formula (IV) with an intermediate of formula (VIII) wherein P represents a suitable protecting group, such as for example tertiair butyloxycarbonyl, in the presence of a suitable solvent, such as for example dichloromethane, followed by deprotecting the resulting intermediate of formula (IX) in the presence of a suitable acid, such as for example trifluoroacetic acid, and in the presence of a suitable solvent, such as for example dichloromethane. Before performing the deprotection reaction, the intermediate of formula (IX) can optionally be converted into an intermediate of formula (IX') by reaction with Ci_4alkyl halide, e.g. CH3I, in the presence of a suitable base, such as for example NaH, and a suitable solvent, such as for example N,Λ/-dimethylformamide.
R2
Figure imgf000036_0001
(DC) deprotection
Figure imgf000036_0002
(π"a<)
Intermediates of formula (II-a) wherein Rx represents hydrogen, said intermediates being represented by formula (II-a-1), can be prepared by reacting an intermediate of formula (IV) with an intermediate of formula (X) in the presence of a suitable solvent, such as for example dichloromethane, followed by hydrogenating (H2 or N2H4. H2O) the resulting intermediate of formula (XI) in the presence of a suitable catalyst, such as for example platinum on charcoal or raney nickel, optionally a suitable catalyst poison, such as for example a thiophene solution, and a suitable solvent, such as for example tetrahydrofuran or an alcohol, e.g. methanol. Before performing the hydrogenation reaction, the intermediate of formula (XI) can optionally be converted into an intermediate of formula (XF) by reaction with Ci_4alkyl halide, e.g. CH3I, in the presence of a suitable base, such as for example NaH, and a suitable solvent, such as for example Λ/,iV-dimethylformamide.
Figure imgf000037_0001
(II-a-1 -)
Intermediates of formula (II-a) wherein Rx represents hydrogen and wherein Xi represents a direct bond, said intermediates being represented by formula (II-a-2), can be prepared by reacting an intermediate of formula (IV) with Cl3COC(=O)-Cl followed by reaction with an intermediate of formula (X) in the presence of a suitable base, such as for example JV,jV-diethyl-ethanamine, and a suitable solvent, such as for example toluene, followed by hydrogenating (H2 or N2H4. H2O) the resulting intermediate of formula (XX) in the presence of a suitable catalyst, such as for example platinum on charcoal or raney nickel, optionally a suitable catalyst poison, such as for example a thiophene solution, and a suitable solvent, such as for example tetrahydrofuran or an alcohol, e.g. methanol. Before performing the hydrogenation reaction, the intermediate of formula (XX) can optionally be converted into an intermediate of formula (XX') by reaction with Ci_4alkyl halide, e.g. CH3I, in the presence of a suitable base, such as for example NaH, and a suitable solvent, such as for example Λ/,iV-dimethylformamide.
Figure imgf000038_0001
(II-a-2')
Intermediates of formula (II) wherein X represents -O-C(=O)-, said intermediates being represented by formula (II-b), can be prepared by reacting an intermediate of formula (XXVII) with an intermediate of formula (XXVIII) wherein W3 represents a suitable leaving group, such as for example halo, e.g. chloro, in the presence of NaH, and a suitable solvent, such as for example tetrahydrofuran, followed by hydrogenating the resulting product of formula (XXIX) in a next step in the presence OfH2, a suitable catalyst, such as for example platina on charcoal, a suitable catalyst poison, such as for example thiophene, and a suitable solvent, such as for example acetic acid.
Figure imgf000039_0001
(XXVIII) (XXIX) hydrogenation
Figure imgf000039_0002
(II-b)
Intermediates of formula (III) can be prepared by hydro lizing an intermediate of formula (XII) with a suitable base, such as for example potassium hydroxide or sodium hydroxide, in the presence of a suitable solvent, such as for example water, tetrahydrofuran, dioxane or an alcohol, e.g. methanol. Intermediates of formula (XII) wherein R1 represents Het1 wherein said Het1 is a heterocycle substituted with optionally substituted phenyl or an optionally substituted heterocycle, can be prepared by reacting the protected heterocycle with optionally substituted phenyl in the presence of a suitable catalyst, such as for example palladium acetate, in the presence of a suitable catalyst ligand, such as for example l,l '-(l,5-pentanediyl)bis[l,l '- diphenylphosphine], a suitable base, such as for example potassium acetate, and a suitable solvent, such as for example JV-methyl-pyrrolidin-2-one or by reacting the optionally substituted heterocyle with optionally substituted phenyl carrying a suitable leaving group, such as for example halo, e.g. bromo, iodo and the like, or an optionally substituted heterocylce carrying a suitable leaving group, such as for example halo, e.g. bromo, iodo and the like, in the presence of a suitable catalyst, such as for example palladium acetate, in the presence of a suitable catalyst ligand, such as for example 1,3- propanediylbis[diphenylphosphine], a suitable base, such as for example potassium acetate or cesium carbonate, and a suitable solvent, such as for example JV-methyl- pyrrolidin-2-one.
Cj-galkyl— O-C-R1 HO-C-R1 O Il O
(XII) (III)
Intermediates of formula (V) wherein Y represents -NRX-C(=O)-, said intermediates being represented by formula (V-a), can be prepared by reacting an intermediate of formula (XIII) wherein P represents a suitable protecting group, such as for example benzyl, with an intermediate of formula (XIV) wherein W2 represents a suitable leaving group, such as for example halo, e.g. chloro and the like, in the presence of a suitable base, such as for example N, JV-diethyl-ethanamine, and a suitable solvent, such as for example dichloromethane, followed by deprotecting the resulting intermediate of formula (XV) with H2 in the presence of a suitable catalyst, such as for example palladium on charcoal, and a suitable solvent, such as for example tetrahydrofuran and/or a suitable alcohol, e.g. methanol.
Figure imgf000040_0001
(V-a) Intermediates of formula (V-a) can also be prepared by reacting an intermediate of formula (XIII) with an intermediate of formula (III) in the presence of a suitable activating agent, such as for example oxalyl chloride, in the presence of a suitable base, such as for example JV,jV-diethyl-ethanamine, and a suitable solvent, such as for example dichloromethane or Λ/,Λf-dimethylformamide, followed by deprotecting the resulting intermediate of formula (XV) with H2 in the presence of a suitable catalyst, such as for example palladium on charcoal, and a suitable solvent, such as for example tetrahydrofuran and/or a suitable alcohol, e.g. methanol. Deprotection can also be performed in the presence of 1-chloroethyl carbonochloridic acid ester as deprotecting agent in the presence of a suitable solvent such as for example dichloroethane and an alcohol, e.g. methanol.
Figure imgf000041_0001
(V-a)
Intermediates of formula (V-a), can also be prepared according to the following reaction scheme wherein an intermediate of formula (XXI) wherein P represents a suitable protecting group, such as for example benzyloxycarbonyl or tertiair butyloxy or benzyl, and wherein W6 represents a suitable leaving group, such as for example halo, e.g. chloro and the like, with an intermediate of formula (X) in the presence of a suitable base, such as for example NaHCCh, and a suitable solvent, such as for example dichloromethane, resulting in an intermediate of formula (XXII), followed in a next step by hydrogenating (H2) said intermediate of formula (XXII) in the presence of a suitable catalyst, such as for example platinum on charcoal, and a suitable solvent, such as for example tetrahydrofuran, and an alcohol, e.g. methanol, resulting in an intermediate of formula (XXIII). In a next step, said intermediate of formula (XXIII) is reacted with an intermediate of formula (XIV) in the presence of a suitable base, such as for example NaHCO3 , and a suitable solvent, such as for example acetonitrile, resulting in an intermediate of formula (XXIV), which is deprotected in a next step in the presence of H2, a suitable catalyst, such as for example palladium on charcoal, and a suitable solvent, such as for example an alcohol, e.g. methanol; or in the presence of a suitable acid, such as for example trifluoroacteic acid or HCl, and a suitable solvent, such as for example dichloromethane or dioxane; or in the presence of ammonium formate, a suitable catalyst, such as for example palladium on charcoal, and a suitable solvent, such as for example an alcohol, e.g. methanol. P-W6 + , (XXI)
Figure imgf000042_0001
(V-a) (XXIV)
In the above reaction scheme, the intermediate of formula (XXIII) can also react with an intermediate of formula (III) in the presence of a suitable activating agent, such as for example SOCl2 or C1-C(=O)-C(=O)-C1, a suitable base, such as for example N,N- diethyl- ethanamine or ΛζΛf-diisopropyl-ethanamine, and a suitable solvent, such as for example dichloromethane or Λ^Λ'-dimethylformamide. Or an intermediate of formula (III) can react with an intermediate of formula (XXIII) in the presence of a suitable dehydrating (coupling) agent, such as for example Λ7>-(ethylcarbonimidoyl)-Λ/,Λ7- dimethyl-l,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), l-[bis(di-methylamino)methylene]-lH- benzotriazo liumhexafluorophosphate( 1 -)3 -oxide (HBTU), 1 - [bis(dimethyl- amino)methylene]-5-chloro-lH-benzotriazolium-hexafluorophosphate(l-) 3-oxide (HCTU), O-benzotriazolyl tetramethylisouronium tetrafluoroborate (TBTU) or diethyl cyanophosphonate (DECP), optionally combined with hydroxy benzotriazole or chloro hydroxybenzotriazole, in the presence of a suitable solvent, such as for example N,N- dimethylformamide, dichloromethane, acetonitrile or tetrahydrofuran, and optionally in the presence of a suitable base, such as for example Λ^Λf-diisopropyl-ethanamine or N, N- diethyl- ethanamine . The intermediate of formula (XXIV) can also react with an Ci_4alkyl halide, e.g. CH3I, in the presence of a suitable base, such as for example NaH, and a suitable solvent, such as for example N,Λ/-dimethylformamide, to form an intermediate of formula (XXIV) which can be deprotected according to the above described protocol to result in an intermediate of formula (V-a').
Intermediates of formula (V) wherein Y represents -C(=O)-NRX-, said intermediates being represented by formula (V-b), can be prepared by reacting an intermediate of formula (XXX) wherein P represents a suitable protecting group, such as for example benzyl or tertiair butyloxycarbonyl, with an intermediate of formula (XXVI) in the presence of a suitable dehydrating (coupling) agent, such as for example TV- (ethylcarbonimidoyl)-Λ/,Λ/-dimethyl-l,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), l-[bis(di- methylamino)methylene]-lH-benzotriazoliumhexafluorophosphate(l-)3-oxide (ΗBTU), 1 -[bis(dimethyl-amino)methylene]-5-chloro- lH-benzotriazolium- hexafluorophosphate(l-) 3-oxide (ΗCTU), O-benzotriazolyl tetramethylisouronium tetrafluoroborate (TBTU) or diethyl cyanophosphonate (DECP), optionally combined with hydroxy benzotriazole or chloro hydroxybenzotriazole, in the presence of a suitable solvent, such as for example N,Λ/-dimethylformamide, dichloro methane, acetonitrile or tetrahydrofuran, and optionally in the presence of a suitable base, such as for example JV,jV-diisopropyl-ethanamine or JV,iV-diethyl-ethanamine, followed by deprotecting the resulting intermediate of formula (XXXI) with H2, in the presence of a suitable catalyst, such as for example palladium on charcoal, and a suitable solvent, such as for example an alcohol, e.g. methanol, or by deprotection with a suitable acid, such as for example HCl, trifluoroacetic acid and the like, in the presence of a suitable solvent, such as for example an alcohol, e.g. isopropanol, or dichloromethane.
Figure imgf000043_0001
(XXX) (XXVI) (χχχl) deprotection
Figure imgf000043_0002
(V-b) Intermediates of formula (IV) wherein Xi represents a direct bond and R2 contains a Het-Ci_4alkyl substituent, wherein Het represents a monocyclic, saturated N containing heterocycle represented by formula (XXXII), said intermediate of formula (IV) being represented by formula (IV-a), can be prepared by reacting an intermediate of formula (XXXII) with an intermediate of formula (XXXIII) in the represence of a suitable dehydrating (coupling) agent, such as for example Λ/I-(ethylcarbonimidoyl)-iV,jV- dimethyl-l,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), l-[bis(di-methylamino)methylene]-lH- benzotriazo liumhexafluorophosphate( 1 -)3 -oxide (ΗBTU), 1 - [bis(dimethyl- amino)methylene]-5-chloro-lH-benzotriazolium-hexafluorophosphate(l-) 3-oxide
(ΗCTU), O-benzotriazolyl tetramethylisouronium tetrafluoroborate (TBTU) or diethyl cyanophosphonate (DECP), optionally combined with hydroxy benzotriazole or chloro hydroxybenzotriazole, in the presence of a suitable solvent, such as for example N,N- dimethylformamide, dichloromethane, acetonitrile or tetrahydrofuran, and optionally in the presence of a suitable base, such as for example JV,jV-diisopropyl-ethanamine or JV,iV-diethyl-ethanamine. The resulting intermediate of formula (XXXIV) can then be reduced in a next step in the presence of a suitable reducing agent, such as for example borane, in the presence of a suitable solvent, such as for example tetrahydrofuran, to an intermediate of formula (XXXV), which can then be converted into an intermediate of formula (IV-a) with phosgene in the presence of HCl in diethylether and a suitable solvent, such as for example toluene or acetonitrile.
Intermediates of formula (XXXIV) can also be converted into an intermediate of formula (IV-b) with phosgene in the presence of HCl in diethylether and a suitable solvent, such as for example toluene or acetonitrile or dichloromethane.
G N H + HOOC — C0-3alkyl — RA — NH2
Figure imgf000045_0001
NH2
(xxxπ) (xxxπi)
Figure imgf000045_0002
NH2
(XXXV)
C0-.3alkyt — R^ — N=C=O (W-V)
G "C0-3alkyl — R^ — N=C=O
(IV-a)
Intermediates of formula (IV-a) can also be prepared by reacting an intermediate of formula (XXXII) with an intermediate of formula (XXXVI) wherein W4 represents a suitable leaving group, such as for example halo, e.g. chloro and the like, in the presence of a suitable solvent, such as for example acetonitrile, resulting in an intermediate of formula (XXXV) with can be converted into an intermediate of formula (IV-a) as described hereinabove for intermediate (XXXV).
Figure imgf000045_0003
► (JN -Cr4alkyl — R21 -NH9
(XXXII) (XXXVI) (XXXV)
Intermediates of formula (VII) can be prepared by hydrolysis of an intermediate of formula (XL) in the presence of LiOH, an acid, such as for example HCl, and a suitable solvent, such as for example an alcohol, e.g. methanol. Intermediates of formula (XL) wherein R2 contains Het-Ci_4alkyl as substituent, said intermediates being represented by formula (XL-a) can be prepared by reacting an intermediate of formula (XLI) wherein W5 represents a suitable leaving group, such as for example halo, e.g. bromo and the like, with an intermediate of formula (XXXII). Intermediates of formula (XLI- a) as depicted below, can be prepared by reacting an intermediate of formula (XLII) with N-bromosuccinimide in the presence of 2,2'-(l,2-diazenediyl)bis[2- methylpropanenitrile] and a suitable solvent, such as for example CCl4. Intermediates of formula (XLII) wherein Xi represents CH2, said intermediates being represented by formula (XLII-a), can be prepared by reacting an intermediate of formula (XLV) with sodium metal, in the presence of a suitable Ci_4alkyl-OH, followed by adding a suitable acid, such as for example sulfuric acid. Intermediates of formula (XLV) can be prepared by reacting an intermediate of formula (IV '-a) with 1,1-dimethylethyl-nitrous acid ester, CuCl2, 1,1-dichloroethene in a suitable solvent, such as for example acetonitrile.
Figure imgf000046_0001
(XL) (VII)
L-N-H + W5-Cr4alkyl R21X1 ^ *~ CN— Cj^alkyl R21X1^1
O-Cr4alkyl O-Cr4alkyl
(XXXII) 1 4
(XLI) (XL-a)
H-Cr2alkyl
Figure imgf000046_0002
(XLII)
(XLI-a)
Figure imgf000046_0003
Intermediates of formula (XXV) wherein X represents -Xi-HN-C(=0)-, said intermediates being represented by formula (XXV-a), can be prepared by hydrolysis of an intermediate of formula (XXXVII) in the presence of a suitable base, such as for example sodium hydroxide, in the presence of a suitable solvent, such as for example dioxane. Intermediates of formula (XXXVII) can be prepared by reacting an intermediate of formula (IV) with an intermediate of formula (XXXVIII) in the presence of a suitable base, such as for example JV,jV-diethyl-ethanamine, and a suitable solvent, such as for example dichloromethane.
Figure imgf000047_0001
Figure imgf000047_0002
(XXV-a)
Intermediates of formula (XXV) wherein X represents -X1-Q=O)-, said intermediates being represented by formula (XXV-b), can be prepared by hydrolysis of an intermediate of formula (XXXVII-a) in the presence of a suitable base, such as for example sodium hydroxide, in the presence of a suitable solvent, such as for example dioxane and optionally an alcohol, e.g. methanol. Intermediates of formula (XXXVII- a) can be prepared by reacting an intermediate of formula (IX) with an intermediate of formula (XXXVIII) in the presence of a suitable dehydrating (coupling) agent, such as for example Λ/"-(ethylcarbonimidoyl)-Λ/,iV-dimethyl- 1 ,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), 1 - [bis(di-methylamino)methylene] - lH-benzotriazo liumhexafluorophosphate( 1 - )3-oxide (ΗBTU), 1 -[bis(dimethyl-amino)methylene]-5-chloro- lH-benzotriazolium- hexafluorophosphate(l-) 3-oxide (ΗCTU), O-benzotriazolyl tetramethylisouronium tetrafluoroborate (TBTU) or diethyl cyanophosphonate (DECP), optionally combined with hydroxy benzotriazole or chloro hydroxybenzotriazole, in the presence of a suitable solvent, such as for example N,Λ/-dimethylformamide, dichloro methane, acetonitrile or tetrahydrofuran, and optionally in the presence of a suitable base, such as for example JV,jV-diisopropyl-ethanamine or JV,Λ/-diethyl-ethanamine.
Figure imgf000047_0003
(xxxvπ-a)
Figure imgf000047_0004
(XXV-b) Intermediates of formula (XLIII-a) can be prepared according to the following reaction scheme. In a first step, an intermediate of formula (XLVI) wherein W12 represents a suitable leaving group, such as for example fluoro, is reacted with 3,4-dihydro-2H- pyran in the presence of 4-methyl-benzenesulfonic acid and a suitable solvent, such as for example dichloromethane, resulting in an intermediate of formula (XLVII). Said intermediate is in a next step reacted with an intermediate of formula (XLVIII) wherein P represents a suitable leaving group, such as for example benzyl, in the presence of Na2CCh and a suitable solvent, such as for example N,Λ/-dimethylformamide resulting in an intermediate of formula (XLIX). In a next step, said intermediate is hydrogenated with H2 in the presence of a suitable catalyst, such as for example platinum on charcoal, a catalyst poison, such as for example thiophene, and a suitable solvent, such as for example tetrahydrofuran, resulting in an intermediate of formula (L). This intermediate is then reacted with an intermediate of formula (III) in the presence of a suitable dehydrating (coupling) agent, such as for example Λ/I-(ethylcarbonimidoyl)-iV,jV- dimethyl- 1,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), l-[bis(di-methylamino)methylene]-lH- benzotriazo liumhexafluorophosphate( 1 -)3 -oxide (HBTU), 1 - [bis(dimethyl- amino)methylene]-5-chloro-lH-benzotriazolium-hexafluorophosphate(l-) 3-oxide (HCTU), O-benzotriazolyl tetramethylisouronium tetrafluoroborate (TBTU) or diethyl cyanophosphonate (DECP), optionally combined with hydroxy benzotriazole or chloro hydroxybenzotriazole, in the presence of a suitable solvent, such as for example N,N- dimethylformamide, dichloromethane, acetonitrile or tetrahydrofuran, and optionally in the presence of a suitable base, such as for example JV,jV-diisopropyl-ethanamine or JV,iV-diethyl-ethanamine. This reaction of an intermediate of formula (L) with an intermediate of formula (III) can also be performed in the presence of a suitable activating agent, such as for example C1-C(=O)-C(=O)-C1, a suitable base, such as for example JV,jV-diethyl-ethanamine, and a suitable solvent, such as for example N,N- dimethylformamide. This reaction can be performed as a fast synthesis reaction thereby using appropriate reagents well-known for fast synthesis, such as for example dicyclohexylcarbodiimide (DCC) linked to an appropriate carrier, e.g. polystyrene.
Also for the purification of the reaction mixture, appropriate fast-synthesis reagents can be used, such as for example l-ethenyl-4-(isocyanatomethyl)-benzene polymer with ethenylbenzene. In a next step, the intermediate of formula (LI) is deprotected with H2, in the presence of a suitable catalyst, such as for example palladium on charcoal, a suitable base, such as for example N,7V-diethyl-ethanamine, and a suitable solvent, such as for example tetrahydrofuran resulting in an intermediate of formula (LII) which can in a next step be reacted with an intermediate of formula (IV) in the presence of a suitable solvent, such as for example dichloro methane, to obtain an intermediate of formula (XLIII-a).
Figure imgf000049_0001
(XLVII)
(XLIX) hydrogenation
Figure imgf000049_0002
(Lπ) (IV) (XLIII-a)
Intermediates of formula (XLIV-a) can be prepared by reacting an intermediate of formula (VII) wherein Xi is substituted with a protected (P, such as for example teriair butyloxycarbonyl) amino group, said intermediate being represented by formula (VII- a), with an intermediate of formula (V) in the presence of a suitable dehydrating (coupling) agent, such as for example Λ/"-(ethylcarbonimidoyl)-Λ/,Λ/-dimethyl-l,3- propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), l-[bis(di-methylamino)methylene]-lH- benzotriazo liumhexafluorophosphate( 1 -)3 -oxide (HBTU), 1 - [bis(dimethyl- amino)methylene]-5-chloro-lH-benzotriazolium-hexafluorophosphate(l-) 3-oxide (HCTU), O-benzotriazolyl tetramethylisouronium tetrafluoroborate (TBTU) or diethyl cyanophosphonate (DECP), optionally combined with hydroxy benzotriazole or chloro hydroxybenzotriazole, in the presence of a suitable solvent, such as for example N,N- dimethylformamide, dichloromethane, acetonitrile or tetrahydrofuran, and optionally in the presence of a suitable base, such as for example JV,jV-diisopropyl-ethanamine or JV,jV-diethyl-ethanamine.
Figure imgf000050_0001
(Vll-a) (XLIV-a)
Intermediates of formula (VII) wherein Xi represents CHOH, said intermediates being represented by formula (VII-b) can be prepared by reducing an intermediate of formula (LIU) in the presence Of ZnBr2, Si(CHs)3-CN and an acid, such as for example HCl, in the presence of a suitable solvent, such as for example dichloromethane. Intermediates of formula (LIII) can be prepared by reacting an intermediate of formula (LIV) wherein Wi3 represents a suitable leaving group, such as for example halo, e.g. bromo and the like, with N,Λ/-dimethylformamide in the presence of BuLi and a suitable solvent, such as for example tetrahydrofuran.
Figure imgf000050_0002
(VII-b)
Pharmacological part As already indicated above, the present invention relates to the use of a DGAT inhibitor, in particular a DGATl inhibitor, to elevate levels of one or more satiety hormones, in particular GLP-I levels. The present invention also relates to the use of a DGAT inhibitor, in particular a DGATl inhibitor, for the manufacture of a medicament for the prevention or the treatment, in particular for the treatment, of a disease which can benefit from an elevated level of one or more satiety hormones, in particular a disease which can benefit from an elevated GLP-I level. In particular, GLP-I levels are elevated in plasma or in portal blood, more in particular in plasma. By elevated GLP-I levels, e.g. elevated GLP-I plasma level or an elevated GLP-I level in portal blood, it is meant that the GLP-I level of a subject having taken a DGATl inhibitor is elevated or increased compared to the subject under the same conditions but not having taken the DGATl inhibitor. In particular GLP-I levels are elevated in fasting conditions or postprandial, more in particular postprandial. Therapeutic uses for a compound which elevates GLP-I level include, but are not limited to, improving learning, enhancing neuro -protection, and/or alleviating a symptom of a disease or disorder of the central nervous system, e.g., through modulation of neurogenesis, and e.g., Parkinson's Disease, Alzheimer's Disease, Huntington's Disease, ALS, stroke, hemorrhage, cerebrovascular accident, ADD, and neuropsychiatric syndromes; converting liver stem/progenitor cells into functional pancreatic cells; preventing beta-cell deterioration and stimulation of beta-cell proliferation; treating pancreatitis; treating obesity; suppressing appetite and inducing satiety; treating irritable bowel syndrome or inflammatory bowel disease such as Crohn's disease and ulcerative colitis; reducing the morbidity and/or mortality associated with myocardial infarction and stroke; treating acute coronary syndrome characterized by an absence of Q-wave myocardial infarction; attenuating post-surgical catabolic changes; treating hibernating myocardium or diabetic cardiomyopathy; suppressing plasma blood levels of norepinepherine; increasing urinary sodium excretion, decreasing urinary potassium concentration; treating conditions or disorders associated with toxic hypervolemia, e.g., renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension; inducing an inotropic response and increasing cardiac contractility; treating polycystic ovary syndrome; treating respiratory distress; improving nutrition via a non-alimentary route, i.e., via intravenous, subcutaneous, intramuscular, peritoneal, or other injection or infusion; treating nephropathy; treating left ventricular systolic dysfunction, e.g., with abnormal left ventricular ejection fraction; inhibiting antro-duodenal motility, e.g., for the treatment or prevention of gastrointestinal disorders such as diarrhea, postoperative dumping syndrome and irritable bowel syndrome, and as premedication in endoscopic procedures; treating critical illness polyneuropathy (CIPN) and systemic inflammatory response syndrome (SIRS); modulating triglyceride levels and treating dyslipidemia; treating organ tissue injury (e.g. brain tissue injury) caused by reperfusion of blood flow following ischemia; improving the function of ischemic and reperfused brain tissue; treating coronary heart disease risk factor (CHDRF) syndrome. Further diseases which can benefit from an elevated GLP-I level, include, but are not limited to, ischemic myocardial stunning; ishemic/reperfusion injury; acute myocardial infarction; left ventricular dysfunction; vascular disease; neuropathy, including periphere sensoric neuropathy associated with type II diabetes; bone-related disorders, including osteoporosis, obesity, diabetes. Because of the effect on GLP-I, the DGAT inhibitors can also be used to provide cardioprotection. References supporting the above indications include Experimental Neurology, Vol. 203(2), pp293-301 (2007); US7,186,683; J. Pharm. Exp. Ther. vol. 312, No. 1, pp 303- 308 (2005); Diabetes, vol. 54, pp 146-151 (2005); US2007/0021339, which are incorporated herein by reference.
In view of the DGAT inhibitory activity, in particular the DGATl inhibitory activity, the present compounds of formula (I), their JV-oxide forms, their pharmaceutically acceptable salts or their solvates, can be used as a medicine. In particular, the present invention relates to a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof for use as a medicine, in particular for use as a medicine for the prevention or the treatment of a disease which can benefit from an elevated GLP-I level. In particular, the present invention also relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of a disease which can benefit from an elevated GLP-I level, such as the diseases and disorders mentioned above.
In view of the above-described utility for a DGAT inhibitor, in particular a DGATl inhibitor, there is provided a method of treating a warm-blooded mammal, including a human, suffering from or a method of preventing a warm-blooded mammal, including a human, to suffer from a disease which can benefit from an elevated level of GLP-I, in particular a method of treating a warm-blooded mammal, including a human, suffering from a disease which can benefit from an elevated level of GLP-I. Said methods comprise the administration of an effective amount of a DGAT inhibitor, in particular a DGATl inhibitor, to a warm-blooded mammal, including a human.
In view of the DGAT inhibitory activity of the compounds of formula (I), there is provided a method of treating a warm-blooded mammal, including a human, suffering from or a method of preventing a warm-blooded mammal, including a human, to suffer from a disease which can benefit from an elevated level of GLP-I, in particular a method of treating a warm-blooded mammal, including a human, suffering from a disease which can benefit from an elevated level of GLP-I . Said methods comprise the administration of an effective amount of a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, to a warmblooded mammal, including a human.
In view of the DGAT inhibitory activity, in particular the DGATl inhibitory activity, the present invention also relates to a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof for use as a medicine, in particular for use as a medicine for the prevention or the treatment of a diseases which can benefit from inhibition of DGAT, in particular DGATl. The invention also relates to the use of a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, for the manufacture of a medicament for the prevention or the treatment of a disease or disorder which can benefit from inhibition of DGAT, in particular DGATl . Diseases or disorders which can benefit from inhibition of DGAT, in particular DGATl include, but are not limited to metabolic disorders, such as obesity and obesity related disorders (including peripheral vascular disease, cardiac failure, myocardial ischaemia, cerebral ischaemia, cardiac myopathies), diabetes, in particular type II diabetes mellitus, and complications arising therefrom (such as retinopathy, neuropathy, nephropathy), syndrome X, insulin resistance, impaired glucose tolerance, conditions of impaired fasting glucose, hypoglycemia, hyperglycemia, hyperuricemia, hyperinsulinemia, pancreatitis, hypercholesterolemia, hyperlipidemia, dyslipidemia, mixed dyslipidemia, hypertriglyceridemia and nonalcoholic fatty liver disease, fatty liver, increased mesenteric fat, non-alcoholic steatohepatitis, liver fibrosis, metabolic acidosis, ketosis, dysmetabolic syndrome; dermatological conditions such as acne, psoriasis; cardiovascular diseases, such as atherosclerosis, arteriosclerosis, acute heart failure, congestive heart failure, coronary artery disease, cardiomyopathy, myocardial infarction, angina pectoris, hypertension, hypotension, stroke, ischemia, ischemic reperfusion injury, aneurysm, restenosis and vascular stenosis; neoplastic diseases, such as solid tumors, skin cancer, melanoma, lymphoma and endothelial cancers, e.g., breast cancer, lung cancer, colorectal cancer, stomach cancer, other cancers of the gastrointestinal tract (e.g., esophageal cancer and pancreatic cancer), prostate cancer, kidney cancer, liver cancer, bladder cancer, cervical cancer, uterine cancer, testicular cancer and ovarian cancer; and other diseases and conditions that are sensitive or responsive to modulation, in particular inhibition, of DGAT function, in particular DGATl function. Particular diseases or disorders which can benefit from inhibition of DGAT, in particular DGATl, are selected from obesity, hypercholesterolemia, hyperlipidemia, dyslipidemia, mixed dyslipidemia, hypertriglyceridemia, fatty liver, nonalcoholic fatty liver disease, liver fibrosis, non-alcoholic steatohepatitis and diabetes, in particular type II diabetes.
In view of the DGAT inhibitory activity of the compounds of formula (I), there is provided a method of treating a warm-blooded mammal, including a human, suffering from or a method of preventing a warm-blooded mammal, including a human, to suffer from a disease which can benefit from inhibition of DGAT, in particular a method of treating a warm-blooded mammal, including a human, suffering from a disease which can benefit from inhibition of DGAT. Said methods comprise the administration of an effective amount of a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, to a warm-blooded mammal, including a human.
The present invention also provides compositions for preventing or treating a disease which can benefit from an elevated GLP-I level or which can benefit from inhibition of DGAT, in particular DGATl, in particular for treating a disease which can benefit from elevated GLP-I levels or which can benefit from inhibition of DGAT, in particular DGATl. Said compositions comprise a therapeutically effective amount of a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier.
The compounds of the present invention may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations, which are intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. The compounds of the present invention may also be administered via inhalation or insufflation by means of methods and formulations employed in the art for administration via this way. Thus, in general the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry powder. Any system developed for the delivery of solutions, suspensions or dry powders via oral or nasal inhalation or insufflation are suitable for the administration of the present compounds.
The compounds of the present invention may also be topically administered in the form of drops, in particular eye drops. Said eye drops may be in the form of a solution or a suspension. Any system developed for the delivery of solutions or suspensions as eye drops are suitable for the administration of the present compounds.
It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.
The exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.
Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 % by weight, more preferably from 0.1 to 70 % by weight, even more preferably from 0.1 to 50 % by weight of the compound of formula (I), and, from 1 to 99.95 % by weight, more preferably from 30 to 99.9 % by weight, even more preferably from 50 to 99.9 % by weight of a pharmaceutically acceptable carrier, all percentages being based on the total weight of the composition.
In view of the above described effects of DGAT inhibitors and/or the effect on GLP-I levels by DGAT inhibitors, the present invention also relates to a) a combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a dipeptidyl peptidase-4 inhibitor (DPP- 4 inhibitor).
DPP-4 is a membrane-spanning cell surface aminopeptidase widely expressed in many tissues, such as liver, lung, kidney, intestinal brush-border membranes, lymphocytes, endothelial cells. DPP-4 cleaves peptides with a proline or alanine residue in the second aminoterminal position. Many gastro -intestinal hormones are substrates for DPP-4, among them GLP-I. A DPP-4 inhibitor thus inhibits cleavage of GLP-I and hence provides for an increase in the level of GLP-I. Therefore, a combination as indicated above can be used to combine the activity of the DGAT inhibitor and the DPP4 inhibitor in order to elevate GLP-I levels. By administering a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N- oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, with a DPP4 inhibitor, different mechanisms may be targeted in order to achieve elevated levels of GLP-I. In this way, the use of such a combination may reduce the dosage of the DGAT inhibitor and the DPP4 inhibitor required for a desired elevation in GLP-I level as compared to when the DGAT inhibitor or the DPP4 inhibitor is administered as a monotherapy. Therefore, these combinations may reduce or eliminate side effects of monotherapy while not interfering with the GLP-I level increasing activity. Also, the combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a DPP4 inhibitor can be used as a medicine. The present invention also relates to a product comprising (a) a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) a DPP4 inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-I . The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers. Said DPP4 inhibitor which may be combined with a DGAT inhibitor according to the present invention, in particular a DGATl inhibitor, may be a known DPP4 inhibitor such as for example sitagliptin, vildagliptin, and saxagliptin. b) a combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a GLP-I analogue. Said GLP-I analogue can be considered as an agonist at the GLP-I receptor. Also, the combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a GLP-I analogue can be used as a medicine. The present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) a GLP-I analogue, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP- 1. The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
Said GLP-I analogue which may be combined with a DGAT inhibitor according to the present invention may be a known GLP-I analogue such as for example exenatide, exenatide LAR or liraglutide. c) a combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an anti-diabeticum. Also, the combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an anti-diabeticum can be used as a medicine. The present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an anti-diabeticum, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-I or DGAT inhibition, such as for example diabetes, in particular type II diabetes. The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers. Said anti-diabeticum which may be combined with a DGAT inhibitor according to the present invention may be a known anti-diabeticum such as for example metformin, glibenclamide, rosiglitazon, pioglitazon, repaglinide, glimepiride, acarbose, glicazide, glipizide, nateglinide, tolbutamide, a protein tyrosine phosphatase 1 inhibitor, or a 11-beta-hydroxysteroid dehydrogenase inhibitor, d) a combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a phosphodiesterase (PDE) inhibitor, in particular a PDElOA or PDEl IA inhibitor. Phosphodiesterase (PDE) inhibitors, in particular PDElOA or PDEl IA inhibitors, are known to be insulin secretagogues, and to enhance the signalling of GLP-I by inhibition of the hydrolysis of cAMP. Also, the combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a phosphodiesterase (PDE) inhibitor, in particular a PDElOA or PDEl IA inhibitor, can be used as a medicine. The present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) a phosphodiesterase (PDE) inhibitor, in particular a PDElOA or PDEl IA inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-I or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity. The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers. Said phosphodiesterase (PDE) inhibitor, in particular a PDElOA or PDEl IA inhibitor, which may be combined with a DGAT inhibitor according to the present invention may be a known PDE inhibitor such as for example papaverine, PQ-10, dipyridamole , ibudilast or tadalafil. e) a combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an appetite suppressant. Also, the combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an appetite suppressant can be used as a medicine. The present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an appetite suppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-I or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity. The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers. Said appetite suppressants, which may be combined with a DGAT inhibitor according to the present invention may be a known appetite suppressant such as for example sibutramine and phentermine. f) a combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an anti-obesity drug with a CNS (central nervous system) mode of action such as for example a CB 1 antagonist or inverse agonists.
Also, the combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an anti-obesity drug with a CΝS (central nervous system) mode of action can be used as a medicine. The present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an anti- obesity drug with a CΝS (central nervous system) mode of action, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-I or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity. The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers. Said anti-obesity drugs with a CΝS (central nervous system) mode of action, which may be combined with a DGAT inhibitor according to the present invention may be a known a anti-obesity drug such as for example Rimonabant, orlistat, SLV-319, or MK-0364. g) a combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an hypolipidemic drug such as for example 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors, squalene synthase inhibitors, FXR (farnesoid X receptor) and LXR (liver X receptor) ligands, cholestyramine, fibrates, nicotinic acid and aspirin.
Also, the combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an hypolipidemic drug can be used as a medicine. The present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an hypolipidemic drug, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-I or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity. The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers. Said hypolipidemic drug which may be combined with a DGAT inhibitor according to the present invention may be a known hypolipidemic drug such as for example lovastatin, pravastatin, simvastatin, pravastatin, cerivastatin, mevastatin, velo statin, fluvastatin, dalvastatin, atorvastatin, rosuvastatin and rivastatin. h) a combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an agonist of peroxisome proliferator- activator receptor such as for example fenofibrate.
Also, the combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an agonist of peroxisome proliferator- activator receptor such as for example fenofibrate, can be used as a medicine. The present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an agonist of peroxisome proliferator-activator receptor such as for example fenofibrate, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-I or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity. The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers, i) a combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an antihypertensive agent. Also, the combination of a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a JV-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an antihypertensive agent, can be used as a medicine. The present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGATl inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an antihypertensive agent, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-I or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity. The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers. Said anti-hypertensive agent which may be combined with a DGAT inhibitor according to the present invention may be a known anti-hypertensive agent, e g loop diuretics such as ethacrynic acid, furosemide and torsemide, angiotensin converting enzyme (ACE) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perinodopril, quinapril, ramipril and trandolapril; inhibitors of the Na-K- ATPase membrane pump such as digoxin; neutralendopeptidase (NEP) inhibitors; ACE/NEP inhibitors such as omapatrilat, sampatrilat and fasidotril; angiotensin II antagonists such as candesartan, eprosartan, irbesartan, losartan, telmisartan and valsartan, in particular valsartan; renin inhibitors such as ditekiren, zankiren, terlakiren, aliskiren, RO 66-1132 and RO-66-1168; β-adrenergic receptor blockers such as acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, sotalol and timolol; inotropic agents such as digoxin, dobutamine and milrinone; calcium channel blockers such as amlodipine, bepridil, diltiazem, felodipine, nicardipine, nimodipine, nifedipine, nisoldipine and verapamil; aldosterone receptor antagonists; and aldosterone synthase inhibitors.
The following examples are intended to illustrate the present invention. Experimental Part
Hereinafter, the term 'm.p." means melting point, 'THF' means tetrahydrofuran, 'EtOAc' means ethyl acetate, 'MeOH' means methanol, 'DIPE' means diisopropyl ether, 'DMF' means N,N-dimethylformamide, 'Et3N' means triethylamine, 'DPPENT' means l,l '-(l,5-pentanediyl)bis[l,r-diphenylphosphine], "resin-linked-N=C=O" means a polystyrene based resin functionalized with isocyanato-groups, such as for example l-ethenyl-4-(isocyanatomethyl)-benzene polymer with ethenylbenzene, "PS- Carbodiimide" means polystyrene resin-bound N-cyclohexylcarbodiimide, "PS-NMM" means 3-(morpholino)propyl polystyrene sulfonamide (a resin-bound equivalent of N- methyl morpholine), "PS-TsOH" means polystyrene-para-toluenesulphonic acid, "PS- Trisamine" means tris-(2-aminoethyl)-amino methyl polystyrene HL (200 - 400 mesh), "DECP" means diethyl cyanophosphonate, "Et2O" means diethyl ether, "p. a." means pro analysis, "eq." means equivalent, "DIPEA" means diisopropylethylamine, "TFA" means trifluoroacetic acid, "TBTU " means O-benzotriazolyl tetramethylisouronium tetrafluoroborate, and "MP-carbonate" is macroporous triethylammonium methylpolystyrene carbonate (a macroporous polystyrene anion-exchange resin that is a resin-bound equivalent of tetraalkylammonium carbonate).
ArgoScoop™ resin (Biotage) dispenser is a variable volumn resin scoop designed for convenient dispensing of polymer scavengers and reagents.
MiniBlock™ (Mettler Toledo) is a flexible, easy to use tool designed for parallel synthesis.
A. Preparation of the intermediates Example Al a. Preparation of intermediate 1
Figure imgf000062_0001
A mixture of [4-(4-piperidinyl)phenyl] carbamic acid 1,1-dimethylethylester (0.025 mol) in CH2Cl2 (100 ml) was stirred while cooling on an ice-bath. A solution of 1,3- dichloro-2-isocyanatobenzene (0.027 mol) in CH2Cl2 (25 ml) was added dropwise. The reaction mixture was allowed to warm to room temperature. The reaction mixture was stirred for one hour at room temperature. The resulting precipitate was filtered off, washed with DIPE and dried. Yield: 6.2 g of intermediate 1. The corresponding filtrate's solvent was evaporated. The residue was triturated under DIPE, filtered off and dried. Yield: 4.2 g of intermediate 1.
b. Preparation of intermediate 2
Figure imgf000063_0001
A mixture of intermediate 1 (prepared according to Al. a) (0.022 mol) and trifluoroacetic acid (25 ml) in CH2Cl2 (250 ml) was stirred for 2 hours at room temperature. The solvent was evaporated. The residue was triturated under DIPE, filtered off and dried. This fraction (11.2 g) was converted into the free base by adding aqueous ammonia. This mixture was extracted with CH2Cl2. The separated organic layer was dried, filtered and the solvent evaporated. Yield: 7.6 g of intermediate 2.
c. Preparation of intermediate 3
Figure imgf000063_0002
2-[[l,l-dimethylethoxy)carbonyl]amino]benzoic acid (0.001 mol) was dissolved in DMF (5 ml) to get stock solution (I). Part of stock solution (I) (1.2 ml, containing 0.00024 mol of 2-[[l,l-dimethylethoxy)carbonyl]amino]benzoic acid) was put into the MiniBlock. PS-Carbodiimide, 1.9 mmol/g (0.0004 mol) was added with ArgoScoop. A solution of 1-hydroxy-iH-benzotriazole (0.00030 mol) in DMF (1 ml) was added and the mixture was shaken for 30 minutes. A solution of intermediate 2 (prepared according to Al.b) (0.0002 mol) in DMF (3.5 ml) was added and the reaction mixture was shaken overnight. MP-carbonate, 2.8 mmol/g (0.00090 mol) and resin- linked- N=C=O, 1.8 mmol/g (0.0002 mol) were added with ArgoScoop. The reaction mixture was shaken overnight, then filtered. CH2Cl2 (4 ml) was added and the mixture was shaken for 2 hours. The mixture was filtered and the filtrate's solvent was evaporated (Genevac® solvent evaporator). The residue (± 0.120 g) was purified by HPLC. The product fractions were collected and worked-up. Yield : 0.008 g of intermediate 3.
Example A2 a. Preparation of intermediate 4
Figure imgf000063_0003
A mixture of l-(4-nitrophenyl)-piperazine (0.02413 mol) in CH2Cl2 p. a. (100 ml) was stirred on an ice bath. Then l,3-dichloro-2-isocyanatobenzene (0.02660 mol) in CH2Cl2 p. a. (20 ml) was added dropwise while the reaction mixture was stirred on the ice bath. For 2 hours, the reaction mixture was let to warm up to room temperature and was stirred at room temperature. The reaction mixture was filtered off and washed with DIPE (q.s.). The precipitate was dried in vacuo. Yield : 8.923 g of intermediate 4 (94 %; yellow powder)
b. Preparation of intermediate 5
Figure imgf000064_0001
A mixture of intermediate 4 (prepared according to A2.a) (0.047 mol) in MeOH (200 ml), THF (200 ml) and NH3 in MeOH (100 ml) was stirred for 15 minutes at room temperature and then hydrogenated at room temperature (atmospheric pressure) with Pt/C 5% (4 g) as a catalyst in the presence of thiophene solution (3 ml; 4 % in DIPE). After uptake of H2 (3 equiv), the catalyst was filtered off (product was also a precipitate and was therefore dissolved by washing the filterresidue with CH2Cl2). The combined filtrate 's solvent was evaporated. Yield : 14.616 g of intermediate 5.
Example A3 a. Preparation of intermediate 6
Figure imgf000064_0002
A mixture of 2-methyl-4-thiazolecarboxylic acid ethyl ester (0.1 mol), l-iodo-4-(l- methylethyl)benzene (0.3 mol), KOAc (0.3 mol), Pd(OAc)2 (0.005 mol) and DPPENT (0.001 mol) in l-methyl-2-pyrrolidinone (150 ml) was stirred for 24 hours at 140 0C. The reaction mixture was poured out into water and extracted four times with EtOAc. The organic layers were combined, washed twice with water, dried, filtered and the solvent evaporated. Yield: intermediate 6 (crude, used in next reaction step, without further purification). . Preparation of intermediate 7
Figure imgf000065_0001
A mixture of intermediate 6 (prepared according to A3. a) (approximately 0.1 mol; crude) in H2O (500 ml) and MeOH (500 ml) was stirred at room temperature. KOH (0.3 mol) was added portionwise and the reaction mixture was stirred over the weekend at room temperature. The solvent was evaporated. The residue was taken up into water. This mixture was washed 3 x with CH2Cl2. The layers were separated. The aqueous phase was acidified until pH = 3. The acidic mixture was extracted four times with CH2Cl2. The separated organic layer was dried, filtered and the solvent evaporated. The residue (21 g) was purified by HPLC (gradient elution with (NH4OAc 0.5% in water/CH3CN 90/10)/MeOH/CH3CN). The product fractions were collected and the solvent was evaporated. The residue was taken up into water and acidified to pH = 2-3. This mixture was extracted with CH2Cl2. The separated organic layer was dried, filtered and the solvent evaporated. The residue (10 g) was stirred in DIPE, filtered off and dried. Yield: Intermediate 7 (crude; used as such in the next reaction step).
Example A4 a. Preparation of intermediate 8
Figure imgf000065_0002
A mixture of 4-[4-(phenylmethyl)-l-piperazinyl]benzenamine (0.185 mol) in CH2Cl2 p. a. (1500 ml) and Et3N (50 ml) was stirred on an ice-bath for 5 minutes. 4'-(trifluoromethyl)-[l,l '-biphenyl]-2-carbonyl chloride (0.37 mol) was added drop wise. The mixture was stirred for 3 hours. The organic layer was washed with water, dried, filtered and the solvent was evaporated. The residue was triturated in
DIPE. The precipitate was filtered off and dried. Yield: 99.8 g of intermediate 8 (100 %). b. Preparation of intermediates 9 and 10
Figure imgf000066_0001
Intermediate 9
Intermediate 10 (HCl salt (1 I))
A mixture of intermediate 8 (prepared according to A4.a) (0.19 mol) in MeOH (600 ml) and THF (600 ml) was hydrogenated overnight with Pd/C 10 % (3 g) as a catalyst. After uptake of H2 (1 equiv), the catalyst was filtered off and the filtrate was evaporated. The residue was triturated in DIPE. The precipitate was filtered off and dried. Yield: 76 g (94 %). Part of the compound was converted into the HCl salt following art-known methods, yielding intermediate 10 (HCl-salt). (A part (1 g) of this fraction was recrystallized from 2-propanol. The precipitate was filtered off and dried. Yield : 0.36 g of intermediate 10.) The rest of the crude product was dissolved in H2O. This mixture was alkalized with Na2CO3 and then extracted with CH2Cl2. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was triturated in DIPE. The precipitate was filtered off and dried. Yield: Intermediate 9.
Example A5 a. Preparation of intermediate 11
Figure imgf000066_0002
A mixture of [4'-(trifluoromethyl)-[l,l '-biphenyl]-2-carboxylic acid (0.09 mol) in CH2Cl2 (500 ml) and DMF (5 ml) was stirred. Ethanedioyl dichloride (0.09 mol) was added dropwise. The mixture was stirred for 1 hour (mixture A). 4-[l-(phenylmethyl)- 4-piperidinyl]-benzenamine .hydrochloride (0.046 mol) in CH2Cl2 (500 ml) and Et3N (20 ml) was stirred on an ice-bath and this mixture was added dropwise to mixture A. The reaction mixture was stirred and refluxed overnight, then cooled and washed with water. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH2C12/CH3OH 98/2). The desired product fractions were collected and the solvent was evaporated. The residue was triturated in DIPE. The precipitate was filtered off and dried. Yield: 5.6 g of intermediate 11. b. Preparation of intermediate 12
Figure imgf000067_0001
A mixture of intermediate 11 (prepared according to A5.a) (0.025 mol) in CH3OH (250 ml) was hydrogenated at 500C overnight with Pd/C 10% (2 g) as a catalyst. After uptake of H2 (1 equiv), the catalyst was filtered off and the filtrate was evaporated. The residue was triturated in DIPE. The precipitate was filtered off and dried. Yield: 7.7 g of intermediate 12 (73 %).
Example A6 a. Preparation of intermediate 13
Figure imgf000067_0002
[4'-(Trifluoromethyl)-l,r-biphenyl]-2-carbonyl chloride (0.12 mol) was added dropwise to a stirring mixture of 441,2,3,6-tetrahydro-l-(phenylmethyl)-4- pyridinyl]benzenamine (prepared according to the teachings in WO2002/081460, said content being incorporated herein by reference) (0.095 mol) in CH2Cl2 p. a. (300 ml) and Et3N (50 ml). The mixture was stirred overnight, poured out into water and then stirred for 30 minutes. The organic layer was separated, washed, dried, filtered and the solvent was evaporated. The residue was triturated in DIPE. The precipitate was filtered off and dried. Yield: 43 g (88 %). A part (2 g) of this fraction was recrystallized from EtOH. The precipitate was filtered off and dried. Yield: 1.32 g of intermediate 13. b. Preparation of intermediate 14
Figure imgf000068_0001
1-Chloroethyl chloro formate (0.078 mol) was added dropwise to a stirring mixture of intermediate 13 (prepared according to A6.a) (0.039 mol) in 1 ,2-dichloroethane (500 ml). The mixture was stirred for 30 minutes and then stirred and re fluxed overnight. The solvent was evaporated. CH3OH (500 ml) was added. The mixture was stirred and refluxed overnight. The solvent was evaporated. The residue was triturated in DIPE. The precipitate was filtered off and dried. Yield: 20.8 g of intermediate 14 (HCl salt).
Example A7 a. Preparation of intermediate 15
Figure imgf000068_0002
A mixture of 2-iodo-benzoic acid methyl ester (0.20 mol), 2-ethyl-4-methylthiazole (0.20 mol), Pd(OAc)2 (1.120 g), l,3-propanediylbis[diphenylphosphine] (4.120 g) and Cs2CO3 (65 g) in l-methyl-2-pyrrolidinone (200 ml) was stirred for 36 hours at 140 0C. More Cs2CO3 (32.5 g) and 2-iodo-benzoic acid methyl ester (0.1 mol) and catalyst was added and the reaction mixture was stirred for 16 hours at 140 0C. The reaction mixture was poured out into water and extracted with EtOAc. The organic layers were combined, washed with water, dried, filtered and the solvent evaporated. Yield: intermediate 15 (crude; used as such in the next reaction step).
b. Preparation of intermediate 16
Figure imgf000068_0003
A mixture of intermediate 15 (prepared according to A7.a) (0.00765 mol) in THF (20 ml), CH3OH (20 ml) and NaOH, IN (20 ml) was stirred for 16 hours at room temperature. The solvent was evaporated. The residue was taken up into water. This mixture was washed 3 x with CH2Cl2. The layers were separated. The aqueous phase was acidified with 1 N HCl (20 ml). The acidic mixture was extracted with CH2Cl2. The separated organic layer was dried, filtered and the solvent evaporated. The residue was stirred in DIPE, filtered off and dried. Yield: 0.450 g of intermediate 16.
Example A8 a. Preparation of intermediate 17
Figure imgf000069_0001
A mixture of 2-methyl-4-thiazolecarboxylic acid ethyl ester (0.054 mol), 5-bromo-l,3- benzodioxole (0.18 mol), Pd(OAc)2 (1.041 g), l,3-propanediylbis[diphenylphosphine] (3.831 g) and KOAc (18.6 g) in l-methyl-2-pyrrolidinone (30 ml) was stirred for 16 hours at 140 0C. The reaction mixture was poured out into water and extracted with EtOAc. The organic layers were combined, washed with water, dried, filtered and the solvent evaporated. Yield: Intermediate 17 (crude, used as such in the next reaction step).
b. Preparation of intermediate 18
Figure imgf000069_0002
A mixture of intermediate 17 (prepared according to A8.a) (0.054 mol) in CH3OH (100 ml) and NaOH, 1 N (100 ml) was stirred for 16 hours at room temperature. The solvent was evaporated. The residue was taken up into water. This mixture was washed 3 times with CH2Cl2. The layers were separated. The aqueous phase was neutralized with IN HCl (100 ml). The mixture was extracted with CH2Cl2 (3 times). The separated organic layer was dried, filtered and the solvent evaporated. Yield: 2.5 g of intermediate 18.
Intermediate
Figure imgf000069_0003
2-methyl-5-(3-trifluoromethyl-phenyl)-thiazole-4- carboxylic acid was made accordingly (see Bl.b) Example A9 a. Preparation of intermediate 19
Figure imgf000070_0001
3-Pyrrolidin-l-ylaniline (8 g, 0.0478 mol) was dissolved in CH2Cl2 (50 ml). First Et3N (25 ml, 0.178 mol) and then 4-[4-(phenylmethyl)-l-piperazinyl]-benzoic acid (11.27 g, 0.038 mol) and more CH2Cl2 (100 ml) were added. Finally, DECP (11.37 ml, 0.0761 mol) was added and the reaction mixture was stirred for 18 hours. Subsequently, the mixture was stirred in a NaHCO3 solution. The layers were separated and the organic layer was dried (MgSO4), filtered and the solvent was evaporated and co-evaporated with toluene. The residue was purified by column chromatography over silica gel (eluent: CH2Cl2/Me0H 98/2). The purest fractions were collected and the solvent was evaporated. The residue was stirred in Et2O, filtered off and washed (Et2O). The product was dried (50 0C, 48 hours, in vacuo). Yield: 9.437 g of intermediate 19 (55 %).
b. Preparation of intermediate 20
Figure imgf000070_0002
Pd/C 10 % (1 g) was suspended in MeOH (150 ml) under N2 flow. Intermediate 19 (5.62 g, 0.0126 mol) was added and the reaction mixture was stirred at 50 0C under H2 atmosphere until 1 eq. of H2 was absorbed. The catalyst was filtered off over diatomaceous earth (Dicalite®). The solvent was evaporated and co-evaporated with toluene. The residue was stirred in Et2O and filtered off. The product was dried (50 0C,
18 hours, in vacuo). Yield: 4.23 g of intermediate 20 (96 %).
Example AlO a. Preparation of intermediate 21
Figure imgf000070_0003
CH2Cl2 (75 ml) was added to 4-amino-3,5-dichloro-benzeneacetic acid (2.86 g, 0.013 mol) and the mixture was stirred. Et3N (5.5 ml, 0.0391 mol) and pyrrolidine (1.3 ml, 0.0158 mol) were added. Finally DECP (2.5 ml, 0.015 mol) was added. The reaction mixture was set under N2 flow for a few minutes and then the vessel was closed. After 18 hours, a NaHCO3 solution was added and the layers were separated. The separated organic layer was dried (MgSO4), filtered and the solvent was evaporated and co- evaporated with toluene. The residue (4.317 g) was purified by column chromatography over silica gel (eluent: CH2Cl2ZMeOH 97/3). The desired fractions were collected and the solvent was evaporated and co-evaporated with toluene. Yield: 3.104 g of intermediate 21 (88 %).
b. Preparation of intermediate 22
Figure imgf000071_0001
A solution of borane in THF (30 ml, 0.03 mol; 1 M solution) was added to intermediate 21 (2.88 g, 0.0105 mol) in THF (60 ml; dry) and the reaction mixture was refluxed for 18 hours. Subsequently, the mixture was cooled to room temperature and the mixture was added to a stirring solution of H2O (300 ml) and concentrated HCl (300 ml) on an ice-bath. This mixture was refluxed for 30 minutes. Then, the mixture was cooled, was put on an ice-bath, and K2CO3 powder was added slowly to alkalize the mixture. At pH 8, CH2Cl2 and H2O were added to the mixture (for an extraction). The layers were separated. The organic layer was dried (MgSO4), filtered and the solvent was evaporated and co-evaporated with toluene. The residue was stirred in Et2O and this mixture was extracted twice with HCl (1 N). The HCl layers were combined, neutralized with (NaHCO3) until pH 8 and extracted with CH2Cl2 and H2O. The layers were separated and the organic layer was dried (MgSO4), filtered and the solvent was evaporated and co-evaporated with toluene. The residue was dried (50 0C, 18 hours, in vacuo). The product was stirred in Et2O with HCl/Et2O (15 ml; 1 M). The product was filtered off and washed with Et2O to yield 3.05 g of intermediate 22 (98 %; .HCl).
c. Preparation of intermediate 23
Figure imgf000071_0002
Intermediate 22 (3 g, 0.0101 mol) was dissolved in a solution of HCl in Et2O (10 ml, 0.01 mol; 1 M solution) and CH3CN (150 ml; dry) at room temperature. The mixture was stirred for 30 minutes. 20 % Phosgene in toluene (7.6 ml, 0.0152 mol) was added portionwise and the mixture was stirred for 20 hours. The mixture was filtered and the turbid filtrate was evaporated and co-evaporated with toluene (dry) to yield 2.89 g of the crude intermediate 23 (quantitative yield; HCl salt). Example Al l a. Preparation of intermediate 24 and 25
Figure imgf000072_0001
Intermediate 24 (free base) Intermediate 25 (.HCl)
2,6-Dichloro-4-chloromethyl-phenylamine (11 g, 0.0445 mol) was added portionwise to a stirring solution of pyrrolidine (15.84 g, 0.223 mol) in CH3CN (250 ml). The reaction mixture was placed in a water bath (exothermic reaction). The solvent was evaporated and the residue was dissolved in CH2Cl2 (150 ml) and a 50 % saturated NaHCO3 solution (100 ml). The mixture was stirred for 15 minutes. The organic layer was separated, dried (MgSO4), filtered and the solvent was evaporated and co- evaporated with toluene. The oily residue (11.46 g) was stirred in DIPE (30 ml) for 15 minutes and then the DIPE was evaporated again. The residue was combined with 2.65 g of another batch and the total amount of crude product was purified by column chromatography over silicagel (eluent: CH2Cl2ZMeOH 95/5). The pure fractions were combined and the solvent was evaporated and co-evaporated with toluene. The residue was stirred in DIPE (25 ml). The DIPE was decanted from the solid, yielding a DIPE layer (*) and a solid. The remaining DIPE on the solid was evaporated and the solid was dried (50 0C, in vacuo), yielding 2.75 g of intermediate 24 (28.18 %). The impure fractions from the column were combined and the solvent was evaporated and co- evaporated with toluene. The residue (7.45 g) was dissolved in DIPE (20 ml) and 6N HCl in 2-propanol (5 ml) was added while the mixture was stirred vigorously. A yellowish oil was formed that became solid after continuous stirring. The solid was filtered off and washed with DIPE, yielding a filtrate (*) and a solid. The solid was dried (50 0C, in vacuo). Yield: 5.19 g of intermediate 25 (41.37 %; .HCl). The filtrate (*) and the DIPE layer (*) were combined and the solvent was evaporated. The residue (2.59 g) was dissolved in CH2Cl2 and NaHCO3 in H2O. The layers were separated and the organic layer was dried (MgSO4), filtered and the solvent was partially evaporated. The concentrated solution was re-purified over silicagel (eluent: CH2Cl2/Me0H 95/5). The pure fractions were collected and the solvent was evaporated and co-evaporated with toluene. The residue was dried (50 0C, 18 hours, in vacuo). Yield: 1.85 g of intermediate 24 (17 %). b. Preparation of intermediate 26
Figure imgf000073_0001
HCl in Et2O (10.32 ml, 0.0206 mol; 1 M) was added to a stirring solution of intermediate 24 (4.6 g, 0.0188 mol) in CH3CN (75 ml; p. a. dried on molecular sieves) and CH2Cl2 (10 ml; p. a.). The mixture was stirred for 1 hour. A precipitate was formed. The reaction mixture was cooled on an ice-bath, and 20 % phosgene in toluene (14.073 ml) was added. The reaction mixture was stirred for 3 hours. An additional amount of 20 % phosgene in toluene (7 ml) was added, and the reaction mixture was stirred further at room temperature for 18 hours. The product was filtered off, washed with CH3CN (3x) and dried (50 0C, 1 hour, in vacuo), yielding 5.45 g of intermediate 26 (94 %; .HCl). This intermediate was immediately used in the next reaction step (hygroscopic intermediate).
c-1. Preparation of intermediate 27
Figure imgf000073_0002
l-(4-Ethoxycarbonylphenyl)piperazine (3.732 g, 0.0159 mol) was added to a stirring mixture of intermediate 26 (4.9 g, 0.0159 mol) and CH2Cl2 (100 ml). Et3N (4.478 ml) was added and the solution was stirred at room temperature for 18 hours. Then, the mixture was washed with a saturated aqueous NaHCO3 solution, dried (MgSO4), filtered and the solvent was evaporated. The residue was stirred in Et2O and the solid was filtered off, washed with Et2O (3 x) and dried (50 0C, in vacuo). Yield: 6.55 g of intermediate 27 (81 %).
c-2. Preparation of intermediate 37
Figure imgf000073_0003
Intermediate 26 (approximately 24 mmol, crude) was added portionwise to a stirring solution of l-(4-nitrophenyl)piperazine (5 g, 24 mmol) in Et3N (10 ml, 7.2 mmol) and CH2Cl2 (125 ml; p. a.) (temperature reached approximately 30 0C). The reaction mixture was stirred for 4 hours at room temperature and was then washed with H2O. The separated organic layer was dried (MgSO4), filtered and the solvent was evaporated. The residue was filtered over silica (eluent: CH2Cl2/Me0H 96/4). The purest fractions were combined and the solvent was evaporated and co-evaporated with toluene. The residue was stirred in DIPE, filtered off and dried (50 0C, in vacuo). Yield: 2.9 g of intermediate 37.
d-1. Preparation of intermediate 28
Figure imgf000074_0001
Intermediate 27 (5.88 g, 0.0116 mol) was added to 1,4-dioxane (75 ml) and the mixture was stirred. A NaOH solution (35 ml, 0.035 mol; 1 M) was added and the mixture was stirred for 72 hours at room temperature. Subsequently, MeOH (25 ml) was added and the mixture was stirred again for 72 hours. Then HCl (35 ml; 1 N) was added and the mixture was stirred for 18 hours. The solid was filtered off and washed with H2O. The solid was dried (50 0C, 24 hours, in vacuo). Yield: 4.88 g of intermediate 28 (88 %).
d-2. Preparation of intermediate 38
Figure imgf000074_0002
A solution of intermediate 37 (2.19 g, 0.00458 mol) in acetic acid (125 ml) was hydrogenated with Pt/C 5% (0.5 g) as a catalyst in the presence of a thiophene solution (0.3 ml; 4 % in DIPE). After 3 eq. of H2 were taken up, the catalyst was filtered off. The solvent was evaporated (water bath at 40 0C). The residue was stirred in CH2Cl2 and this solution was washed with a half saturated aqueous NaHCO3 solution. The organic layer was dried (MgSO4), filtered and the solvent was evaporated. The residue was purified over silicagel (eluent: CH2Cl2/Me0H 93/7). The desired fractions were combined and the solvent was evaporated and co-evaporated with toluene, yielding intermediate 38. Example Al 2 a. Preparation of intermediate 29
DECP (12.5 ml, 0.0836 mol) was added to a stirring solution of 1-tert-butoxycarbonyl- 4-(4-aminophenyl)piperazine (15.12 g, 0.0545 mol) and 3-(l-pyrrolidinyl)benzoic acid (11.47 g, 0.06 mol) in Et3N (23 ml, 0.164 mol) and CH2Cl2 (200 ml) at room temperature. After 20 hours, a saturated NaHCO3 solution was added and the layers were separated. The CH2Cl2 layer was dried (MgSO4), filtered and the solvent was evaporated and co-evaporated with toluene. The residue was stirred in Et2O, filtered off, washed with E 2O and dried (50 0C, 20 hours, in vacuo). Yield: 24.682 g of intermediate 29 (90 %).
b. Preparation of intermediate 30
Figure imgf000075_0001
TFA (25 ml) was added to a stirring solution of intermediate 29 (15 g, 0.03 mol) in CH2Cl2 (50 ml) at room temperature. After 18 hours, the solvent was evaporated. The residue was stirred in H2O and CH2Cl2 and neutralized with Na2CO2 powder and NaHCO3 until the mixture was alkaline. The reaction mixture was stirred for 48 hours. Then, the layers were separated. The organic layer was dried (MgSO4), filtered and the solvent was evaporated and co-evaporated with toluene. The residue was stirred in DIPE, filtered off and dried (50 0C, 18 hours, in vacuo). Subsequently, the product was refluxed in CH3CN. The mixture was cooled to room temperature and the solid was filtered off and dried (50 0C, 18 hours, in vacuo). Yield: 8.580 g of intermediate 30 (75 %).
Example Al 3 a. Preparation of intermediate 31
Figure imgf000075_0002
CH2Cl2 (25 ml) was added to 4-amino-3,5-dichloro-benzeneacetic acid (0.754 g, 0.00343 mol) and the mixture was stirred. Et3N (1.45 ml, 0.0103 mol) and 1- methylpiperazine (0.46 ml, 0.00415 mol) were added. DECP (0.65 ml, 0.00391 mol) was added and the mixture was flushed with N2 and closed off. The reaction mixture was stirred for 72 hours at room temperature. Subsequently, the mixture was stirred in a saturated solution of NaHCOs in H2O and the layers were separated. The organic layer was dried (MgSO4), filtered and the solvent was evaporated and co-evaporated with toluene. The residue was stirred in CH2Cl2 and a saturated aqueous K3CO3 solution. The layers were separated (an extra amount of H2O was added for good separation). The CH2Cl2 layer was dried (MgSO4), filtered and the solvent was evaporated and co- evaporated with xylene. The residue was dissolved in DIPE and HCl/2-propanol (3 ml; 6 N) was added. The mixture was stirred for 15 hours and then the solid was filtered off, washed with DIPE and dried (50 0C, 1 hour, in vacuo). Yield: 1.3 g of intermediate 31 (99 %; .HCl).
b. Preparation of intermediate 32
Figure imgf000076_0001
Intermediate 31 (1.3 g, 0.00384 mol) was dissolved in HCl in Et2O (4.2 ml, 0.0042 mol;l M solution) and CH3CN (20 ml; dry) at 0 0C. A 20 % phosgene solution in toluene (5.8 ml, 0.0116 mol) was added while stirring. After 2 hours, the ice-bath was removed and the mixture was stirred at room temperature for 50 hours. An extra amount of the 20 % phosgene solution in toluene (1.92 ml) was added and the mixture was stirred for 36 hours. Then a third amount of the 20 % phosgene solution in toluene (1 ml) was added and the mixture was stirred for 18 hours. The solvent was evaporated and co-evaporated with dry toluene. The residue (I g crude intermediate 32; quantitative yield; HCl-salt) was directly used as such in the next reaction step.
Example Al 4 a. Preparation of intermediate 33 and 33'
Figure imgf000076_0002
Intermediate 33 Intermediate 33' 2,6-Dichloro-4-chloromethyl-phenylamine (3.68 g, 0.0149 mol) was added portionwise to a stirred solution of 1-mesylpiperazine (2.971 g, 0.0181 mol) and diisopropylamine (8.2 ml, 0.058 mol) in CH3CN (100 ml) on a water bath. The reaction mixture was stirred for 18 hours at room temperature. The product was purified by reversed phase high-performance liquid chromatography (Shandon Hyperprep® Cl 8 BDS (Base Deactivated Silica) 8 μm, 250 g, LD. 5 cm). A gradient with 3 mobile phases was applied. Phase A: 90 % of a 0.5 % NH4OAc solution in water + 10 % CH3CN; phase B: CH3OH; phase C: CH3CN). The different product fractions were collected and worked- up. The solvents were evaporated and co-evaporated with toluene, yielding 2.24 g of intermediate 33', and 0.732 g of the desired intermediate 33 (18 %).
b. Preparation of intermediate 34
Figure imgf000077_0001
Intermediate 33 (0.732 g, 0.00266 mol) was dissolved in a HCl solution in Et2O (3.2 ml, 0.0032 mol; 1 M) and CH3CN (20 ml; dry) and the mixture was stirred at room temperature for 30 minutes. Then a 20 % phosgene solution in toluene (2 ml, 0.004 mol; 2 M) was added portionwise. The reaction mixture was stirred for 3 hours and then the solvent was evaporated and co-evaporated with dry toluene. The residue (crude intermediate 34 as a HCl-salt) was dissolved in CH2Cl2 and this solution was used immediately in the next reaction step.
Example Al 5 a. Preparation of intermediate 35
Figure imgf000077_0002
NaH (0.396 g, 0.0099 mol; 60 %) was added portionwise to a stirring solution of 2,6- dichlorophenol in THF (50 ml; p. a. dried on molecular sieves) under N2 atmosphere. The mixture was stirred for 15 minutes and then 4-(4-nitrophenyl)-l- piperazinecarbonyl chloride (0.89 g, 0.0033 mol) was added. The reaction mixture was continued stirring for 1 hour at room temperature and was then re fluxed for 18 hours. The mixture was cooled to room temperature and poured into ice-water (200 ml). This mixture was stirred for 15 minutes and then the product was filtered off, washed with H2O and dried (50 0C, in vacuo). Yield: 1.3 g of intermediate 35 (99 %). b. Preparation of intermediate 36
Figure imgf000078_0001
A solution of intermediate 35 (1.3 g, 0.00328 mol) in acetic acid (50 ml) and a thiophene solution (6.901 ml, 0.00328 mol; 4 % in DIPE) was hydrogenated with Pt/C 5 % (0.3 g) as a catalyst. After 3 eq. of H2 were taken up, the catalyst was filtered off. The filtrate was evaporated and co-evaporated with toluene (2 x). The residue was dissolved in CH2Cl2 and the solution was washed with an aqueous saturated NaHCO3 solution. The layers were separated and the organic layer was dried (MgSO4), filtered and the solvent was evaporated and co-evaporated with toluene. The residue was stirred in Et2O, filtered off and washed with Et2O (3x). The product was dried (50 0C, in vacuo). Yield: 0.94 g of intermediate 36.
Example Al 6 a. Preparation of intermediate 39
Figure imgf000078_0002
2,6-Dichloro-4-methyl-benzeneacetic acid methyl ester (10.27 g, 0.044 mol) was dissolved in 100 ml of CCl4. Then, N-bromosuccinimide (0.053 mol) and 2,2'-(l,2- diazenediyl)bis[2-methylpropanenitrile] (0.0022 mol) were added to the solution. The resulting mixture was refluxed for 10 hours. The solution was cooled and passed through a silica gel layer. The silica gel was washed with CCl4 (about 100 ml) and hexane (about 200 ml). The combined filtrates were concentrated in vacuo. The obtained residue became crystalline after cooling (12.85 g). After recrystallisation from hexane 10.30 g of intermediate 39 was obtained.
b. Preparation of intermediate 40
Figure imgf000078_0003
Intermediate 39 (8.682 g) and pyrrolidine (6.86 ml) were mixed and heated at 90-100 0C for 5 minutes. H2O (50 ml) was added, and the resulting mixture was extracted with CH2Cl2 (3 x 50 ml). The combined organic layer was separated, dried over sodium sulphate and evaporated in vacuo. The obtained residue (8.178 g as a brown oil) was treated with an ether solution of HCl (2 M, 25 ml). A semi-crystalline precipitate was obtained. An excess of HCl ether solution was decanted, some ether was added (about 30 ml) and some acetone was added dropwise at stirring till crystalline product formed. The formed precipitate was filtered off, washed with acetone and dried on the air. Yield : 5.347 g of intermediate 40 (.HCl).
c. Preparation of intermediate 41
Figure imgf000079_0001
Intermediate 40 (5.00 g, 14.76 mmol) and LiOKH2O (1.24 g, 29.53 mmol) were dissolved in a mixture Of H2O (20 ml) and MeOH (40 ml) and re fluxed for 20 minutes. Then HClconc (3 ml) was added and the mixture was evaporated in vacuo. Then HClconc was added (5 ml) and the resulting suspension was diluted with acetone (about 20 ml). The suspension was refluxed for 5 minutes and cooled till room temperature. The formed yellowish crystalline product was filtered off, washed with acetone and dried on the air. Yield: 3.791 g of intermediate 41 (.HCl) (79 %).
Example Al 7 a. Preparation of intermediate 42
Figure imgf000079_0002
4-(4-Aminophenyl)-l-piperazinecarboxylic acid 1,1-dimethylethyl ester (1.00 g, 3.61 mmol), 1,3-benzenedicarboxylic acid 1 -methyl ester (4.33 mmol), O-benzotriazolyl tetramethylisouronium tetrafluoroborate (TBTU) (5.03 mmol) and Et3N (1.50 ml, 10.7 mmol) were mixted in CH3CN (10 ml) and stirred at room temperature for 5 hours. The crystalline product was filtered off from the reaction mixture, washed with H2O and dried on the air. Yield: 1.262 g of intermediate 42 (80 %).
b. Preparation of intermediate 43
Figure imgf000079_0003
A 4 N HCl solution in 1,4-dioxane (5 ml, 20 mmol) was added to a mixture of intermediate 42 (1.262 g, 2.87 mmol) and 15 ml of dioxane. The resulting slurry was stirred at 45-500C for 30 minutes. The mixture was cooled to room temperature, and the crystalline product was filtered off, washed with acetone, hexane and dried in vacuo. Yield: 1.118 g of intermediate 43 (95 %; .2 HCl). B. Preparation of the final compounds Example Bl a. Preparation of compound 1
Figure imgf000080_0001
l-(l,l-dimethylethyl)-l,3-azetidinedicarboxylic acid ester (0.001 mol) was dissolved in DMF (5 ml) to get stock solution (I). Part of stock solution (I) (1.2 ml, containing 0.00024 mol of l-(l,l-dimethylethyl)-l,3-azetidinedicarboxylic acid ester) was put into the MiniBlock. PS-Carbodiimide, 1.9 mmol/g (0.0004 mol) was added with ArgoScoop. A solution of 1-hydroxy-iH-benzotriazole (0.00030 mol) in DMF (1 ml) was added and the mixture was shaken for 30 minutes. A solution of intermediate 2 (prepared according to Al. b) (0.0002 mol) in DMF (3.5 ml) was added and the reaction mixture was shaken overnight. MP-carbonate, 2.8 mmol/g (0.00090 mol) and resin- linked-NCO, 1.8 mmol/g (0.0002 mol) were added with ArgoScoop. The reaction mixture was shaken overnight, then filtered. CH2Cl2 (4 ml) was added and the mixture was shaken for 2 hours. The mixture was filtered and the filtrate's solvent was evaporated (Genevac® solvent evaporator). The residue (± 0.120 g) was purified by HPLC. The product fractions were collected and worked-up. Yield: 0.014 g of compound 1.
b. Preparation of compound 2
Figure imgf000080_0002
Intermediate 7 (prepared according to A3.b) (0.00012 mol) was dissolved in DMF (1.2 ml). PS-Carbodiimide, 2.1 mmol/g (0.0002 mol) and 1-hydroxy-iH-benzotriazole (0.00015 mol) were added. The reaction mixture was shaken for 30 minutes. A solution of intermediate 5 (prepared according to A2.b) (0.0001 mol) in DMF (2 ml) was added. The reaction mixture was shaken overnight. MP-carbonate, 6.2 mmol/g (0.00045 mol) and resin- linked-N=C=O were added. The mixture was shaken overnight at room temperature. The mixture was filtered. CH2Cl2 (2 ml) was added. The mixture was shaken for one hour, then filtered again. The filtrate's solvent was evaporated (Genevac® solvent evaporator). Impure residues were purified by HPLC. The product fractions were collected and worked-up. Yield: 0.0128 g of compound 2. Compound 65 was prepared according to the above-described procedure except for reactant intermediate 7 which should be replaced by 2-methyl-5-(3-trifluoromethyl- phenyl)-thiazole-4-carboxylic acid (prepared according to A8.b).
Compound 18 was prepared according to the above-described procedure except for reactant intermediate 7 which should be replaced by intermediate 16 (prepared according to A7.b).
c. Preparation of compound 3
Figure imgf000081_0001
Intermediate 7 (prepared according to A3.b) (0.00012 mol) was dissolved in DMF (1.2 ml). PS-Carbodiimide, 2.1 mmol/g (0.0002 mol) and 1-hydroxy-iH-benzotriazole (0.00015 mol) were added. The reaction mixture was shaken for 30 minutes. A solution of intermediate 2 (prepared according to Al. b) (0.0001 mol) in DMF (2 ml) was added. The reaction mixture was shaken overnight. MP-carbonate, 6.2 mmol/g (0.00045 mol) and resin- linked-N=C=O (0.0001 mol) were added. The mixture was shaken overnight at room temperature. The mixture was filtered. CH2Cl2 (2 ml) was added. The mixture was shaken for one hour, then filtered again. The filtrate's solvent was evaporated (Genevac® solvent evaporator). The impure residue was purified by HPLC. The product fractions were collected and worked-up. Yield: 0.015 g of compound 3.
Compound 54 was prepared according to the above-described procedure except for reactant intermediate 7 which should be replaced by 2-methyl-5-(3-trifluoromethyl- phenyl)-thiazole-4-carboxylic acid (prepared according to A8.b).
Compound 55 was prepared according to the above-described procedure except for reactant intermediate 7 which should be replaced by intermediate 18 (prepared according to A8.b). d. Preparation of compound 4
Figure imgf000082_0001
A solution of PS-Carbodiimide and 1-hydroxy-iH-benzotriazole in DMF (1 ml) was added to a solution of 2-(2-furanyl)benzoic acid in DMF (1.2 ml) and then shaken for 1 hour at room temperature. Then a solution of intermediate 5 (prepared according to A2.b) in DMF (1 ml) was added to the reaction mixture. The reaction mixture was shaken overnight at room temperature. MP-carbonate (q.s.) and resin-linked N=C=O polymer (q.s.) were added to the reaction mixture and again shaken overnight. The reaction mixture was filtered to result in filtrate Fl. The residue was shaken for 2 hours in CH2Cl2 (3 ml). This mixture was filtered to result in filtrate F2. Fl and F2 were combined and the solvents were evaporated. The residue was purified by reversed- phase high-performance liquid chromatography (Shandon Hyperprep® C18 BDS (Base Deactivated Silica) 8 μm, 250 g, LD. 5 cm). A gradient with the mentioned mobile phases was applied (phase A: (0.5% NH4OAc in H2O)/CH3CN 90/10); phase B: CH3OH (optional); phase C: CH3CN). The desired product fractions were collected and worked-up. Yield: 0.002 g of compound 4.
Example B2 a. Preparation of compound 5
Figure imgf000082_0002
(Isocyanatomethyl)-cyclohexane (0.00011 mol) was dissolved in DMF (3 ml). Intermediate 9 (prepared according to A4.b) (0.0001 mol) was added. The reaction mixture was shaken for 2 hours at room temperature. PS-Trisamine (3.2 mmol/g) (0.0001 mol) and resin-linked-N=C=O, 1.8 mmol/g (0.0001 mol) were added. The reaction mixture was shaken overnight at room temperature. The mixture was filtered. CH2Cl2 (2 ml) was added. The mixture was shaken for one hour, filtered and the filtrate's solvent was evaporated. Yield: 0.051 g of compound 5. b. Preparation of compound 6
Figure imgf000083_0001
A mixture of intermediate 9 (prepared according to A4.b) (0.00023 mol) and PS-NMM (2.03 mmol/g) (0.00023 mol) in DMF (3 ml) was stirred for 15 minutes. A solution of 2,6-dichlorobenzoyl chloride (0.00035 mol) in DMF (1 ml) was added and the mixture was stirred for 2 hours. More PS-NMM (2.03 mmol/g; Argonaut) (0.05 g) was added and the mixture was stirred for 10 minutes. Extra 2,6-dichlorobenzoyl chloride was added and the reaction mixture was stirred overnight at room temperature. PS- Trisamine (4.35 mmol/g; Novabiochem) (0.0002 mol) was added and the mixture was stirred for 4 hours. The reaction mixture was filtered and the filtrate was stirred with PS-TsOH (0.1 g) overnight. The mixture was filtered and the filtrate was purified by HPLC over Purospher Star RP- 18 (20 g, 5 μm; eluent: ((0.5% NH4OAc in
H2O)/CH3CN 90/10)/CH3OH/CH3CN (0 minutes) 75/25/0, (10.00 minutes) 0/50/50, (16.00 minutes) 0/0/100, (18.10-20 minutes) 75/25/0). The desired fractions were collected and the organic solvent was evaporated. The aqueous concentrate was extracted with CH2Cl2 and the solvent was evaporated. Yield: 0.127 g of compound 6
c. Preparation of compound 7
Figure imgf000083_0002
l-isocyanato-2-methylbenzene (0.00011 mol) was dissolved in DMF (3 ml). Intermediate 12 (prepared according to A5.b) (0.0001 mol) was added. The reaction mixture was shaken for 2 hours at room temperature. PS-Trisamine (0.0001 mol; 3.2 mmol/g) and resin- linked-N=C=O, 1.8 mmol/g (0.0001 mol) were added. The reaction mixture was shaken overnight at room temperature. The mixture was filtered. CH2Cl2 (2 ml) was added. The mixture was shaken for one hour, filtered and the filtrate's solvent was evaporated. The less pure residues were purified by HPLC. The product fractions were collected and worked-up Yield: 0.0048 g of compound 7. Example B3 a. Preparation of compound 8
Figure imgf000084_0001
A mixture of intermediate 9 (prepared according to A4.b) (0.00023 mol) and Et3N (0.1 ml) in CH2Cl2 (5 ml) was stirred until complete dissolution. l,3-Dichloro-2- isothiocyanotobenzene (0.0003 mol) was added and the mixture was shaken overnight. The mixture was washed with a saturated aqueous NH4CI solution (2 ml), then filtered through Extrelut and the extract's solvent was evaporated. The residue was purified by HPLC over Hyperprep RP-C 18 BDS (100 g, 100 A, 8 μm; eluent: [(0.5% NH4OAc in H2O)/CH3CN 90/10)]/CH3OH/CH3CN (0 min) 75/25/0, (10 min) 0/50/50, (16 min) 0/0/100, (18.10-20.00 min) 75/25/0). The pure fractions were collected and worked-up. Yield: 0.059 g of compound 8. Melting point: 224.5 0C
b. Preparation of compound 9
Figure imgf000084_0002
A mixture of intermediate 9 (prepared according to A4.b) (0.00023 mol) and Et3N (0.1 ml) in CH2Cl2, anhydrous (5 ml) was stirred until complete dissolution. 1,3-Dichloro- 2-isocyanatobenzene (0.0003 mol) was added and the reaction mixture was shaken overnight, then filtered and the precipitate was washed with CH2CI2, then dried. Yield: 0.104 g of compound 9. Melting point: 289.0 0C Example B4
Preparation of compound 10
Figure imgf000085_0001
tnfluoroacetate
A mixture of intermediate 3 (prepared according to Al. c) (0.0002 mol; approximately, crude intermediate) and trifluoroacetic acid (0.2 ml) in CH2Cl2 (2 ml) was shaken for 4 hours at room temperature. The solvent was partially evaporated (Genevac® solvent evaporator). Toluene was added to the concentrate and the mixture was azeotroped on the rotary evaporator. Yield: 0.008 g of compound 10.
Example B5
Preparation of compound 11
Figure imgf000085_0002
N'-(ethylcarbonimidoyl)-Λ/,Λ/-dimethyl- 1 ,3-propanediamine monohydrochloride (0.000302 mol) was added to a mixture of intermediate 5 (prepared according to A2.b) (0.000275 mol), l-methyl-5-oxo-3-pyrrolidinecarboxylic acid (0.000275 mol), 1- hydroxy-iH-benzotriazole (0.000028 mol) and N-ethyl-N-(l-methylethyl)-2- propanamine (0.000329 mol) in TΗF, dried over 3A molecular sieves (5 ml) and then stirred for 64 hours at room temperature. The solvent was evaporated (under N2). The residue was stirred in CΗ3OΗ (5 ml) and H2O (5 ml) and then heated to boiling point. The mixture was let to cool to room temperature without stirring. The precipitate was filtered off, washed with CH3OH and dried (vacuum, overnight). Yield : 0.082 g of compound 11.
Example B6
Preparation of compound 129
Figure imgf000085_0003
Intermediate 20 (0.55 g, 1.569 mmol) (prepared according to A9.b) was dissolved in Et3N (1.1 ml) and CH2Cl2 (50 ml). The crude intermediate 23 (0.448 g) (prepared according to AlO. c) and CH2Cl2 (100 ml) were added. The reaction mixture was stirred for 48 hours and then the mixture was stirred in a saturated solution of NaHCOs in H2O. CH2Cl2/Me0H 90/10 and H2O were added and the layers were separated. The separated organic layer was dried (MgSO4), filtered and the solvent was evaporated. The residue was stirred in DIPE and was filtered off. The product was washed with EtOH and DIPE (once). The product was dried (50 0C, 18 hours, in vacuo). Yield: 0.727 g of compound 129 (73 %).
Example B7
Preparation of compound 130
Figure imgf000086_0001
DECP (0.357 ml, 0.00239 mol) was added to a stirring solution of intermediate 28 (0.57 g, 0.00119 mol) (prepared according to Al l.d-1) and 3-(l-pyrrolidinyl)- benzenamine (0.25 g, 0.00143 mol) in Et3N (0.671 ml, 0.00478 mol) and CH2Cl2 (35 ml) at room temperature. After 48 hours, more DECP (0.0893 ml) was added and the mixture was stirred at room temperature for 3 hours. More Et3N (0.336 ml) was added and the mixture was stirred for 18 hours. A saturated aqueous NaHO3 solution was added and the mixture was stirred. The layers were separated and the CH2Cl2 layer was dried (MgSO4), filtered and the solvent was evaporated and co-evaporated with toluene. The residue was purified by FLASH chromatography(silica; eluent: CH2Cl2/Me0H from 99/1 till 97/3). The desired fractions were collected and the solvent was evaporated. The residue (0.491 g) was purified by reversed phase high-performance liquid chromatography (Shandon Hyperprep® Cl 8 BDS (Base Deactivated Silica) 8 μm, 250 g, LD. 5 cm). A gradient with 3 mobile phases was applied. Phase A: 90 % of a 0.5 % NH4OAc solution in water + 10 % CH3CN; phase B: CH3OH; phase C: CH3CN). The desired fractions were collected and the solvents were partially evaporated. A saturated aqueous NaHCO3 solution was added and the organic products were extracted with CH2Cl2. The layers were separated and the CH2Cl2 layer was dried (MgSO4), filtered and the solvent was evaporated and co-evaporated with toluene. The residue was stirred in DIPE and the solid was filtered off and dried (50 0C, 72 hours, in vacuo). Yield: 0.184 g of compound 130. Example B8
Preparation of compound 131
Figure imgf000087_0001
2,6-Dichloro-benzeneacetic acid (0.102 g, 0.499 mmol) and DIPEA (0.6 ml) were added to a solution of intermediate 20 (0.175 g, 0.499 mmol) in CH3CN (5 ml; dry) and DMF (2 ml; dry). DEPC (1.2 eq) was added and the reaction mixture was stirred at room temperature for 1 hour. The solvent was evaporated and the residue was purified by flash silica chromatography. The desired fractions were collected and the solvent was evaporated to yield 0.155 g of compound 131 (58 %).
Example B9
Preparation of compound 136
Figure imgf000087_0002
Intermediate 32 (0.5 g, 0.00152 mol) (prepared according to Al 3.b) in CH2Cl2 (10 ml) was stirred. This mixture was added to a stirring solution of intermediate 30 (0.54 g, 0.00153 mol) (prepared according to A12.b) in Et3N (1 ml, 0.00712 mol) and CH2Cl2 (20 ml). After 2 hours, CH2Cl2 (50 ml) and a half saturated NaHCO3 solution (q.s.) were added and the mixture was stirred. Subsequently, MeOH (10 ml) and CH2Cl2 (10 ml) were added and the mixture was stirred for 18 hours. Then the mixture was left without stirring for 48 hours, but the layers were not separated properly. Therefore, the mixture was filtered over diatomaceous earth (Dicalite®). The layers were separated and the organic layer was dried (MgSO4), filtered and the solvent was evaporated and co-evaporated with toluene, yielding 1.006 g. The crude compound was purified by reversed-phase high-performance liquid chromatography (Shandon Hyperprep® Cl 8 BDS (Base Deactivated Silica) 8 μm, 250 g, LD. 5 cm). A gradient with 3 mobile phases was applied. Phase A: a 0.25 % NH4HCO3 solution in water; phase B: CH3OH; phase C: CH3CN). The desired fractions were collected and the solvent was evaporated until only the water layer was obtained. This water layer was neutralized with NaHCO3 and was extracted with CH2Cl2. The separated organic layer was dried (MgSO4), fϊltered and the solvent was evaporated and co-evaporated with toluene. The residue was stirred in Et2O and the solid was filtered off, yielding 0.032 g of compound 136.
Example BlO
Preparation of compound 137
Figure imgf000088_0001
Intermediate 30 (0.465 g, 0.00133 mol) (prepared according to A12.b) was dissolved in CH2Cl2 (10 ml) and Et3N (1 ml, 0.00712 mol) resulting in a brown turbid mixture. Intermediate 34 (0.4 g, 0.00133 mol) (prepared according to A14.b) was dissolved in CH2Cl2 (10 ml) and this solution was added to the brown turbid mixture. The reaction mixture was stirred for 1 hour and was then filtered off and washed (2 x with CH2Cl2, 1 x with CH3CN and again 1 x with CH2Cl2). The solid was dried (50 0C, 18 hours, in vacuo). Yield: 0.505 g of compound 137 (56 %).
Example BI l
Preparation of compound 139
Figure imgf000088_0002
DECP (0.253 ml, 0.00169 mol) was added to a stirring solution of intermediate 36 (0.564 g, 0.00154 mol) (prepared according to A15.b) and 3-(l-pyrrolidinyl)benzoic acid (0.309 g, 0.00162 mol) in CH2Cl2 (20 ml; p.a.) and Et3N (0.433 ml, 0.00308 mol).
The reaction mixture was stirred for 18 hours under N2 atmosphere. Then an aqueous saturated NaHCO3 solution (15 ml) was added and the mixture was stirred for 2 hours.
CH2Cl2/Me0H 90/10 (10 ml) was added and the mixture was stirred for 1 hour. The layers were separated and the organic layer was washed (H2O), dried (MgSO4), filtered and the solvent was evaporated. The residue was stirred in Et2O/EtOAc (10 ml/10 ml), filtered off, washed (EtOAc/Et2O first 1/1, then 0/1) and dried (50 0C, in vacuo). Yield:
0.655 g of compound 139 (79 %). Example B12
Preparation of compound 140
Figure imgf000089_0001
DECP (1.167 ml, 0.00703 mol) was added to a stirring solution of intermediate 38 (2.1 g, 0.00468 mol) (prepared according to Al l.d-2) and 1,3-benzenedicarboxylic acid 1 -methyl ester (0.886 g, 0.00492 mol) in Et3N (1.316 ml, 0.00937 mol) and CH2Cl2 (100 ml; p. a.). The reaction mixture was stirred for 18 hours at room temperature and then an aqueous saturated NaHCO3 solution (50 ml) and CH2Cl2/Me0H 1/1 (40 ml) was added. The mixture was stirred for 15 minutes. The layers were separated and the organic layer was stirred with H2O (50 ml) and left standing overnight in a separated funnel. The precipitate in the organic layer was filtered off, washed (CH2Cl2) and dried (50 0C, in vacuo), yielding 0.54 g of compound 140 (19 %). The filtrate was evaporated and the residue was stirred in acetone, filtered off, washed (acetone) and dried (50 0C, in vacuo), yielding 1 g of compound 140 (35 %).
Example B13
Preparation of compound 145
Figure imgf000089_0002
TBTU (4.20 mmol) and Et3N (2.08 ml, 15.0 mmol) were added to a suspension of intermediate 41 (3.60 mmol) (prepared according to A16.c) in CH3CN (10 ml). The mixture was stirred for 10 minutes at room temperature. Then, intermediate 43 (2.71 mmol) (prepared according to A17.b) was added to the reaction mixture. The mixture was stirred for 5 hours at room temperature. The crystalline product was filtered off, washed with small amount of acetone and dried on the air. Yield: 1.406 g of compound 145 (85 %).
Tables 1 to 7 list the compounds that were prepared by analogy to one of the above Examples. Table 1 :
Figure imgf000090_0001
Figure imgf000090_0002
Figure imgf000091_0001
Figure imgf000092_0002
Table 2 :
Figure imgf000092_0001
Figure imgf000092_0003
Figure imgf000093_0001
Figure imgf000094_0001
Table 3 :
Figure imgf000094_0002
Figure imgf000094_0003
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0002
Table 4:
Figure imgf000097_0001
Figure imgf000097_0003
Figure imgf000098_0002
Table 5:
Figure imgf000098_0003
Table 6:
Figure imgf000099_0001
Figure imgf000099_0003
Table 7:
Figure imgf000099_0002
Comp. Ex.
X R2 Rla Rlb Rlc no. no.
144 B2 -NH-C=O H H
Figure imgf000100_0001
C. Analytical part
(LC)MS
For (LC)MS-characterization of the compounds of the present invention, the following methods were used.
General procedure A
The HPLC measurement was performed using an Alliance HT 2790 (Waters) system comprising a quaternary pump with degasser, an autosampler, a column oven (set at 40 °C, unless otherwise indicated), a diode-array detector (DAD) and a column as specified in the respective methods below. Flow from the column was split to a MS spectrometer. The MS detector was configured with an electrospray ionization source. Mass spectra were acquired by scanning from 100 to 1000 in 1 second using a dwell time of 0.1 second. The capillary needle voltage was 3 kV and the source temperature was maintained at 140 0C. Nitrogen was used as the nebulizer gas. Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
General procedure B
The LC measurement was performed using an Acquity UPLC (Waters) system comprising a binary pump, a sample organizer, a column heater (set at 55 °C), a diode- array detector (DAD) and a column as specified in the respective methods below. Flow from the column was split to a MS spectrometer. The MS detector was configured with an electrospray ionization source. Mass spectra were acquired by scanning from 100 to 1000 in 0.18 seconds using a dwell time of 0.02 seconds. The capillary needle voltage was 3.5 kV and the source temperature was maintained at 140 0C. Nitrogen was used as the nebulizer gas. Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
General procedure C The LCMS analyses for the compounds were done at the Surveyor MSQ™ (Thermo Finnigan, USA) comprising a photo diode array detector (PDA; 190-800 nm) and a column as specified in the respective methods below. Flow from the column was split to a MS spectrometer. The MS detector was configured with APCI (atmospheric pressure chemical ionization, + or - ions). Mass spectra were acquired by scanning from 45 to 1000 (of atomic mass unit) in 0.3 seconds. Typical APCI conditions use a corona discharge current of 10 μA and a cone voltage of 30 V. The APCI probe temperature was 640 0C. Nitrogen was used as the nebulizer gas. Data acquisition was performed with an Xcalibur™ data system.
Method 1 In addition to general procedure B: Reversed phase UPLC (Ultra Performance Liquid Chromatography) was carried out on a bridged ethylsiloxane/silica hybrid (BEH) Cl 8 column (1.7 μm, 2.1 x 50 mm; Waters Acquity) with a flow rate of 0.8 ml/min. Two mobile phases (mobile phase A: 0.1 % formic acid in IHtO/methanol 95/5; mobile phase B: methanol) were used to run a gradient condition from 95 % A and 5 % B to 5 % A and 95 % B in 1.3 minutes and hold for 0.2 minutes. An injection volume of 0.5 μl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
Method 2 In addition to general procedure A: Reversed phase HPLC was carried out on an Xterra MS Cl 8 column (3.5 μm, 4.6 x 100 mm) with a flow rate of 1.6 ml/min. Three mobile phases (mobile phase A: 95% 25 mM ammoniumacetate + 5 % acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 1 % A, 49 % B and 50 % C in 6.5 minutes, to 1 % A and 99 % B in 1 minute and hold these conditions for 1 minute and reequilibrate with 100 % A for 1.5 minutes. An injection volume of 10 μl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
Method 3 (only MS) For a number of compounds only the mass spectra were recorded (no R(t)). The MS detector was configured with an electrospray ionization source. Mass spectra were acquired by scanning from 100 to 1000 in 1 second using a dwell time of 0.1 second. The capillary needle voltage was 3 kV and the source temperature was maintained at 140 0C. Nitrogen was used as the nebulizer gas. Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
Method 4
In addition to general procedure A: Column heater was set at 45 0C. Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 μm, 4.6 x 100 mm) with a flow rate of 1.6 ml/min. Three mobile phases (mobile phase A: 0.1 % formic acid in H2θ/methanol 95/5; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 1 % A, 49 % B and 50 % C in 7 minutes and hold these conditions for 1 minute. An injection volume of 10 μl was used. Cone voltage was 10 V for positive ionization mode.
Method 5
In addition to general procedure A: Column heater was set at 45 0C. Reversed phase HPLC was carried out on an Atlantis Cl 8 column (3.5 μm, 4.6 x 100 mm) with a flow rate of 1.6 ml/min. Two mobile phases (mobile phase A: 70 % methanol + 30 % H2O; mobile phase B: 0.1 % formic acid in H2θ/methanol 95/5) were employed to run a gradient condition from 100 % B to 5 % B + 95 % A in 9 minutes and hold these conditions for 3 minutes. An injection volume of 10 μl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
Method 6 In addition to general procedure A: Column heater was set at 60 0C. Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 μm, 4.6 x 100 mm) with a flow rate of 1.6 ml/min. Three mobile phases (mobile phase A: 95% 25 mM ammoniumacetate + 5 % acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50 % B and 50 % C in 6.5 minutes, to 100 % B in 0.5 minute and hold these conditions for 1 minute and reequilibrate with 100 % A for 1.5 minutes. An injection volume of 10 μl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
Method 7
In addition to general procedure C: Reversed phase HPLC was carried out on a Waters XTerra MS Cl 8 column (3.5 μm, 2.1 x 30 mm) with a flow rate of 1.0 ml/min. Two mobile phases (mobile phase A: 0.1 % aqueous solution of formic acid; mobile phase B: acetonitrile) were used. First, 100 % A was hold for 0.1 minutes. Then a gradient was applied to 5 % A and 95 % B in 3 minutes and hold for 0.8 minutes. The injection volume was 1 μl. The column was at room temperature.
Table 8: (LC)MS analytical data - Rt means retention time (in minutes), [MH]+ means the protonated mass of the compound (free base), Method refers to the method used for (LC)MS.
Figure imgf000104_0001
Figure imgf000104_0002
Figure imgf000105_0001
Figure imgf000106_0001
Table 9: (LC)MS analytical data - Rt means retention time (in minutes), [MH]" means the deprotonated mass of the compound (negative mode), Method refers to the method used for (LC)MS.
Figure imgf000106_0002
Melting Points
For a number of compounds, melting points (m.p.) were determined by using a DSC823e (Mettler-Toledo). Melting points were measured with a temperature gradient of 30 °C/minute. Maximum temperature was 400 0C. Values are peak values. The results are gathered in Table 10
Table 10
Figure imgf000106_0003
For a number of compounds, m.p. were determined by using a Gallenkamp apparatus from Sanyo Gallenkamp.
Comp. Nr. 138: 198-199 0C; Comp. Nr. 143: 249-250 0C; Comp. Nr. 133: 237-239 0C; Comp. Nr. 145: 218-221 0C; Comp. Nr. 146: 208-210 0C.
D. Pharmacological example
A) Measurement of inhibition of DGATl activity by the present compounds
The inhibiting activity of the present compounds on DGATl activity was screened in a single well procedure assay using DGATl comprising membrane preparations and DGATl substrate comprising micelles and determining formed radio-active triacylglycerol coming in close proximity of a flashplate surface by radio luminescence.
Said assay is described in full detail in WO2006/067071, the content of which is incorporated herein by reference.
By DGATl activity is meant the transfer of coenzyme A activated fatty acids to the 3- position of 1,2-diacylglycerols, thus forming a triglyceride molecule, by enzyme DGATl.
STEP 1 OF THE ASSAY: Expression of DGATl human DGATl (NMO 12079.2) was cloned into the pFastBac vector, containing translation start, a FLAG-tag at the N-terminus as described in literature and a viral Kozak sequence (AAX) preceding the ATG to improve expression in insect cells. Expression was done as described in literature (Cases, S., Smith, S.J., Zheng, Y., Myers H.M., Lear, S.R., Sande, E., Novak, S., Collins, C, Welch, C.B., Lusis, A.J., Erickson, S.K. and Farese, R.V. (1998) Proc. Natl Acad. Sci. USA 95, 13018-13023.) using SF9 cells.
STEP 2 OF THE ASSAY: Preparation of DGATl membranes
72h transfected SF9 cells were collected by centrifugation (13000rpm-15 min-4°C) and lysed in 2x 500ml lysisbuffer (0.1M Sucrose, 5OmM KCl, 4OmM KH2PO4, 3OmM EDTA pH 7.2. Cells were homogenized by cell disruptor. After centrifugation 1380rpm-15min-4°C (SN discarded), pellet was resuspended in 500 ml lysisbuffer and total cell membranes collected by ultracentrifugation at 34000rpm(100 00Og) for 60 min (4°C). The collected membranes were resuspended in lysis buffer, divided in aliquots and stored with 10% glycerol at -800C until use. STEP 3 OF THE ASSAY: Preparation of DGAT substrate comprising micelles Materials a) 1,2-dioleoyl-sn-glycerol, 10 mg/ml (1,2-diacylglycerol (DAG)) Dissolve in acetonitrile; evaporate the acetonitrile solution under nitrogen and reconstitute in chloroform at a final concentration of 10 mg/ml. b) L-α-phosphatidylcholine, 1 mg/ml (phosphatidylcholine (PC))
Dissolve in chloroform at a final concentration of 1 mg/ml and store at 4°C. c) L-α-phosphatidyl-L-serine, 1 mg/ml (phophatidylserine (PS)) Dissolve in chloroform at a final concentration of 1 mg/ml and store at 4°C.
Method
Add 1 ml dioleoyl-sn-glycerol (lOmg/ml) to 10 ml of L-α-phosphatidylcholine
(lmg/ml) and 10 ml of L-α-phosphatidyl-L-serine (lmg/ml) in a thick glass recipient. Evaporate under nitrogen and put on ice for 15 minutes. Reconstitute in 10 ml
Tris/HCl (10 mM, pH 7.4) by sonication on ice. The sonification process consists of sonification cycles of 10 seconds in the sonification bath followed by 10 seconds cool down on ice and repeating this sonification cycle till a homogeneous solution is obtained (takes about 15 minutes). The thus obtained micelles are stored at -200C till later use and contain DAG at a final concentration of 1.61 mM.
STEP 4 OF THE ASSAY: DGAT FlashPlate™ assay Materials a) Assaybuffer 5OmM Tris-HCl (pH 7.4), 15OmM MgCl2, ImM EDTA, 0.2% BSA. b) N-ethylmaleimide, 5M
Dissolve 5g into a final volume of 8 ml DMSO 100% and store at -200C in aliquots till later use. c) Substrate mix (for 1 384 well plate = 3840 μl) 612 μl micelles stock (51μM final)
16.6 μl oleoylCoA 9.7mM
23 μl [3H]-oleoylCoA (49 Ci/mmol, 500 μCi/ml)
3188.4 μl Tris pH 7.4, 1OmM d) Enzyme mix (for 1 384 well plate = 3520 μl) (5 μg/ml) Add 11.73μl of DGAT membrane stock (1500 μg/ml stock) to 3508 μl assay buffer. e) Stop mix (for 1 384 well plate = 7.68 ml) (250 mM) Add 384 μl of N-ethylmaleimide (5M) to 3.456 ml DMSO 100%, and further dilute 3.84 ml of said solution with 3.84 ml DMSO 10%.
Method DGAT activity in membrane preparations was assayed in 5OmM Tris-HCl (pH 7.4), 150 mM MgCl2, ImM EDTA and 0.2% BSA, containing 50 μM DAG, 32μg/ml PC/PS and 8.4μM [3H]-oleoylCoA (at a specific activity of 30 nCi/well) in a final volume of 50 μl in 384-well format using the red shifted Basic Image FlashPlate™ (Perkin Elmer Cat.No. SMP400). In detail, 10 μl enzyme mix and 10 μl substrate mix were added to 30 μl of assay buffer, optionally in the presence of 1 μl DMSO (blank and controls) or 1 μl of the compound to be tested. This reaction mixture was incubated for 120 minutes at 37°C and the enzymatic reaction stopped by adding 20 μl of the stop mix. The plates were sealed and the vesicles allowed to settle overnight at room temperature. Plates were centrifuged for 5 minutes at 1500rpm and measured in Leadseeker.
Experiments with different concentrations of the test compound were performed and curves were calculated and drawn based on % CTRL min (% of normalized control). % CTRL mm was calculated according to equation 1 ,
Equation 1 : %CTRLmin =(sample - LC) / (HC - LC)
where HC (high control) refers to the median of radio luminescence value measured in the wells with enzyme and substrate but without test compound, LC (low control) refers to median background radioluminescence value measured in the wells with substrate without enzyme and without test compound, and sample refers to the radioluminescence value measured in the wells with substrate, enzyme and test compound at a particular concentration.
The calculated % CTRLmin values form a sigmoidal dose response descending curve and from this curve pICso values were calculated (-logICso where IC50 represents the concentration at which the test compound gives 50% inhibition of DGATl activity). Table 11 shows the pICso values for the compounds of formula (I).
In order to determine selectivity of the present compounds for DGATl compared to DGAT2, the inhibiting activity of the compounds on DGAT2 was also determined in the above assay, slightly modified to obtain optimal assay conditions for DGAT2. The tested compounds did not show inhibiting activity for DGAT2 (Human DGAT2 (NM032564) was cloned and expressed as described in J.Biolog. Chem. 276(42), pp38870-38876 (2001)).
Table 11 : pICso values (IC 50 values expressed in
Figure imgf000110_0001
Figure imgf000110_0002
Figure imgf000111_0001
B) In vivo study for effect of test compound on GLP-I plasma levels
Elevation of GLP-I plasma levels by a DGAT inhibitor can be studied as follows :
Dogs are deprived from food for a period of 22hours. At time 0, animals are given a liquid meal, containing 18% fat (w/w), by gavage with a stomach tube. The test compound is given orally together with the meal. Afterwards, a postprandial plasma profile is determined for GLP-I. Therefore, blood is collected at predetermined time intervals in ice-cooled Vacutainers EDTA-plasma tubes and GLP-I levels are measured in the samples taken at 0 hour (just before the meal) and at 0.5, 1, 2, 4, 6, 8 and 24 hours after dosing. Six dogs (3 males and 3 females) are included per dosage group and the plasma GLP-I profile is compared with their own GLP-I profile previously determined in the same conditions but without administration of the test compound.
GLP-I determinations in plasma are performed with a Glucagon- like peptide- 1 (active) ELISA kit 96-well plate of LINCO Research.
E. Composition examples
"Active ingredient" (a.i.) as used throughout these examples relates to a compound of formula (I), including any stereochemically isomeric form thereof, a JV-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; in particular to any one of the exemplified compounds.
Typical examples of recipes for the formulation of the invention are as follows: 1. Tablets
Active ingredient 5 to 50 mg
Di-calcium phosphate 20 mg
Lactose 30 mg
Talcum 10 mg
Magnesium stearate 5 mg
Potato starch ad 200 mg
2. Suspension An aqueous suspension is prepared for oral administration so that each milliliter contains 1 to 5 mg of active ingredient , 50 mg of sodium carboxymethyl cellulose, 1 mg of sodium benzoate, 500 mg of sorbitol and water ad 1 ml.
3. Injectable A parenteral composition is prepared by stirring 1.5 % (weight/volume) of active ingredient in 0.9 % NaCl solution.
4. Ointment
Active ingredient 5 to 1000 mg
Stearyl alcohol 3 g
Lanoline 5 g
White petroleum 15 g
Water ad 100 g

Claims

-I l l-Claims
1. A compound of formula
Figure imgf000113_0001
including any stereochemical^ isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents -O-C(=O)-; -C(=O)-C(=O)-; -NRX-C(=O)-; -Z-C(=O)-; -Z-NRX-C(=O)-; -C(=O)-Z-; -NRX-C(=O)-Z-; -C(=S)-; -NRX-C(=S)-; -Z-C(=S)-; -Z-NRX-C(=S)-; -C(=S)-Z-; -NRX-C(=S)-Z-; Z represents a bivalent radical selected from Ci_6alkanediyl, C2-6alkenediyl or C2-6alkynediyl; wherein each of said Ci_6alkanediyl, C2-6alkenediyl or C2-6alkynediyl may optionally be substituted with hydroxyl or amino; and wherein two hydrogen atoms attached to the same carbon atom in Ci_6alkanediyl may optionally be replaced by Ci_6alkanediyl; Rx represents hydrogen or Ci_4alkyl;
Y represents -C(=O)-NRX- or -NRX-C(=O)-;
R1 represents adamantanyl, C3-6Cy cloalkyl; aryl1 or Het1;
R2 represents C3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-l,4-benzodioxinyl, 1,3- benzodioxolyl, 2,3-dihydrobenzofuranyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C3_6Cycloalkyl, phenyl, naphtalenyl, 2,3- dihydro-l,4-benzodioxinyl, 1,3-benzodioxolyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms may optionally be substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently selected from hydroxyl; carboxyl; halo; Ci_6alkyl optionally substituted with hydroxy; polyhaloCi_6alkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhalo-Ci_6alkyloxy; Ci_ βalkyloxycarbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; Ci_ 4alkylcarbonylamino; -S(=O)p-Ci-4alkyl; R4R3N-C(=O)-; R4R3N-C i-6alkyl; C3- βcycloalkyl; C3-6cycloalkylCi_4alkyl; C3-6cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_
4alkyl; aryl-C(=O)-Ci_4alkyl; aryl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-Ci_4alkyl; Het-C(=O)-; Het-O-; R represents hydrogen; Ci_4alkyl optionally substituted with hydroxyl or Ci_4alkyloxy;
R6R5N-Ci.4alkyl; Ci.4alkyloxy; Het; Het-CMalkyl; aryl; R6R5N-C(=O)-Ci.4alkyl; R4 represents hydrogen or Ci_4alkyl; R , 5 represents hydrogen; Ci_4alkyl; Ci_4alkylcarbonyl;
R > 6 represents hydrogen or Ci_4alkyl; or
R5 and R6 may be taken together with the nitrogen to which they are attached to form a saturated monocyclic 5, 6 or 7-membered heterocycle which may further contain one or more heteroatoms each independently selected from O, S, S(=O)P or N; and which heterocycle may optionally be substituted with Ci_4alkyl; R7 represents hydrogen, halo, Ci_4alkyl, Ci_4alkyl substituted with hydroxyl; aryl represents phenyl or phenyl substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; carboxyl; halo; Ci_6alkyl optionally substituted with
Ci_4alkyloxy, amino or mono-or di(Ci_4alkyl)amino; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxycarbonyl; cyano; amino carbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; -S(=O)p-Ci_4alkyl; aryl1 represents phenyl, naphthalenyl or fluorenyl; each of said phenyl, naphthalenyl or fluorenyl optionally substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with carboxyl, C i_4alkyloxy carbonyl or aryl-C(=O)-; hydroxyCi-βalkyl optionally substituted with aryl or aryl-C(=O)-; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxy-carbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_6alkyl)amino; R4R3N-C i_6alkyl; C3-6cycloalkyl-NRx-; aryl-NRx-; Het-NRX-;
C3-6cycloalkylCi.4alkyl-NRx-; arylCi.4alkyl-NRx-; HetCi.4alkyl-NRx-; -S(=O)p-Ci_4alkyl; C3-6cycloalkyl; C3-6cycloalkylCi.4alkyl; C3.6cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_4alkyl; aryl-C(=O)-Ci_4alkyl; aryl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-Ci_4alkyl; Het-C(=O)-; Het-O-; Het represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=O)P or N; or a bicyclic or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=O)P or N; said monocyclic heterocycle or said bi-or tricyclic heterocycle optionally being substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with Ci_4alkyloxy, amino or mono-or di(Ci_4alkyl)amino; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxycarbonyl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; -S(=O)p-Ci_4alkyl;
Het1 represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=O)P or N; or a bicyclic or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=O)P or N; said monocyclic heterocycle or said bi- or tricyclic heterocycle optionally being substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with aryl-C(=O)-; hydroxyCi-βalkyl optionally substituted with aryl or aryl-C(=O)-; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxy-carbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_6alkyl)amino; R4R3N-C i_6alkyl C3-6cycloalkyl-NRx-; aryl-NRx-; Het-NRX-; C3-6cycloalkylCi.4alkyl-NRx-; arylCi.4alkyl-NRx-; HetCi.4alkyl-NRx-; -S(=O)p-Ci_4alkyl; C3-6cycloalkyl; C3.6cycloalkylCi.4alkyl; C3_6cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_4alkyl; aryl-C(=O)-Ci_4alkyl; aryl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-Ci_4alkyl; Het-C(=O)-; Het-O-; p represents 1 or 2; provided that the following compounds
Figure imgf000115_0001
are excluded; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.
2. The compound as claimed in claim 1 having the following formula
Figure imgf000115_0002
including any stereochemically isomeric form thereof, wherein
A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom;
X represents -NRX-C(=O)-; -Z-C(=O)-; -Z-NRX-C(=O)-; -C(=O)-Z-; -NRX-C(=O)-Z-; -C(=S)-; -NRX-C(=S)-; -Z-C(=S)-; -Z-NRX-C(=S)-; -C(=S)-Z-; -NRX-C(=S)-Z-;
Z represents a bivalent radical selected from Ci_6alkanediyl, C2-6alkenediyl or C2-6alkynediyl; wherein each of said Ci_6alkanediyl, C2-6alkenediyl or C2-6alkynediyl may optionally be substituted with hydroxyl;
Rx represents hydrogen or Ci_4alkyl; Y represents -C(=O)-NRX- or -NRX-C(=O)-;
R1 represents C3-6cycloalkyl; aryl1 or Het1;
R2 represents C3_6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-l,4-benzodioxinyl, 1,3- benzodioxolyl, wherein said C3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-l,4- benzodioxinyl, 1,3-benzodioxolyl may optionally be substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently selected from hydroxyl; carboxyl; halo; Ci_6alkyl optionally substituted with hydroxy; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhalo-Ci_6alkyloxy; Ci_6alkyloxycarbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; -S(=O)p-Ci_4alkyl; R4R3N-C(=O)-;
R4R3N-Ci_6alkyl; C3-6cycloalkyl; C3-6cycloalkylCi.4alkyl; C3-6cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_4alkyl; aryl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-; Het-O-;
R3 represents hydrogen; Ci_4alkyl optionally substituted with hydroxyl or Ci_4alkyloxy;
R6R5N-Ci_4alkyl; Ci_4alkyloxy; Het; aryl; R6R5N-C(=O)-Ci_4alkyl; R represents hydrogen or Ci_4alkyl;
R , 5 represents hydrogen; Ci_4alkyl; Ci_4alkylcarbonyl;
R6 represents hydrogen or Ci_4alkyl; or
R5 and R6 may be taken together with the nitrogen to which they are attached to form a saturated monocyclic 5, 6 or 7-membered heterocycle which may further contain one or more heteroatoms each independently selected from O, S, S(=O)P or N; and which heterocycle may optionally be substituted with Ci_4alkyl; aryl represents phenyl or phenyl substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; carboxyl; halo; Ci_6alkyl optionally substituted with Ci_4alkyloxy, amino or mono-or di(Ci_4alkyl)amino; polyhaloCi-βalkyl;
Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxycarbonyl; cyano; amino carbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; -S(=O)p-Ci_4alkyl; aryl1 represents phenyl, naphthalenyl or fluorenyl; each of said phenyl, naphthalenyl or fluorenyl optionally substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with aryl-C(=O)-; hydroxyCi-βalkyl optionally substituted with aryl or aryl-C(=O)-; polyhaloCi-βalkyl;
Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxy-carbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; amino carbonyl; mono-or di(Ci_4alkyl)aminocarbonyl;
Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_6alkyl)amino; C3-6cycloalkyl-NRx-; aryl-NRx-; Het-NRX-; C3-6cycloalkylCi.4alkyl-NRx-; arylCi_4alkyl-NRx-;
HetCi.4alkyl-NRx-;-S(=O)p-Ci.4alkyl; C3-6cycloalkyl; C3-6cycloalkylCi.4alkyl;
C3-6cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_4alkyl; aryl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-; Het-O-;
Het represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=O)P or N; or a bicyclic or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=0)p or N; said monocyclic heterocycle or said bi-or tricyclic heterocycle optionally being substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with Ci_4alkyloxy, amino or mono-or di(Ci_4alkyl)amino; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxycarbonyl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl;
Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; -S(=O)p-Ci_4alkyl; Het1 represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=0)p or N; or a bicyclic or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=O)P or N; said monocyclic heterocycle or said bi- or tricyclic heterocycle optionally being substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with aryl-C(=O)-; hydroxyCi-βalkyl optionally substituted with aryl or aryl-C(=O)-; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxy-carbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; amino carbonyl; mono-or di(Ci_4alkyl)aminocarbonyl;
Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_6alkyl)amino; C3-6cycloalkyl-NRx-; aryl-NRx-; Het-NRX-; C3-6cycloalkylCi.4alkyl-NRx-; arylCi_4alkyl-NRx-;
HetCi.4alkyl-NRx-;-S(=O)p-Ci.4alkyl; C3-6cycloalkyl; C3-6cycloalkylCi.4alkyl;
C3-6cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_4alkyl; aryl-C(=O)-; Het; HetCi_4alkyl;
Het-C(=O)-; Het-O-; p represents 1 or 2; provided that the following compounds
Figure imgf000118_0001
are excluded; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.
3. The compound as claimed in claim 1 or 2 wherein X represents -O-C(=O)-; -NRX-C(=O)-; -Z-C(=O)-; -Z-NRX-C(=O)-; -NRX-C(=S)-.
4. The compound as claimed in claim 3 wherein X represents -NRX-C(=O)- or -Z-C(O)-.
5. The compound as claimed in any one of the preceding claims wherein A represents
N.
6. The compound as claimed in any one of the preceding claims wherein R1 represents aryl1 or Het1.
7. The compound as claimed in claim 6 wherein R1 represents optionally substituted phenyl, optionally substituted fluorenyl or an optionally substituted monocyclic non- aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=0)p or N.
8. The compound as claimed in any one of the preceding claims wherein R2 represents C3_6Cycloalkyl, phenyl, 2,3-dihydro-l,4-benzodioxinyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said phenyl or heterocycle are optionally substituted with one to four substituents.
9. The compound as claimed in any one of the preceding claims wherein Y represents -C(=O)-NRX- or -NRX-C(=O)-.
10. The compound as claimed in any one of claims 1, 3 to 9 wherein the compound has the following formula
Figure imgf000119_0001
wherein R3a and R3a each independently represent hydrogen; hydroxyl; carboxyl; halo;
Ci_6alkyl; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy;
Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxycarbonyl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; -S(=O)p-Ci_4alkyl; and wherein R3c represents hydrogen; hydroxyl; carboxyl; halo; Ci_6alkyl; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with
Ci_4alkyloxy; Ci_6alkylthio; polyhalo-Ci_6alkyloxy; Ci_6alkyloxycarbonyl wherein
Ci_6alkyl may optionally be substituted with aryl; cyano; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; -S(=O)p-Ci_4alkyl; R4R3N-C(=O)-;
R4R3N-Ci_6alkyl; C3-6cycloalkyl; aryl; aryloxy; arylCi_4alkyl; aiyl-C(=O)-CMalkyl; aryl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-Ci_4alkyl; Het-C(=O)-; Het-O-.
11. The compound as claimed in claim 10 wherein the compound has the following formula
Figure imgf000119_0002
12. The compound as claimed in claim 10 or 11 wherein R3a and R3b each independently represent halo or Ci_6alkyl.
13. The compound as claimed in any one of the preceding claims wherein R7 represents hydrogen.
14. The compound as claimed in claim 1 wherein X represents -O-C(=O)-; -NRX-C(=O)-; -Z-C(=O)-; -Z-NRX-C(=O)-; -NRX-C(=S)-; Z represents Ci_6alkanediyl; Rx represents hydrogen; Y represents -C(=O)-NRX- or -NRX-C(=O)-; R1 represents aryl1 or Het1; R2 represents C3-6cycloalkyl, phenyl, 2,3-dihydro-l,4-benzodioxinyl, or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C3-6cycloalkyl, phenyl, 2,3-dihydro-l,4-benzodioxinyl, or heterocycle may optionally be substituted with one to four substituents, each substituent independently selected from halo; Ci_6alkyl; Ci_6alkyloxy; Ci_6alkylthio; Ci_6alkyloxycarbonyl; nitro; mono-or di(Ci_4alkyl)amino; R4R3N-C i_6alkyl; aryloxy; Het-C(=O)-Ci_4alkyl; R3 represents
Ci_4alkyl; R4 represents Ci_4alkyl; R7 represents hydrogen or halo; p represents 1 or 2.
15. The compound as claimed in claim 14 wherein aryl represents phenyl or phenyl substituted with halo; Ci_6alkyl; polyhaloCi-βalkyl; Ci_6alkyloxycarbonyl; aryl1 represents phenyl or fluorenyl; each of said phenyl or fluorenyl optionally substituted with one or two substituents, each substituent independently being selected from oxo; carboxyl; halo; Ci_6alkyl optionally substituted with carboxyl or Ci_4alkyloxycarbonyl; Ci_6alkyloxy; Ci_6alkyloxy-carbonyl; amino; aryl; Het; Het represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=O)P or N; or a bicyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from N; said monocyclic heterocycle or said bicyclic heterocycle optionally being substituted with one or two substituents, each substituent independently being selected from oxo or Ci_6alkyl; Het1 represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each indenpendently selected from S or N; said monocyclic heterocycle optionally being substituted with one or two substituents, each substituent independently being selected from hydroxyl; oxo; Ci_6alkyl; Ci_6alkyloxy-carbonyl; aryl; Het.
16. The compound as claimed in claim 1 wherein the compound is selected from
Figure imgf000121_0001
a JV-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.
17. A compound as claimed in any one of the preceding claims for use as a medicine.
18. A compound as claimed in any one of claims 1 to 16 for use in the treatment of obesity, hypercholesterolemia, hyperlipidemia, dyslipidemia, mixed dyslipidemia, hypertriglyceridemia, fatty liver, nonalcoholic fatty liver disease, liver fibrosis, non- alcoholic steatohepatitis or diabetes.
19. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as claimed in any one of claims 1 to 16.
20. Use of a compound for the manufacture of a medicament for the prevention or the treatment of a disease which can benefit from inhibition of DGATl, wherein the compound is a
Figure imgf000122_0001
including any stereochemical^ isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents -O-C(=O)-; -C(=O)-C(=O)-; -NRX-C(=O)-; -Z-C(=O)-; -Z-NRX-C(=O)-; -C(=O)-Z-; -NRX-C(=O)-Z-; -C(=S)-; -S(=O)p-; -NRX-C(=S)-; -Z-C(=S)-; -Z-NRX- C(=S)-; -C(=S)-Z-; -NRX-C(=S)-Z-;
Z represents a bivalent radical selected from Ci_6alkanediyl, C2-6alkenediyl or C2-6alkynediyl; wherein each of said Ci_6alkanediyl, C2-6alkenediyl or C2-6alkynediyl may optionally be substituted with hydroxyl or amino; and wherein two hydrogen atoms attached to the same carbon atom in Ci_6alkanediyl may optionally be replaced by Ci_6alkanediyl;
Rx represents hydrogen or Ci_4alkyl; Y represents -C(=O)-NRX- or -NRX-C(=O)-; R1 represents adamantanyl, C3-6cycloalkyl; aryl1 or Het1;
R2 represents hydrogen, Ci_6alkyl, C2-6alkenyl, C3_6Cycloalkyl, phenyl, naphtalenyl, 2,3- dihydro-l,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or a
6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-l,4-benzodioxinyl, 1,3-benzodioxolyl or 6-membered aromatic heterocycle containing 1 or 2 N atoms may optionally be substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently selected from hydroxyl; carboxyl; halo; Ci_6alkyl optionally substituted with hydroxy; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy;
Ci_6alkylthio; polyhalo-Ci_6alkyloxy; Ci_6alkyloxycarbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; Ci_4alkylcarbonylamino; -S(=O)p-Ci_4alkyl; R4R3N-C(=O)-;
R4R3N-C i-ealkyl; C3-6cycloalkyl; C3-6cycloalkylCi_4alkyl; C3-6cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_4alkyl; aryl-C(=O)-Ci_4alkyl; aryl-C(=O)-; Het; HetCi_4alkyl;
Het-C(=O)-Ci_4alkyl; Het-C(=O)-; Het-O-;
R3 represents hydrogen; Ci_4alkyl optionally substituted with hydroxyl or Ci_4alkyloxy; R6R5N-Ci_4alkyl; Ci_4alkyloxy; Het; Het-Ci_4alkyl; aryl; R6R5N-C(=O)-Ci_4alkyl;
R4 represents hydrogen or Ci_4alkyl; R5 represents hydrogen; Ci_4alkyl; Ci_4alkylcarbonyl; R6 represents hydrogen or Ci_4alkyl; or
R5 and R6 may be taken together with the nitrogen to which they are attached to form a saturated monocyclic 5, 6 or 7-membered heterocycle which may further contain one or more heteroatoms each independently selected from O, S, S(=O)P or N; and which heterocycle may optionally be substituted with Ci_4alkyl; R7 represents hydrogen, halo, Ci_4alkyl, Ci_4alkyl substituted with hydroxyl; aryl represents phenyl or phenyl substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; carboxyl; halo; Ci_6alkyl optionally substituted with
Ci_4alkyloxy, amino or mono-or di(Ci_4alkyl)amino; polyhaloCi-βalkyl;
Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxycarbonyl; cyano; amino carbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; -S(=O)p-Ci_4alkyl; aryl1 represents phenyl, naphthalenyl or fluorenyl; each of said phenyl, naphthalenyl or fluorenyl optionally substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with carboxyl,
C i_4alkyloxy carbonyl or aryl-C(=O)-; hydroxyCi-βalkyl optionally substituted with aryl or aryl-C(=O)-; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with
Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxy-carbonyl wherein
Ci_6alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_6alkyl)amino; R4R3N-C i_6alkyl; C3.6cycloalkyl-NRX-; aryl-NRx-; Het-NRX-;
C3_6CycloalkylCi.4alkyl-NRx-; arylCi.4alkyl-NRx-; HetCi.4alkyl-NRx-; -S(=O)p-Ci_4alkyl; C3-6cycloalkyl; C3_6cycloalkylCi_4alkyl; C3-6cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_4alkyl; aryl-C(=O)-Ci_4alkyl; aiyl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-Ci_4alkyl; Het-C(=O)-; Het-O-;
Het represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=0)p or N; or a bicyclic or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=0)p or N; said monocyclic heterocycle or said bi-or tricyclic heterocycle optionally being substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with Ci_4alkyloxy, amino or mono-or di(Ci_4alkyl)amino; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxycarbonyl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_4alkyl)amino; -S(=O)p-Ci_4alkyl;
Het1 represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=0)p or N; or a bicyclic or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom each independently selected from O, S, S(=0)p or N; said monocyclic heterocycle or said bi- or tricyclic heterocycle optionally being substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; Ci_6alkyl optionally substituted with aryl-C(=O)-; hydroxyCi-βalkyl optionally substituted with aryl or aryl-C(=O)-; polyhaloCi-βalkyl; Ci_6alkyloxy optionally substituted with Ci_4alkyloxy; Ci_6alkylthio; polyhaloCi-βalkyloxy; Ci_6alkyloxy-carbonyl wherein Ci_6alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(Ci_4alkyl)aminocarbonyl; Ci_6alkylcarbonyl; nitro; amino; mono-or di(Ci_6alkyl)amino; R4R3N-C i_6alkyl; C3-6cycloalkyl-NRx-; aryl-NRx-; Het-NRX-; C3_6cycloalkylCi_4alkyl-NRx-; arylCi_4alkyl-NRx-; HetCi_4alkyl-NRx-;-S(=O)p-Ci_4alkyl; C3.6cycloalkyl;
C3_6CycloalkylCi_4alkyl; C3_6Cycloalkyl-C(=O)-; aryl; aryloxy; arylCi_4alkyl; aryl-C(=O)-Ci_4alkyl; aryl-C(=O)-; Het; HetCi_4alkyl; Het-C(=O)-Ci_4alkyl; Het-C(=O)-; Het-O-; p represents 1 or 2; a JV-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.
21. Use of a compound of formula (I) as claimed in any one of claims 1 to 16 for the manufacture of a medicament for the treatment of obesity, hypercholesterolemia, hyperlipidemia, dyslipidemia, mixed dyslipidemia, hypertriglyceridemia, fatty liver, nonalcoholic fatty liver disease, liver fibrosis, non-alcoholic steatohepatitis or diabetes.
22. Use according to claim 21 for the treatment of type II diabetes.
23. A process of preparing a compound as defined in claim 1 characterized by a) reacting an intermediate of formula (II) with an intermediate of formula (III) in the presence of a suitable dehydrating (coupling) agent, a suitable solvent and optionally a suitable base,
Figure imgf000125_0001
(II) (in) C-) with the variables as defined in claim 1 ; b) reacting an intermediate of formula (II) with an intermediate of formula (HF) wherein Wi represents a suitable leaving group, in the presence of a suitable base and a suitable solvent,
Figure imgf000125_0002
(H)
(HI1) (I-a) with the variables as defined in claim 1 ; c) reacting an intermediate of formula (IV) with an intermediate of formula (V) in the presence of a suitable solvent, optionally in the presence of a suitable base,
R2— X1-N=C=O + HN ,-A~\ / ~Y~R1 *~
Figure imgf000125_0003
with the variables as defined in claim 1 and with Xi representing a direct bond or Z; d) reacting an intermediate of formula (IV) with C13COC(=O)-C1 or C(=O)C12 in the presence of a suitable solvent, followed by reaction with an intermediate of formula (V) in the presence of a suitable solvent and optionally in the presence of a suitable base,
Figure imgf000126_0001
(V)
(I-b-1) with the variables as defined in claim 1 ; e) reacting an intermediate of formula (VI) with an intermediate of formula (V) in the presence of a suitable base and a suitable solvent,
Figure imgf000126_0002
with the variables as defined in claim 1 and with Xi representing a direct bond or Z; f) reacting an intermediate of formula (VII) with an intermediate of formula (V) in the presence of a suitable dehydrating (coupling) agent, a suitable solvent and optionally a suitable base; or reacting an intermediate of formula (VII) with an intermediate of formula (V) in the presence of a suitable activating agent, a suitable base and a suitable solvent,
R2— X1- COOH + HN .A— 4 V- Y-R1 >-
Figure imgf000126_0003
with the variables as defined in claim 1 and with Xi representing a direct bond or Z; g) reacting an intermediate of formula (VIF) wherein Wi represents a suitable leaving group, with an intermediate of formula (V) in the presence of a suitable base and a suitable solvent,
Figure imgf000126_0004
(V) (VH') (I-d-1) with the variables as defined in claim 1 ; h) reacting an intermediate of formula (XVIII) with an intermediate of formula (V) in
Figure imgf000126_0005
(XVIII) (γ)
(I-f) with the variables as defined in claim 1 ; i) reacting an intermediate of formula (IXX) wherein W4 represents a suitable leaving group, with NHR > 3r R, 4 in the presence of a suitable solvent,
R'
W4 — Cr6alkyl Rz-X— N ,A — <\ /> — Y-R1 + NHRJR*
(IXX)
R4R3N — Cr6alkyl R21X-N ,A-
\ /
(i-g) with the variables as defined in claim 1 and with R2 being substituted with R3R4N-Ci. 6alkyl, said R2 being represented by -R2'-Ci_6alkyl-NR3R4; j) reacting an intermediate of formula (XXV) with an intermediate of formula (XXVI) in the presence of DECP, a suitable base and a suitable solvent,
Figure imgf000127_0001
(XXVI)
(XXV) (I-h) with the variables as defined in claim 1 ; k) reacting an intermediate of formula (XLIII) with an appropriate acid in the presence of a suitable solvent,
Figure imgf000127_0002
(XLIII) (I-i) with the variables as defined in claim 1 ;
1) deprotecting an intermediate of formula (XLIV) wherein P represents a suitable leaving group, with a suitable acid in the presence of a suitable solvent,
Figure imgf000127_0003
(XLIV) fl-J) with the variables as defined in claim 1 and with X containing Z1, said Z1 being Z substituted with amino, said X being represented by Z1 (NE^)-X2, wherein X2 represents the remainder of the linker X; or, if desired, converting compounds of formula (I) into each other following art-known transformations, and further, if desired, converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; or, if desired, preparing stereochemically isomeric forms, quaternary amines, solvates or iV-oxide forms thereof.
PCT/EP2008/057008 2007-06-08 2008-06-05 Piperidine/piperazine derivatives WO2008148849A2 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
EP08760584.6A EP2155198B1 (en) 2007-06-08 2008-06-05 Piperidine/piperazine derivatives
RU2009148796/04A RU2478628C2 (en) 2007-06-08 2008-06-05 Piperidine/piperazine derivatives
BRPI0812923-1A2A BRPI0812923A2 (en) 2007-06-08 2008-06-05 PIPERIDINE / PIPERAZINE Derivatives
JP2010510806A JP5443343B2 (en) 2007-06-08 2008-06-05 Piperidine / piperazine derivatives
AU2008258558A AU2008258558B2 (en) 2007-06-08 2008-06-05 Piperidine/piperazine derivatives
MX2009013334A MX2009013334A (en) 2007-06-08 2008-06-05 Piperidine/piperazine derivatives.
ES08760584.6T ES2522617T3 (en) 2007-06-08 2008-06-05 Piperidine / Piperazine Derivatives
CN200880018624.9A CN101678013B (en) 2007-06-08 2008-06-05 Piperidine/piperazine derivatives
CA2687243A CA2687243C (en) 2007-06-08 2008-06-05 Piperidine/piperazine derivatives
US12/663,011 US8946228B2 (en) 2007-06-08 2008-06-06 Piperidine/piperazine derivatives
JP2011512112A JP5579170B2 (en) 2008-06-05 2009-06-03 Pharmaceutical combination comprising a DGAT inhibitor and a PPAR agonist
US12/993,491 US9107946B2 (en) 2008-06-05 2009-06-03 Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
UY0001031863A UY31863A (en) 2008-06-05 2009-06-03 DRUG COMBINATIONS UNDERSTANDING A DGAT INHIBITOR AND A PPAR AGONIST
EP09757551.8A EP2296659B1 (en) 2008-06-05 2009-06-03 Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
ES09757551.8T ES2617619T3 (en) 2008-06-05 2009-06-03 Drug combinations comprising a DGAT inhibitor and a PPAR agonist
AU2009253892A AU2009253892B2 (en) 2008-06-05 2009-06-03 Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
PE2009000769A PE20100083A1 (en) 2008-06-05 2009-06-03 DRUG COMBINATIONS INCLUDING A DGAT INHIBITOR AND A PPAR AGONIST
CA2725933A CA2725933C (en) 2008-06-05 2009-06-03 Drug combinations comprising a dgat inhibitor and a ppar-agonist
PE2013002163A PE20140572A1 (en) 2008-06-05 2009-06-03 DRUG COMBINATIONS INCLUDING A DGAT INHIBITOR AND A PPAR AGONIST
PCT/EP2009/056800 WO2009147170A2 (en) 2008-06-05 2009-06-03 Drug combinations comprising a dgat inhibitor and a ppar-agonist
TW098118476A TWI460175B (en) 2008-06-05 2009-06-04 Drug combinations comprising a dgat inhibitor and a ppar-agonist
ARP090102006A AR073450A1 (en) 2008-06-05 2009-06-04 DRUG COMBINATIONS UNDERSTANDING A DGAT INHIBITOR AND A PPAR AGONIST
US14/561,252 US9227935B2 (en) 2007-06-08 2014-12-05 Piperidine/piperazine derivatives
US14/793,896 US9724418B2 (en) 2008-06-05 2015-07-08 Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
US14/957,924 US20160081997A1 (en) 2007-06-08 2015-12-03 Piperidine/piperazine derivatives
US15/627,475 US20180028660A1 (en) 2008-06-05 2017-06-20 Drug combinations comprising a dgat inhibitor and a ppar-agonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109866.9 2007-06-08
EP07109866 2007-06-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/663,011 A-371-Of-International US8946228B2 (en) 2007-06-08 2008-06-06 Piperidine/piperazine derivatives
US14/561,252 Division US9227935B2 (en) 2007-06-08 2014-12-05 Piperidine/piperazine derivatives

Publications (3)

Publication Number Publication Date
WO2008148849A2 true WO2008148849A2 (en) 2008-12-11
WO2008148849A3 WO2008148849A3 (en) 2009-04-16
WO2008148849A8 WO2008148849A8 (en) 2009-07-09

Family

ID=38616252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/057008 WO2008148849A2 (en) 2007-06-08 2008-06-05 Piperidine/piperazine derivatives

Country Status (18)

Country Link
US (3) US8946228B2 (en)
EP (1) EP2155198B1 (en)
JP (1) JP5443343B2 (en)
CN (1) CN101678013B (en)
AR (1) AR066153A1 (en)
AU (1) AU2008258558B2 (en)
BR (1) BRPI0812923A2 (en)
CA (1) CA2687243C (en)
CL (1) CL2008001668A1 (en)
ES (1) ES2522617T3 (en)
JO (1) JO2972B1 (en)
MX (1) MX2009013334A (en)
PA (1) PA8783401A1 (en)
PE (1) PE20090820A1 (en)
RU (1) RU2478628C2 (en)
TW (1) TWI438197B (en)
UY (1) UY31134A1 (en)
WO (1) WO2008148849A2 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009147170A2 (en) * 2008-06-05 2009-12-10 Janssen Pharmaceutica Nv Drug combinations comprising a dgat inhibitor and a ppar-agonist
US7749997B2 (en) 2005-12-22 2010-07-06 Astrazeneca Ab Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
US7795283B2 (en) 2004-12-14 2010-09-14 Astrazeneca Ab Oxadiazole derivative as DGAT inhibitors
US20100273781A1 (en) * 2009-04-27 2010-10-28 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
US7879850B2 (en) 2007-09-28 2011-02-01 Novartis Ag Organic compounds
US8084478B2 (en) 2006-05-30 2011-12-27 Asstrazeneca Ab Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
US8450317B2 (en) 2009-04-27 2013-05-28 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
US8633197B2 (en) 2007-06-08 2014-01-21 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8835451B2 (en) 2006-03-31 2014-09-16 Novartis Ag Compounds
US8835437B2 (en) 2007-06-08 2014-09-16 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8946228B2 (en) 2007-06-08 2015-02-03 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
US8981094B2 (en) 2007-06-08 2015-03-17 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
AU2010335277B2 (en) * 2009-12-22 2016-07-07 F. Hoffmann-La Roche Ag Substituted benzamide derivatives
US10508107B2 (en) 2016-03-17 2019-12-17 Hoffmann-La Roche Inc. Morpholine derivative
CN111936137A (en) * 2018-03-16 2020-11-13 安济药业公司 Compositions and methods for treating severe constipation

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
WO2009017831A1 (en) * 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Vinyl-aryl derivatives for inflammation and immune-related uses
CN108440468B (en) * 2018-04-17 2022-09-23 南华大学 2- (benzofuran-5-yl) phenol and application thereof as anticancer drug
CN110128346A (en) * 2019-05-17 2019-08-16 南开大学 A kind of biaryl amide pyrazole derivatives and its preparation method and application

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032582A1 (en) 1998-12-03 2000-06-08 Glaxo Group Limited Benzamide derivatives and their use as apob-100 secretion inhibitors
WO2001097810A2 (en) 2000-06-01 2001-12-27 Glaxo Group Limited Use of therapeutic benzamide derivatives
WO2002081460A1 (en) 2001-04-06 2002-10-17 Janssen Pharmaceutica N.V. Lipid lowering biphenylcarboxamides
WO2004047755A2 (en) 2002-11-22 2004-06-10 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles
WO2005072740A2 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
WO2006004200A1 (en) 2004-07-02 2006-01-12 Sankyo Company, Limited Urea derivative
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2006067071A1 (en) 2004-12-22 2006-06-29 Janssen Pharmaceutica N.V. Diacylglycerol acyltransferase assay
WO2006086445A2 (en) 2005-02-09 2006-08-17 Xenon Pharmaceuticals Inc. Combination therapy
US20070021339A1 (en) 2005-06-30 2007-01-25 Resurreccion Alloza Miravete GLP-1 pharmaceutical compositions
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
JP2007131584A (en) 2005-11-11 2007-05-31 Sankyo Co Ltd New benzoxazole derivative

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1383906A (en) 1971-02-22 1974-02-12 Bdh Pharmaceuticals Ltd Pyridazinones
JPS5692887A (en) 1979-12-05 1981-07-27 Sumitomo Chem Co Ltd N-substituted imidazole derivative
DE3338846A1 (en) * 1982-10-29 1984-05-03 Toyama Chemical Co. Ltd., Tokyo NEW 4-OXO-1,4-DIHYDRONICOTINE ACID DERIVATIVES AND SALTS THEREOF, METHOD FOR THEIR PREPARATION AND ANTIBACTERIAL AGENTS WITH A CONTENT THEREOF
GB8729083D0 (en) 1987-12-12 1988-01-27 Pfizer Ltd Triazole antifungal agents
JP2969359B2 (en) 1989-01-13 1999-11-02 武田薬品工業株式会社 Cyclic amine compounds
DE4317093A1 (en) 1993-05-21 1994-11-24 Basf Ag Low molecular weight and polymeric liquid crystalline benzotriazoles and their use
TW286317B (en) 1993-12-13 1996-09-21 Hoffmann La Roche
US5637592A (en) 1994-07-12 1997-06-10 Janssen Pharmaceutica N.V. Acyl derivatives of azolones
US5639754A (en) 1994-07-12 1997-06-17 Janssen Pharmaceutica N.V. Urea and thiourea derivatives of azolones
FR2722788B1 (en) * 1994-07-20 1996-10-04 Pf Medicament NOVEL PIPERAZIDES DERIVED FROM ARYL PIPERAZINE, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
KR100233202B1 (en) 1994-09-30 1999-12-01 가나이 쓰도무 Magnetic recording/reproducing device having high-speed reproduction mode
US5780472A (en) 1995-01-11 1998-07-14 Samjin Pharmaceuticazl Co., Ltd. Piperazine derivatives and methods for the preparation thereof and compositions containing the same
WO1997005878A1 (en) 1995-08-10 1997-02-20 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
CA2228136A1 (en) 1995-08-10 1997-02-20 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
GB9702213D0 (en) 1996-02-24 1997-03-26 Zeneca Ltd Chemical compounds
HN1997000027A (en) 1996-12-06 1997-06-05 Pfizer Prod Inc DERIVATIVES OF 6-PHENYL PIRIDIL - 2 AMINE
JPH11139969A (en) 1997-08-07 1999-05-25 Tanabe Seiyaku Co Ltd Pharmaceutical composition
DE19743435A1 (en) * 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidine derivatives
CN1309654A (en) 1998-07-20 2001-08-22 默克专利股份有限公司 Biphenyl derivs.
AUPP999799A0 (en) * 1999-04-27 1999-05-20 Fujisawa Pharmaceutical Co., Ltd. New compound
AP2001002326A0 (en) 1999-05-21 2001-12-31 Pfizer Prod Inc New pharmaceuticals combinations for nos inhibitors.
EP1194410B1 (en) * 1999-06-22 2006-01-18 Neurosearch A/S Benzimidazole derivatives and pharmaceutical compositions comprising these compounds
CA2395648A1 (en) 2000-02-10 2001-08-16 Pharmacia & Upjohn Company Oxazolidinone thioamides with piperazine amide substituents
WO2001095856A2 (en) 2000-06-15 2001-12-20 Chaconne Nsi Co., Ltd. Urea derivative useful as an anti-cancer agent and process for preparing same
US20030060472A1 (en) * 2000-06-21 2003-03-27 Learmonth David Alexander Novel substituted nitrocatechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
GB2363792A (en) 2000-06-21 2002-01-09 Portela & Ca Sa Nitrocatechols
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Polyarylcarboxamides useful as lipid lowering agents
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
DE10063008A1 (en) * 2000-12-16 2002-06-20 Merck Patent Gmbh carboxamide
CN100509794C (en) * 2001-01-16 2009-07-08 阿斯特拉曾尼卡有限公司 Therapeutic heterocyclic compounds
DE10204116A1 (en) 2002-02-01 2003-08-07 Bayer Cropscience Ag DELTA · 1 · -pyrrolines
PL220783B1 (en) 2002-03-13 2016-01-29 Janssen Pharmaceutica Nv Sulfonyl-derivatives as novel inhibitors of histone deacetylase
EP1485353B1 (en) 2002-03-13 2011-08-24 Janssen Pharmaceutica NV New inhibitors of histone deacetylase
EP1495021A2 (en) 2002-04-01 2005-01-12 Cadila Healthcare Ltd. Antiinfectve compounds, process for their preparation and pharmaceutical compositions containing them
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
CA2513416A1 (en) 2002-08-22 2004-03-04 Orchid Chemicals & Pharmaceuticals Ltd. Novel antibacterial agents
ATE551324T1 (en) * 2003-02-03 2012-04-15 Janssen Pharmaceutica Nv QUINOLINE AMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTORS
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
DE10306250A1 (en) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals
AR044152A1 (en) 2003-05-09 2005-08-24 Bayer Corp RENTAL DERIVATIVES, METHOD OF PREPARATION AND USE FOR THE TREATMENT OF OBESITY
EP1635832A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
JP4920410B2 (en) * 2003-07-14 2012-04-18 アリーナ ファーマシューティカルズ， インコーポレイテッド Fused aryl and heteroaryl derivatives as metabolic modulators and prevention and treatment of metabolic-related disorders
KR100774622B1 (en) * 2003-08-11 2007-11-08 에프. 호프만-라 로슈 아게 Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors
JP2005206492A (en) 2004-01-21 2005-08-04 Sankyo Co Ltd Sulfonamide compound
JP4787529B2 (en) 2004-04-09 2011-10-05 大塚製薬株式会社 Pharmaceutical composition
PE20060417A1 (en) * 2004-08-03 2006-06-13 Wyeth Corp INDAZOLES AS LXRS MODULATORS
CN100360525C (en) 2004-09-16 2008-01-09 中国科学院上海药物研究所 Novel oxazolidone derivative, its preparing method and use
GB0421908D0 (en) * 2004-10-01 2004-11-03 Angeletti P Ist Richerche Bio New uses
KR20070063546A (en) 2004-10-15 2007-06-19 바이엘 파마슈티칼스 코포레이션 Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
EA013250B1 (en) * 2004-10-22 2010-04-30 Янссен Фармацевтика, Н.В. Inhibitors of c-fms kinase
KR20070087096A (en) 2004-12-14 2007-08-27 아스트라제네카 아베 Oxadiazole derivatives as dgat inhibitors
GB0505084D0 (en) 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
EP1866298A2 (en) 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
CA2601983A1 (en) 2005-04-06 2006-10-12 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
US20090215780A1 (en) * 2005-04-19 2009-08-27 Bayer Pharmaceuticals Corporation Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity
BRPI0611956A2 (en) 2005-06-11 2018-07-31 Astrazeneca Ab compound, use thereof, pharmaceutical composition, and process for preparing a compound
AU2006326815A1 (en) 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase
AR058562A1 (en) 2005-12-22 2008-02-13 Astrazeneca Ab PIRIMIDO DERIVATIVES [4,5 B] (1,4) OXAZINES, OBTAINING PROCEDURES AND ITS USE AS COA AND DGAT ACETIL INHIBITORS 1
EP1810974A1 (en) 2006-01-18 2007-07-25 Ludwig-Maximilians-Universität München Preparation and use of magnesium amides
TW200804364A (en) 2006-02-22 2008-01-16 Boehringer Ingelheim Int New compounds
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
EP1997804A1 (en) * 2006-03-03 2008-12-03 Shionogi & Co., Ltd. Mmp-13-selective inhibitor
CA2654670A1 (en) 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh New compounds
EP1918285A1 (en) 2006-11-03 2008-05-07 Merck Sante Diazepane-acetamide derivatives as selective 11beta-HSD1 inhibitors
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
MX2009012285A (en) * 2007-05-22 2009-12-15 Via Pharmaceuticals Inc Diacylglycerol acyltransferase inhibitors.
CN101678019B (en) 2007-06-08 2016-03-30 詹森药业有限公司 Piperidine/piperazine derivatives
WO2008148851A1 (en) 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine/Piperazine derivatives
EP2152271B1 (en) 2007-06-08 2015-10-21 Janssen Pharmaceutica, N.V. Piperidine/piperazine derivatives
WO2009147170A2 (en) 2008-06-05 2009-12-10 Janssen Pharmaceutica Nv Drug combinations comprising a dgat inhibitor and a ppar-agonist

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032582A1 (en) 1998-12-03 2000-06-08 Glaxo Group Limited Benzamide derivatives and their use as apob-100 secretion inhibitors
WO2001097810A2 (en) 2000-06-01 2001-12-27 Glaxo Group Limited Use of therapeutic benzamide derivatives
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
WO2002081460A1 (en) 2001-04-06 2002-10-17 Janssen Pharmaceutica N.V. Lipid lowering biphenylcarboxamides
WO2004047755A2 (en) 2002-11-22 2004-06-10 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles
WO2005072740A2 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
WO2006004200A1 (en) 2004-07-02 2006-01-12 Sankyo Company, Limited Urea derivative
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2006067071A1 (en) 2004-12-22 2006-06-29 Janssen Pharmaceutica N.V. Diacylglycerol acyltransferase assay
WO2006086445A2 (en) 2005-02-09 2006-08-17 Xenon Pharmaceuticals Inc. Combination therapy
US20070021339A1 (en) 2005-06-30 2007-01-25 Resurreccion Alloza Miravete GLP-1 pharmaceutical compositions
JP2007131584A (en) 2005-11-11 2007-05-31 Sankyo Co Ltd New benzoxazole derivative

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
BAST ET AL.: "Cancer Medicine, 5th Ed.,", 2000, B.C. DECKER
BUHMAN ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 25474
CASES ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 38870
CASES ET AL., PRO.C NAT.L ACAD. SCI., vol. 95, 1998, pages 13018
CASES, S.; SMITH, S.J.; ZHENG, Y.; MYERS H.M.; LEAR, S.R.; SANDE, E.; NOVAK, S.; COLLINS, C.; WELCH, C.B.; LUSIS, A.J., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 13018 - 13023
CHEN ET AL., J. CLIN. INVEST., vol. 109, 2002, pages 1049
CHEN; FARESE, TRENDS CARDIOVASC. MED., vol. 10, 2000, pages 188
DIABETES, vol. 54, 2005, pages 146 - 151
EXPERIMENTAL NEUROLOGY, vol. 203, no. 2, 2007, pages 293 - 301
FARESE ET AL., CURR. OPIN. LIPIDOL., vol. 11, 2000, pages 229
FARESE ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 11767
J. PHARM. EXP. THER., vol. 312, no. 1, 2005, pages 303 - 308
J.BIOLOG. CHEM., vol. 276, no. 42, 2001, pages 38870 - 38876
LEWIS ET AL., ENDOCRINE REVIEWS, vol. 23, 2002, pages 201
MALLOY; KANE, ADV. INTERN. MED., vol. 47, 2001, pages 11 1
OELKERS ET AL., J. BIOL. CHEM., vol. 273, 1998, pages 26765
SMITH ET AL., NATURE GENETICS, vol. 25, 2000, pages 87

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795283B2 (en) 2004-12-14 2010-09-14 Astrazeneca Ab Oxadiazole derivative as DGAT inhibitors
US8017603B2 (en) 2005-12-22 2011-09-13 Astrazeneca Ab Pyrimido [4,5-B]-oxazines for use as DGAT inhibitors
US7749997B2 (en) 2005-12-22 2010-07-06 Astrazeneca Ab Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
US8912208B2 (en) 2006-03-31 2014-12-16 Novartis Ag (4-{4-[5-(benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid useful for treating or preventing conditions or disorders associated with DGAT1 activity
US8835451B2 (en) 2006-03-31 2014-09-16 Novartis Ag Compounds
US8084478B2 (en) 2006-05-30 2011-12-27 Asstrazeneca Ab Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
US9688696B2 (en) 2007-06-08 2017-06-27 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US9499567B2 (en) 2007-06-08 2016-11-22 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US9227935B2 (en) 2007-06-08 2016-01-05 Janssen Pharmaceutical N.V. Piperidine/piperazine derivatives
US9120821B2 (en) 2007-06-08 2015-09-01 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8981094B2 (en) 2007-06-08 2015-03-17 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8946228B2 (en) 2007-06-08 2015-02-03 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8633197B2 (en) 2007-06-08 2014-01-21 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8835437B2 (en) 2007-06-08 2014-09-16 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8217065B2 (en) 2007-09-28 2012-07-10 Novartis Ag Organic compounds
US7879850B2 (en) 2007-09-28 2011-02-01 Novartis Ag Organic compounds
US9724418B2 (en) 2008-06-05 2017-08-08 Janssen Pharmaceutica Nv Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
WO2009147170A3 (en) * 2008-06-05 2010-06-10 Janssen Pharmaceutica Nv Drug combinations comprising a dgat inhibitor and a ppar-agonist
US9107946B2 (en) 2008-06-05 2015-08-18 Janssen Pharmaceutica Nv Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
WO2009147170A2 (en) * 2008-06-05 2009-12-10 Janssen Pharmaceutica Nv Drug combinations comprising a dgat inhibitor and a ppar-agonist
US20100273781A1 (en) * 2009-04-27 2010-10-28 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
US8450317B2 (en) 2009-04-27 2013-05-28 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
US8362249B2 (en) * 2009-04-27 2013-01-29 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
AU2010335277B2 (en) * 2009-12-22 2016-07-07 F. Hoffmann-La Roche Ag Substituted benzamide derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
US10508107B2 (en) 2016-03-17 2019-12-17 Hoffmann-La Roche Inc. Morpholine derivative
US11312711B2 (en) 2016-03-17 2022-04-26 Hoffmann-La Roche Inc. Morpholine derivative
CN111936137A (en) * 2018-03-16 2020-11-13 安济药业公司 Compositions and methods for treating severe constipation
EP3765012A4 (en) * 2018-03-16 2021-12-15 Anji Pharmaceuticals Inc. Compositions and methods for treating severe constipation
US11224590B2 (en) 2018-03-16 2022-01-18 Anji Pharmaceuticals Inc. Compositions and methods for treating severe constipation
CN111936137B (en) * 2018-03-16 2023-09-08 安济药业公司 Compositions and methods for treating severe constipation
US11819495B2 (en) 2018-03-16 2023-11-21 Anji Pharmaceuticals Inc. Compositions and methods for treating severe constipation

Also Published As

Publication number Publication date
BRPI0812923A2 (en) 2014-12-09
EP2155198B1 (en) 2014-08-13
AR066153A1 (en) 2009-07-29
CA2687243A1 (en) 2008-12-11
TWI438197B (en) 2014-05-21
CL2008001668A1 (en) 2009-07-17
US20100210618A1 (en) 2010-08-19
WO2008148849A3 (en) 2009-04-16
JP5443343B2 (en) 2014-03-19
PE20090820A1 (en) 2009-06-27
CN101678013A (en) 2010-03-24
ES2522617T3 (en) 2014-11-17
UY31134A1 (en) 2009-03-02
US20150087629A1 (en) 2015-03-26
US8946228B2 (en) 2015-02-03
CA2687243C (en) 2016-07-12
MX2009013334A (en) 2010-01-20
US9227935B2 (en) 2016-01-05
JO2972B1 (en) 2016-03-15
EP2155198A2 (en) 2010-02-24
WO2008148849A8 (en) 2009-07-09
RU2478628C2 (en) 2013-04-10
TW200916449A (en) 2009-04-16
RU2009148796A (en) 2011-07-20
AU2008258558A1 (en) 2008-12-11
JP2010529085A (en) 2010-08-26
AU2008258558B2 (en) 2013-11-07
PA8783401A1 (en) 2009-01-23
US20160081997A1 (en) 2016-03-24
CN101678013B (en) 2014-05-07

Similar Documents

Publication Publication Date Title
EP2155198B1 (en) Piperidine/piperazine derivatives
EP2152270B1 (en) Piperidine/piperazine derivatives
EP2152271B1 (en) Piperidine/piperazine derivatives
AU2008258560C1 (en) Piperidine/piperazine derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880018624.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08760584

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2687243

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010510806

Country of ref document: JP

Ref document number: 2008760584

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12663011

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/013334

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008258558

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 36/MUMNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009148796

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2008258558

Country of ref document: AU

Date of ref document: 20080605

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0812923

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091208